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I have investigated epigenetic mechanisms of acquired endocrine-resistance in breast
cancer using an in vitro model system based on estrogen-dependent MCF7 cells and
their derivatives, LCC1 and LCC9.  LCC1 cells, derived from MCF7 after passage in
ovariectomised mice and routinely cultured in vitro in the absence of estrogen,
exhibit estrogen-independent growth.  They retain sensitivity to tamoxifen and
fulvestrant.  LCC9 cells, derived from LCC1 cells by growing them in increasing
concentrations of fulvestrant, are completely estrogen-independent and are resistant
to fulvestrant and cross-resistant to tamoxifen.  When compared to MCF7 cells,
LCC1 cells have marked up-regulation of the estrogen receptor  (ERα) protein that
is not concomitant with increased estrogen receptor 1 (ESR1) transcription,
suggesting a role for estrogen in controlling the proteasomal degradation of ER.
However, despite being grown in the same estrogen-deprived conditions, LCC9 cells
do not have up-regulated ER levels.  As LCC1 cells retain sensitivity to tamoxifen
and fulvestrant, these data suggest that LCC1 have developed estrogen-independence
through ERα uncoupled from its ligand.  However, LCC9 cells appear to have
developed an alternative mechanism which is not dependent on ER, presumably
explaining their resistance to fulvestrant.
I have studied global gene expression changes in the presence and absence of
estrogen in these cell lines, using oligonucleotide microarrays, and correlated these
data with global DNA methylation data derived from methylation arrays, which
interrogate the methylation status of approximately 27,000 CpG dinucleotides in the
genome.
The analysis led to the discovery of more than 5,000 genes that were potentially
either up-regulated or down-regulated by estrogen in MCF7 cells, either directly or
indirectly. The transcriptional response to estrogen was generally muted in LCC1
and LCC9 compared with MCF7, but was not completely absent. I used various
methods based on differential gene expression to parse the data, including gene
viii
ontology analysis, aiming to select genes for further mechanistic study.  However,
none of these methods led to the conclusive identification of a specific gene (or set of
genes) that might have accounted for the physiological differences between the cell
lines.  In one strategy, I reasoned that, as the endocrine-resistant cells had lost their
estrogen-dependence, genes involved might be regulated in an estrogen-dependent
manner in MCF7 cells, without exhibiting misregulation in LCC9. This led to the
identification of DUSP1 as a candidate gene, which was taken forward for
mechanistic study because of its potential role in regulating ERα expression.
However, when over-expressing DUSP1 in LCC9 cells, I could not demonstrate any
effect on ERα levels.
The final approach taken was to identify genes that might have been epigenetically
deregulated, being both estrogen-regulated and deregulated in association with
aberrant DNA methylation in the estrogen-independent cell lines. Surprisingly,
given the phenotypic differences between the cell lines, only a very few genes were
significantly methylated between cell lines. Of those that were differentially
methylated between MCF7 cells and LCC1/9, only three exhibited the expected
inverse correlation between methylation and expression. Of these, the gene CYBA
was selected for further investigation. CYBA is a critical component of the NAPDH
oxidase complex which is involved in generating oxygen free-radicals. My work
suggests CYBA expression is estrogen-dependent, and that chronic estrogen
deprivation leads to the epigenetic inactivation of CYBA in breast cancer cells. I
speculate that the epigenetic suppression of CYBA may protect cells from the oxidant
damage that results from estrogen deprivation and may be part of the mechanism that
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1.1 Breast cancer – the clinical problem
Breast cancer is the most common cause of cancer death in the UK, with 48,034 new
cases in 2008 and 11,728 deaths in 2009 (Cancer Research U.K. 2011), with
approximately 1 in 9 women suffering from the disease at some point.  According to
the World Health Organisation, there were 460,000 deaths attributable to breast
cancer in 2008 (World Health Organisation 2012). However, breast cancer is not a
homogeneous disease, with prognosis heavily dependent on the type of tumour, as
defined by a variety of clinical indicators.
1.1.1 Breast cancer stratification
Breast tumours are stratified into several types, dependent on the expression of
various receptors, such as Estrogen Receptor alpha (ERα), Progesterone Receptor
(PR) and Human Epidermal growth factor Receptor 2 (HER2/ErbB2) (Figure 1.1).
The use of immunohistochemistry (IHC) for detecting expression of these receptors
and giving the tumour a score based on the level of staining is standard practice for
the diagnosis of tumour type. Using the Allred score (Allred et al. 1998), a tumour is
scored on the proportion of cells with positive staining and by the intensity of that
staining, with a range of 0-8. A score of zero for a given receptor means that the
tumour is negative for that marker. Increasingly, molecular biology techniques are
used to supplement this categorisation, particularly in research environments.
Tumours can be typed based on the global gene expression profile as determined by
oligonucleotide microarrays (Sørlie et al. 2001) (Figure 1.2).  These subtypes include
luminal A, B and C, basal-like or triple negative, normal breast-like and HER2+.
Luminal epithelial breast cancer is the most common type, and usually correlates
with ER positivity as determined by IHC.
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Figure 1.1:  Representative staining for tumour markers in cell lines.
(A) H&E staining in HS-598T cells, (B) IHC of ERα in MCF-7, (C) IHC of PR in BT-474, (D) IHC of
HER2 in SKBR-3.
400× magnification
Adapted from Subik et al. (2010).
Figure 1.2:  Tumour stratification based on gene expression profiles can distinguish between
tumour types.
(A) Stratification into luminal subtype A, dark blue; luminal B, yellow; luminal C, light blue; normal
breast-like, green; basal-like, red; and HER2+, pink. (B) Hierarchical clustering of 456 genes used to
profile the tumours. Gene expression clusters indicate amplicons within the ERBB2+, Luminal C,
basal-epithelial, normal breast-like cluster and luminal epithelial expression profiles.  Adapted from
Sørlie et al. (2001).
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1.2 Estrogen receptor positive breast cancer
Tumours over-expressing ERα are the most common type, comprising approximately
75% of all diagnosed tumours (Harvey et al. 1999).  The majority of these tumours
are luminal epithelial tumours, so called because they express the cell surface
markers associated with luminal mammary cells which line the ducts in the breast
(Perou et al. 2000). These tumours often also over-express PR and have low levels
of HER2 (reviewed in Schnitt (2010)).  Luminal A tumours have higher ERα and PR
than luminal B, which also show variable levels of HER2 expression.  Luminal B
tumours provide a significantly worse prognosis than luminal A.  ERα drives tumour
growth and proliferation in these cancers, both genomically, through its function as a
transcription factor and a co-factor, and non-genomically, activating cellular
pathways without having direct effects on transcription.  Although luminal tumours
are named because of some similarities to normal luminal cells, it is important to
remember that they are not “normal” or “normal-like” tumours, which display basal
epithelial markers and exhibit markedly lower expression of proliferation-associated
genes (Perreard et al. 2006).
1.2.1 ERα – structure and function
ERα is a nuclear hormone receptor that forms a dimer with itself (a homodimer) or
with estrogen receptor beta (ERβ), a related estrogen receptor that also binds
estrogen but has significantly different effects on gene transcription (Powell & Xu
2008).  The 595 amino acid ERα protein (Figure 1.3) is comprised of several
domains:  A/B, which contains activating function 1 (AF-1); C, containing the DNA
binding and dimerisation domain (DBD); D, the hinge region; E, where both
activating function 2 (AF-2) and the ligand binding domain (LBD) are located; and
F, which is relatively poorly understood, but may be involved in dimerisation and
transcriptional regulation (Schodin et al. 1995).
Figure 1.3:  A schematic of ERα.
Adapted from Schodin et al. (1995).
1 595
AF-1 DBD AF-2
A/B C D E F
180 263 302 553
LBD
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Unliganded ERα is normally localised in the cytosol until estrogen diffuses through
the cell membrane to bind to the LBD.  This causes the receptor to dissociate from its
chaperones and translocate to the nucleus (Htun et al. 1999), where the receptor
dimerises and either binds to DNA directly or indirectly, through protein-protein
interaction. Once at the DNA, the receptor acts as a transcriptional regulator,
primarily acting to repress gene expression at target genes (Stossi et al. 2009),
regulating protein production at a transcriptional level, through both AF-1 and AF-2.
AF-2 activity is the primary driver of estrogen-dependent transcriptional regulation,
but AF-1 activity is also modulated by ligand-binding.  However, the receptor is also
constitutively activated in the absence of estrogen, through the ligand-independent
pathway.  Here, ERα activity is conferred by post-translational modifications to it,
which are brought about by co-factors. This latter pathway functions solely through
AF-1, with no AF-2-dependent transcription occurring (Tremblay et al. 1999).
In the “classical” pathway ERα binds to DNA at estrogen response elements (EREs),
which are palindromic 15 base pair sequence motifs (Carroll et al. 2006) (Figure 1.4)
that occur throughout the genome.  Computational estimates indicate that there are
70,000 EREs in humans (Bourdeau et al. 2004). However, this may be an
overestimate, as genuine estrogen-responsiveness may be dependent on a variety of
other factors. By looking at those genes with EREs within 5kb of their promoters,
there are over 1,000 putative promoter EREs that have been identified in MCF-7
cells (Lin et al. 2007).  In addition, the estrogen receptor can bind to partial EREs,
albeit with correspondingly lower affinity (Loven et al. 2001).
Figure 1.4:  A schematic of the ERE sequence motif.
Adapted from Carroll et al. (2006).
Upon binding to these motifs, transcription is stimulated or repressed, in part
dependent on the binding of co-factors.  These co-factor proteins bind to the estrogen
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receptor dimer, leading to modulation of ERα-dependent transcription.  Known co-
activators include members of the Steroid Receptor Coactivator (SRC) family
(Anzick et al. 1997) and p300 (Hanstein et al. 1996), with co-repressors such as
Nuclear Receptor Co-Repressor (NCoR) (Chien et al. 1999) acting against them.
The activity of the receptor is largely determined by the composition of the ERα-
complex and the relative levels of these co-factors, the levels of which are, in turn,
dependent on the tissue and cell type (reviewed in Green and Carroll (2007)).
In the “non-classical” pathway, ERα does not bind directly to DNA, but binds
indirectly through other transcription factors, such as Specificity Protein 1 (Sp1), the
Activating Protein 1 (AP-1) complex or Nuclear Factor kappa b (NF-κB) (reviewed
in Safe and Kim (2008)).  These proteins can bind to promoter DNA that does not
contain an ERE, but the corresponding genes are still estrogen-responsive.
Microarray studies suggest that expression of these non-classically regulated genes is
enriched in breast cancer (Glidewell-Kenney et al. 2005), including Epidermal
Growth Factor Receptor (EGFR).  Over-expression of EGFR is associated with poor
prognosis and increased tumour aggression (Witton et al. 2003), and is known to be
regulated by AP-1 (Johnson et al. 2000).
In addition to co-factors that form a complex with the receptor, ERα is also regulated
via post-translational modification of the receptor, taking place through acetylation,
methylation, sumoylation, palmitoylation and phosphorylation.  The most studied
type of modification is phosphorylation, with well characterised effects of
phosphorylation known to occur at multiple residues on the protein (reviewed in
Murphy et al. (2011)).  These sites are instrumental in the activation of the protein in
both a ligand-dependent and an aberrant estrogen-independent manner.  In ligand-
dependent activation, ERα is phosphorylated after estrogen binding, at serine 118
(Ser-118), Ser-106 and/or Ser-104.  These phosphorylation events involve different
kinases, with Ser-118 putatively phosphorylated by Transcription Factor IIH (TFIIH)
(Chen et al. 2000), and Ser-106 and Ser-104 phosphorylated by a Cyclin A/Cyclin-
Dependent Kinase 2 (CDK2) complex (Rogatsky et al. 1999). Whilst Ser-106/104
phosphorylation only occurs in the presence of estrogen, Ser-118 phosphorylation
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can be found in both liganded and unliganded receptor (Joel et al. 1998).  Although it
can be constitutive, it is much more efficiently carried out in the presence of
estrogen, due to the binding of estrogen at the LBD and the interaction between
TFIIH and AF-2 which leads to an increase in AF-1 regulated transcription (Chen et
al. 2000).
In estrogen-independent activation of ERα, the additional phosphorylation of Ser-167
aids receptor activation, occurring through activation of the Mitogen Activated
Protein Kinase (MAPK) pathway. Ser-167 phosphorylation is carried out in vitro by
both p90 ribosomal S6 kinase (Rsk) (Joel et al. 1998) and Akt (Vilgelm et al. 2006).
This phosphorylation was once thought to be the major phosphorylation caused by
estrogen binding (Arnold et al. 1994), but subsequent experiments have shown that,
in fact, it does not take place in direct response to estrogen.  It is now known to be an
important phosphorylation event that activates ERα in the absence of ligand, with
Ser-118 phosphorylation alone being insufficient to activate the unliganded receptor
(Bunone et al. 1996).  In contrast to Ser-118, Ser-167 phosphorylation is not directly
modulated by the binding of ligand, taking place through activation of the MAPK
pathway (Yamnik & Holz 2009).   However, given that the MAPK family can be
activated by estrogen through a non-genomic pathway (Klinge et al. 2005), it seems
likely that estrogen can indirectly effect Ser-167 phosphorylation.  The importance of
the phosphorylation of ERα is clinically relevant to breast cancer acquisition,
prognosis and therapeutic resistance (Yamashita et al. 2005; Guo et al. 2006; Sarwar
et al. 2006). In addition, the interplay between the phosphorylation events appears to
be important, with low Ser-118 and high Ser-167 phosphorylation associated with
improved survival (Yamashita et al. 2008).
As previously mentioned, in addition to these well-characterised phosphorylation
events, it has been shown that other modifications can affect the receptor. These
modifications are more recent discoveries and are correspondingly less well
understood. Acetylation of ERα at the conserved lysine 268 (Lys-268) and Lys-266
residues, through the activity of p300, can increase the activity and DNA binding
capacity of the receptor (Kim et al. 2006).  In addition, methylation at Lys-302 by
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SET7 lysine methyltransferase increases the stability of the receptor, with reduced
SET7 expression associated with increased turnover of ERα, potentially through
proteasomal degradation (Subramanian et al. 2008). ERα is also targeted by Small
Ubiquitin-like MOdifier 1 (SUMO-1), with sumoylation of several lysine residues in
the hinge region acting to enhance ERα transcriptional activity (Sentis et al. 2005).
Through the palmitoylation of the LBD of ERα, the receptor can be associated with
the cell surface membrane, possibly potentiating some non-genomic effects
(Acconcia et al. 2004).
These post-transcriptional events can be induced through the activation of growth
factor receptors such as EGFR at the plasma membrane, and downstream signalling
(reviewed in Anbalagan et al. (Anbalagan et al. 2012)). Interestingly in the context
of tumour biology, it has recently been shown that reactive oxygen species (ROS)
can play a role in inducing the ERα phosphorylation that has been correlated with
estrogen-independent signalling (Weitsman et al. 2009). Whether or not this is the
result of a direct relationship, or a consequence of ROS effects on growth factor
signalling pathways remains to be seen.
1.2.2 Treatment of ER+ tumours
Since George Beatson’s discovery that inoperable breast cancers could be treated
with ovariectomisation (Beatson 1896), there has been an understanding that a
subtype of breast cancers is stimulated by hormones.  Thus, interfering with this
hormonal signalling is an important therapy in specific types of breast cancer. Given
their high reliance on aberrant estrogen signalling, ER+ tumours are typically treated
with drugs that interfere with ERα and estrogen-regulated transcription.  These drugs
generally come in three forms:  Selective Estrogen Receptor Modulators (SERMs),
pure anti-estrogens and aromatase inhibitors.
Selective estrogen receptor modulators
SERMs are chemicals that bind to the estrogen receptor, acting as both an agonist
and antagonist, dependent on the tissue type. These drugs are the most widely




Originally developed as a contraceptive, tamoxifen is an estrogen analogue that
competitively binds to the LBD of ERα with a binding affinity that is 2.5% that of
estrogen (Katzenellenbogen et al. 1984), reducing estrogen receptor activity in the
breast. It is, however, an agonist in the uterus (Gottardis et al. 1988) and bone (Love
et al. 1992). Given as a prodrug, it is metabolised into the more active forms, 4-
hydroxytamoxifen (4-OHT) and N-desmethyl-4-hydroxytamoxifen (endoxifen) in
the liver, predominantly by Cytochrome P450 (CYP) 2D6, with a smaller
contribution from CYP3A4 and CYP2C9 (Crewe et al. 2002). These active
metabolites have approximately one hundred times the binding affinity of tamoxifen
itself (Coezy et al. 1982; Lim et al. 2005). In breast cells, the active metabolites of
tamoxifen act as antagonists of ERα, inhibiting ERα-dependent transcription. When
the activated forms of tamoxifen bind to the receptor, they induce a conformational
change different to that caused by estrogen-binding (Shiau et al. 1998), which
prevents the recruitment of co-activators, but allows the formation of a co-repressor
complex (reviewed in Graham et al. (2000)). The drug/receptor complex binds to
EREs within promoter regions, with lower affinity and more rapid dissociation than
estrogen/receptor after DNA binding (Klinge et al. 1998). By recruiting co-
repressors such as NCoR and Histone Deacetylase (HDAC), gene transcription is
ablated (Liu & Bagchi 2004).  Thus, genes which are normally induced by ERα are
repressed when a tumour is treated with tamoxifen.
Whilst tamoxifen is one of the great success stories in anti-cancer therapy, it is not
without problems.  The drug is not always effective, a problem known as intrinsic, or
de novo, resistance. In the past, this was most frequently observed when tumours
that failed to express ERα (ER–) were subjected to tamoxifen.  Advances in
pathology and tumour stratification have lowered the incidence of this form of
mistreatment. However, there are still ER+ tumours that fail to respond at all,
despite over-expressing the target receptor. A partial explanation for this is provided
by the fact that, in about 8% of cases, patients can carry an inactive form of
CYP2D6, which may prevent the metabolism of tamoxifen into the active form,
rendering these patients resistant to the therapy (reviewed in Hoskins et al. (2009)).
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However, a complete explanation for intrinsic resistance in ER+ tumours remains
elusive. As well as de novo resistance, there is a major problem of acquired
resistance, a point which will be further explored later.
In addition to drug resistance, tamoxifen causes several harmful side-effects, due to
its activity on ERα in other tissues, most critical of which are an increased risk of
cataracts, thromboembolism and higher incidence of endometrial cancer (reviewed in
Colleoni & Giobbie-Hurder (2010)). Whilst these risks are generally outweighed by
the benefits of the drug in treating breast cancer, they raise questions about the
potential use of tamoxifen as a preventative medication.
Raloxifene
Raloxifene, originally called keoxifene, is structurally distinct from tamoxifen, but
has similar anti-estrogenic properties (Vogel et al. 2006). Whilst it is an antagonist
in breast tissue and an agonist in bone, unlike tamoxifen it is an antagonist in uterine
tissue. Like tamoxifen, it competitively binds to ERα in the LBD (Brzozowski et al.
1997). Given the tissue-specific differences in effect, it is not unsurprising that the
receptor exhibits differences in conformation, albeit subtle ones, depending on which
analogue is bound (Paige et al. 1999).  Both drugs appear to exhibit similar
mechanisms of action, interfering with the receptor to induce the binding of co-
repressors (Shang & Brown 2002) and prevent the binding of co-activators in vitro
(Liu et al. 2003).  Whilst raloxifene and tamoxifen have extremely similar efficacy in
treating breast cancer, raloxifene has a reduced risk of cataracts and endometrial
cancer when compared to tamoxifen, but a higher chance of thromboembolism
(Vogel et al. 2006).  Raloxifene is also used as an anti-osteoporosis drug in post-
menopausal women, with raloxifene-treated osteoporotic women being 75% less
likely to develop new breast tumours (Cummings et al. 1999).
Toremifene
Used clinically since 1995, toremifene is a chlorinated analogue of tamoxifen,
developed as a less toxic alternative to tamoxifen.  Perhaps because of its structural
similarity, it has a very similar efficacy (Pagani et al. 2004) and mode of action to
tamoxifen.  There is a lack of good clinical data on the drug, particularly in reference
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to its effects on bone density and the risks of endometrial cancer, but in rats,
toremifene lacks the hepatocarcinogenicity of tamoxifen (Hard et al. 1993).  A recent
study appeared to show that toremifene exhibits a similar side-effect profile to
tamoxifen (Su et al. 2012), but this study only examined pre-menopausal patients.
Limited evidence showing that toremifene may compare favourably to tamoxifen
with respect to bone mineral density side-effects exists (Erkkola et al. 2005), but the
authors acknowledge that further studies need to be carried out.
Selective estrogen receptor down-regulators
Sometimes known as pure anti-estrogens, Selective Estrogen Receptor
Downregulators (SERDs) are typically used in the treatment of advanced metastatic
ER+ breast cancer, and in the treatment of recurrent cancer resistant to SERMs.
Since the purification of ICI 164,384 (Bucourt et al. 1978), and the subsequent
derivation of ICI 182,870 (fulvestrant), pure anti-estrogens have been shown not only
to bind ERα (Wakeling & Bowler 1987), but to prevent ERα dimerisation (Fawell et
al. 1990) and induce ERα degradation (Dauvois et al. 1992).
Fulvestrant
Given as a monthly injection, fulvestrant has, unlike tamoxifen, absolutely no ERα
agonist activity, in spite of the fact it is an estrogen analogue.  It competitively binds
ERα, with a binding affinity that is nearly 90% that of estrogen (Wakeling et al.
1991). Upon binding, the long side chain disrupts the conformation of the LBD and
the hinge domain (Pike et al. 2001), which contains the dimerisation domain.
The mechanism of action of fulvestrant can be conceptually divided into three, all of
which are related to the fulvestrant-binding site.  Firstly, the drug impairs the
nucleoplasmic shuttling of the receptor, physically preventing ERα from getting to
the DNA to regulate transcription (Dauvois et al. 1993).  The nuclear localisation
signal (NLS) is found within the hinge region, with mutations in this region entirely
abrogating nucleocytoplasmic shuttling (Burns et al. 2011).  Thus it seems likely that
fulvestrant’s disruption of the hinge domain’s conformation may be a factor in the
failure of ERα transport into the nucleus.  Secondly, the fulvestrant/ERα complex is
transcriptionally inactive, due to both a dramatically reduced affinity for DNA
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caused by the receptor’s inability to dimerise (Fawell et al. 1990) and the blockage of
transcription mediated by both AF-1 and AF-2 (Wijayaratne et al. 1999) by what
little receptor actually does bind to DNA.  Thirdly, the receptor/drug complex is
targeted for proteasomal degradation.  Upon fulvestrant treatment, the half-life of
ERα is drastically reduced, from approximately five hours in the presence of
estrogen, to one hour in the presence of fulvestrant (Dauvois et al. 1992).  This is
thought, again, to be a function of fulvestrant preventing dimerisation of the receptor,
leading to the recruitment of the proteasomal degradation pathway. This
proteasomal degradation is dependent on co-factor recruitment, with siRNA for
Cytokeratin (CK) 8 or 18 preventing receptor-depletion in MCF7 cells treated with
fulvestrant (Long & Nephew 2006). In addition to these effects, it has been
suggested that fulvestrant induces oxidant damage to cells through an interaction
with ERα (Newton et al. 1999). Fulvestrant is becoming more clinically relevant in
light of the development of resistance to other endocrine therapies, as tamoxifen-
resistant cells are not cross-resistant to fulvestrant (Hu et al. 1993).
Aromatase inhibitors
These drugs inhibit the aromatase enzyme CYP19, involved in the biosynthesis of
estrogen (Figure 1.5), effectively removing the supply of ligand to ER+ tumours
(reviewed in Dodwell et al. (2006)).  Typically, these drugs are only used in post-
menopausal women, in whom the primary site of estrogen biosynthesis has moved
from the ovaries to peripheral tissues such as the breast (reviewed in Simpson &
Dowsett (2002)). Although it is well established that estrogen levels within breast
tumours are significantly higher than those observed in plasma (van Landeghem et
al. 1985), there is some debate as to the role of intra-tumoural aromatase. In patients
with ER+ tumours, intra-tumoural and stromal aromatase activities have long been
proposed to play an important part in tumour growth (O'Neill & Miller 1987; Santner
et al. 1997). However, more recent studies have suggested that the correlation
between ERα positivity and intra-tumoural estrogen shows that the uptake of
estrogen from the circulation is the dominant mechanism by which estrogen
influences tumour growth (Haynes et al. 2010). Whilst there is debate over where it
occurs, it is clear that estrogen biosynthesis is important in ER+ tumour growth.
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Thus, by blocking estrogen production in patients with these tumours, tumour growth
can be reduced and tumour size decreases (Buzdar et al. 2008). Aromatase Inhibitors
(AIs) tend not to be used in pre-menopausal women for two reasons (reviewed in
Goss & Strasser (2001)).  Firstly, pre-menopausal women tend to have high levels of
androstenedione, which compete with the inhibitors.  Secondly, pre-menopausal
ovaries can overcome the enzyme inhibition, as reduced serum-estrogen levels
stimulate the production of gonadotrophin, which stimulates the ovaries to produce
more estrogen, eventually overwhelming the drug-induced effect.  There is some
evidence that inhibiting gonadotrophin-release increases the efficacy of aromatase
inhibitors in pre-menopausal women (Celio et al. 1999; Dowsett et al. 1999; Carlson
et al. 2010), but larger scale trials are probably required.
Figure 1.5:  The estrogen biosynthesis pathway.
Adapted from Olivo-Marston et al. (2010).
AIs used in breast cancer can be classified as either Type I, irreversible (non-
competitive) steroidal inhibitors, or Type II, competitive non-steroidal inhibitors.
Type I aromatase inhibitors
Type I AIs are steroidal analogues of aromatase substrates that compete with the
substrate of estrogen biosynthesis enzymes.  Upon binding, they are catalysed into a
molecule that irreversibly binds to the enzyme’s active site, thereby removing the
enzyme’s reactivity.  The prototypical Type I inhibitor is exemestane, an
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androstenedione analogue that competitively binds to CYP19, binding to the active
site of the enzyme, where it is hydroxylated to a reactive intermediate.  This
intermediate then binds irreversibly to the active site, preventing the enzyme from
catalysing any further reactions (Hong et al. 2007). The drug shows almost complete
inhibition of aromatase, reducing patients’ serum estrogen levels to below 20% of
pretreatment levels (Lonning et al. 2005).
Type II aromatase inhibitors
Whilst Type I inhibition is achieved through analogues of CYP19’s substrate, Type
II AIs competitively bind to the haem group of CYP19, interfering with the enzyme’s
ability to hydroxylate its substrate (Loge et al. 2005). With the discovery that the
anti-convulsant drug aminoglutethimide inhibited the growth of breast tumours
(reviewed in Hughes & Burley (1970)), aromatase inhibition became a promising
avenue for breast cancer therapy.  This first generation AI lacked specificity,
inhibiting several cytochrome p450s, and inducing enzymes in the liver (reviewed in
Cocconi (1994)). Second generation inhibitors, such as fadrozole, were derivatives
of aminoglutethimide.  They suffered from a lack of specificity and potency
(Sainsbury 2004). The so-called third generation AIs that were subsequently derived
were highly specific and effective.  They contain a nitrogenous triazole ring, N-4 of
which interacts with the haem co-factor to reduce the efficacy of the enzyme (Hong
et al. 2009). The most studied third generation aromatase inhibitors are letrozole and
anastrozole, both of which are used clinically to treat post-menopausal ER+ tumours.
Clinical trials suggest that anastrozole is more desirable as a treatment for these
tumours than tamoxifen, both in terms of efficacy and side-effects (Howell et al.
2005).  Letrozole is approximately ten times more effective (as measured by IC50)
than anastrozole at inhibiting aromatase (Bhatnagar et al. 2001), making it an
extremely attractive therapy for ER+ tumours.
As successful as these therapies may be, resistance to endocrine therapy has become
an important clinical problem, as over the course of time these drugs either lose their
efficacy, or patients relapse with drug-resistant tumours.
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1.3 Resistance to endocrine therapy
In breast cancer, adjuvant treatment is therapy (chemotherapy, radiation, or
endocrine therapy) that is offered after a surgical procedure to remove the cancer.
Neo-adjuvant therapy can also be given, which is used to shrink tumours before
surgery, increasing the likelihood of successful surgery. The aim of adjuvant therapy
is to improve the outcome for patients at high risk of relapse.  In breast cancer,
adjuvant endocrine therapy is typically given for five years, despite some evidence
that longer therapy is correlated with a better outcome (Fisher et al. 1996), and
disease-free survival is used as the measurement of success at the end of this time.
Approximately 50% of cases are disease-free after five years, but approximately half
of all patients develop recurrent cancer (reviewed in Osborne (1998)).  Given enough
time, it is thought that all patients with significant residual disease after surgery
would develop a recurrent tumour, due to the development of tumour drug-
resistance. The current solution to overcoming this resistance is to treat tumours
sequentially, so that once they are resistant to one type of endocrine inhibition, a
subsequent drug can be used to inhibit growth via another pathway, and so on
(Figure 1.6).
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Figure 1.6:  Sequential treatment strategies in the fight against acquired resistance to endocrine
therapy.
Adapted from Dodwell et al (2006).
However, even this strategy still eventually results in drug-resistant tumours.
Conceptually, the causes of this resistance can be divided into several categories.
1.3.1 Acquisition of endocrine resistance – paradigms
Clearly the evolution of resistance to endocrine therapy could take place through
multiple pathways, with multiple mechanisms employed by cells to overcome the
inhibition of ERα.  Just as these mechanisms are many and varied, there are several
schools of thought as to the way in which resistance develops.  To further complicate
matters, there are two schools of thought as to how these initial events arise.  It is
unclear whether the tumour population is sufficiently heterogeneous to contain cells
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which have an inherent resistance to endocrine therapy, or whether the treatment is
the causative agent, triggering the changes that lead to resistance to therapy.  This
lack of clarity has led to a schism in the scientific community, with conflicting
theories causing widespread debate.  Because the paradigms are generally considered
to be mutually exclusive, it has become a divisive issue.
Heterogeneity and selection pressure
In the past, tumours have been viewed as coherent, clonal populations of cells, all of
which rely on the same growth pathways and exhibit the same sensitivities to
therapy.  However, it is now known that tumour populations are extremely
heterogeneous, with cells of the same origin differentiating divergently.  Not only are
different cell morphologies present, but gene expression patterns differ significantly
across a tumour, and there is a great deal of diversity in terms of cell surface markers
and cell cycle progression (reviewed in Marusyk & Polyak (2009)).
Clonal evolution
Thinking of a tumour as a population of cells that stem from a single initiating cell, it
is easy to imagine how this population can become heterogeneous over the course of
time.  Because of genetic instability in the tumour population, a high degree of
genetic drift can take place (Shah et al. 2009), with natural selection taking place for
the most fit cells, a mechanism which has been previously demonstrated in colorectal
cancer (Losi et al. 2005; Siegmund et al. 2011).  As the tumour cells proliferate, each
subsequent generation of cells gains advantages and disadvantages over the previous
generation, creating new subpopulations of cells.  Convincing evidence to support
this model is found in studies using microdissection on single tumours, wherein
multiple subpopulations exist, with heritable characteristics (Li, J. et al. 2010).  In
this model, drug-resistance is acquired because of the very heterogeneity of the cells,
with therapy adding a selection pressure to the tumour.  Those cells more able to
resist therapy survive and proliferate, and those incapable of overcoming the drug
die.  These resistant subpopulations do not make up the bulk of the original tumour,
as, until treated with therapy, they possess no growth advantage over the majority of
the cells.  On receiving treatment, the majority of the tumour cells die, with the
remaining cells possessing a survival advantage through alternate signalling
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pathways or inherent resistance to therapy.  An elegant experiment on cell lines, in
which monoclonal sublines were derived and exposed to tamoxifen or fulvestrant,
shows that these subpopulations of resistant cells can exist and can be selected for by
treatment with a drug (Coser et al. 2009).
Cancer stem cells
An alternate hypothesis to clonal evolution is that tumours contain so-called Cancer
Stem Cells (CSCs).  The idea behind this hypothesis is that a subset of cells within a
tumour possess stem-like properties and drive tumour growth and proliferation
(reviewed in Campbell & Polyak (2007)).  The stem-like properties they are thought
to possess include the ability to self-renew and differentiate into several cell types.
This means that, whilst non-stem-like cells within a tumour cannot indefinitely
renew themselves, the CSCs drive the production of tumour cells, conferring tumour
heterogeneity.  Evidence for this is provided by the fact that some tumour
subpopulations display stem cell surface markers and activated stem cell pathways.
When xenografting small numbers of the tumour cells that present these markers into
mice, they retained the ability to form tumours, whereas large numbers of cells from
subtypes without these markers had dramatically reduced tumourigenicity (Al-Hajj et
al. 2003).  A key tenet of this hypothesis is that recurrence of tumours is driven by
the inherent ability of CSCs to survive therapy (Fillmore & Kuperwasser 2008;
Lagadec et al. 2010). Whilst in the clonal evolution model the acquisition of
resistance is driven by natural selection, in the CSC model therapy kills the majority
of tumour cells, but not the CSCs, leaving them to repopulate the tumour.  The
prediction of this model is that treatment with endocrine therapy would leave
residual stem cells, allowing the tumour to be repopulated.  However, this does not
explain the acquisition of resistance per se, given that even the experiments
advocating their importance show that tumours repopulated by stem cells retain
similar levels of heterogeneity to the cells of origin (Al-Hajj et al. 2003; Ponti et al.
2005).  This suggests that, whilst therapy-resistant CSCs may be important in the
initiation of a tumour, they are not the mechanism by which resistance is acquired by
whole populations of cells.
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Therapy as a causative agent of resistance
In addition to the idea that resistance to endocrine therapy evolves as a consequence
of treatment providing some form of selection, whether for fitness of subpopulations
or for CSCs, it is also possible that the therapy itself induces the changes that
inevitably lead to resistance.  In this model, endocrine therapy is not a driver of
natural selection in an already heterogeneous population, but the cause of the
changes in the tumour population that lead to resistance. A point in favour of this
model is that the resistance mechanisms observed in acquired resistance are not the
same as those found in de novo resistance.  If tumour heterogeneity were the only
mechanism by which resistance occurred, one might expect the resultant resistant
cells to exhibit similar phenotypes to cells with intrinsic resistance, but this is not the
case.
Instead, it might be argued that therapy itself induces a change in the cells. Recently,
deep sequencing of DNA from patients with relapsed acute myeloid leukaemia has
demonstrated that relapse can be associated with transversion mutations, which are
induced by the chemotherapy itself (Ding et al. 2012). In addition, this therapy-
induced resistance was recently shown to exist in acute lymphoblastic leukaemia,
wherein therapy directly results in feedback signalling that causes the up-regulation
of a protective mechanism against the drug (Duy et al. 2011).  Whilst these studies
focus on resistance to chemotherapy in leukaemias, they suggest that there might be
potential for other cancer therapies to induce genetic or epigenetic changes in tumour
cells.  The potential for steroids to induce epigenetic changes in cells was first
demonstrated at an enhancer of the rat liver-specific tyrosine amino transferase gene
(TAT). Here it was established that glucocorticoids induce active demethylation of
the enhancer, which led to faster and stronger transcriptional effects on a subsequent
exposure to glucocorticoids (Thomassin et al. 2001).  Thus it appears entirely
possible that endocrine therapies could lead to active epigenetic changes in tumours,
as opposed to changes arising due to selection pressure.
Whilst there are several hypotheses as to the root causes of the development of
endocrine resistance, what is clear is that cellular alterations must take place in order
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for a once responsive tumour to acquire resistance.  In addition to the paradigms that
exist for how resistance is acquired, there are multiple routes through which this
resistance is thought to develop.  However, there are multiple conflicting reports and
a clear consensus is yet to emerge as to the mechanisms by which resistance occurs.
1.3.2 ERα signalling overcoming antagonism
In the presence of estrogen antagonists such as tamoxifen, ERα function is
dramatically reduced, resulting in widespread inhibition of ERα-regulated gene
expression. The simplest mechanism by which tumours might potentially overcome
endocrine therapy is by altering the expression of ERα.  The most easily imagined
potential mechanism is that ERα over-expression acts to compensate for ERα
antagonism, to overcome endocrine therapy.  By over-expressing ERα, aberrant
signalling might take place through a normally estrogen-independent pathway.
Indeed, in cell lines that have acquired fulvestrant-resistance, raised levels of ERα
expression have been observed (Kuske et al. 2006), and in the majority of recurrent
tumours after tamoxifen treatment, ERα levels remain high, with the over half
maintaining or increasing ERα expression (Johnston et al. 1995).  Whether this
expression is causative or correlative remains to be seen, with a definitive
mechanism by which ERα over-expression overcomes tamoxifen treatment
remaining elusive.  Whilst this raised ERα expression could be a corollary to
resistance, in those cases where there has been loss of expression, tumour growth
must, by necessity, be promoted by an estrogen-independent mechanism.  Quite how
this arises is uncertain, but low frequency genetic (or epigenetic) events within
tumours may render some cells less dependent on estrogen for growth.  Treatment
with ERα antagonists would then promote the selective growth of these cells.  This
evolution of the cells, to facilitate growth and proliferation through the activation of
alternate pathways, will be explored further later.
Without altering ERα protein expression, post-translational modifications to the
protein might render it insensitive to the effects of inhibition, gaining ligand-
independence.  Because estrogen induces dimerisation and phosphorylation of the
receptor, these modifications to the receptor could potentially be sufficient to result
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in estrogen-independence, overcoming drug-induced inhibition. However, the data
in support of this mechanism are conflicting. Aberrant ligand-independent ERα
phosphorylation at Ser-118 (Bunone et al. 1996) and Ser-167 (Joel et al. 1998) can
result in ERα-regulated transcription in the absence of estrogen. In addition,
phosphorylation can induce conformational changes that correlate with an
insensitivity to the binding of tamoxifen (Michalides et al. 2004). Given that these
phosphorylation events tend to be caused by elements of the MAPK family, as
discussed previously, which are over-expressed and hyper-activated in a significant
proportion of breast cancer (Adeyinka et al. 2002), this seems to be a reasonable and
logical explanation for the development of endocrine resistance. Yet high
phosphorylation of Ser-118 (which is normally phosphorylated on estrogen binding)
has been shown to be predictive of improved tamoxifen-response (Murphy et al.
2004). On the other hand, another study suggests that high levels of phosphorylation
at Ser-167 (which is normally involved in ligand-independent activation of ERα),
and not Ser-118, is predictive of better response to tamoxifen (Yamashita et al.
2008). In cell line models, a reduction in overall ERα phosphorylation was reported
to be associated with tamoxifen-resistance (Kuske et al. 2006). Another study has
suggested that Ser-305 phosphorylation of ERα might occur through the deregulation
of the Protein Kinase A (PKA) family and confer tamoxifen-resistance (Michalides
et al. 2004). Tamoxifen-resistance is also reported to be correlated with p38 activity
(Gutierrez et al. 2005), a protein which is involved in phosphorylating ERα at
threonine-311 (Thr-311) (Lee & Bai 2002).
As well as increased kinase and decreased phosphorylase activity, less obvious
mechanisms exist through which ERα can be aberrantly phosphorylated.  Upon
tamoxifen treatment, cellular levels of ROS are dramatically increased (Kallio et al.
2005). ROS could be damaging to the cells and inducing their involution. If this
mechanism is important in mediating the effects of tamoxifen, then it is conceivable
that cells could evade it by down-regulating processes that produce ROS.
Interestingly, the glucose oxidase-induced generation of ROS was shown to induce
ERα phosphorylation at both Ser-118 and Ser-167 in MCF7 cells (Weitsman et al.
2009).
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The mechanisms involved in promoting tamoxifen-resistance may be significantly
different to those involved in promoting resistance to aromatase inhibitors (ligand-
independence).  Studies in cell lines deprived of estrogen suggest that induced hyper-
sensitivity to estrogen might play a role in the development of endocrine resistance.
In cells chronically deprived of estrogen, growth-factor signalling and estrogen-
induced transcriptional changes are disproportionately high, observations reported to
be largely due to the non-genomic functions of ERα (Santen et al. 2005). This
hyper-sensitivity may be a key mechanism in the acquired resistance to AIs, where
the availability of estrogen is greatly reduced and the tumour has far less estrogen
with which to stimulate growth.  In common with the acquisition of ligand-
independence, hyper-sensitivity appears to be caused by the phosphorylation of the
estrogen receptor, with MAPK and Phosphoinositide 3-kinase (PI3K) family
inhibition leading to complete reversal of hyper-sensitivity in vitro (Yue et al. 2003).
1.3.3 Altered co-regulator activity
Because ERα relies on co-regulators to modulate its function (see chapter 1.2.1),
misexpression of, or alterations to, these co-factors could play a role in the
development of endocrine-resistance.  This is particularly relevant in SERM
treatment, where the drug functions by recruiting co-repressors to the ERα complex,
inhibiting transcription.  Increases in co-activator levels have been correlated with
endocrine-resistance, with high expression of the gene Amplified In Breast Cancer 1
(AIB1) being associated with faster relapse in tamoxifen treated patients (Osborne et
al. 2003).  Evidence for the inverse, that reduced co-repressor expression leads to
endocrine resistance, is slightly more limited, but gene expression analysis of breast
tumours suggests that low NCOR1 expression is associated with tamoxifen-
resistance (Girault et al. 2003), and low levels of NCOR1 are correlated with the
acquisition of tamoxifen-resistance in a mouse model (Lavinsky et al. 1998).
1.3.4 Alternate pathway compensation
If endocrine therapy is successful, tumours lose the ability to regulate their growth
and proliferation through the ERα pathway.  However, if cells evolve the ability to
regulate genes and pathways silenced by therapy through other means, they will,
inevitably, develop resistance.  By increasing growth-factor signalling, tumours are
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able to circumvent ERα, ablating the inhibitory effect of endocrine therapy.  Raised
levels of Epidermal Growth Factor Receptor (EGFR) and HER2 are typically
correlated with de novo (Benz et al. 1992; Nicholson et al. 1994; Gee et al. 2005)
and acquired resistance to tamoxifen (Massarweh et al. 2008).
In cell line models, increased signalling through these pathways leads to a reduction
in ERα expression (Stoica et al. 2000), a potential mechanism for endocrine-
resistance.  This observation is reflected by the inverse correlation of HER2 and ERα
in primary tumours (Konecny et al. 2003). In addition, tamoxifen-resistant cells
have been shown to have increased EGFR-signalling, through raised protein levels
and enhanced receptor-activation (Massarweh et al. 2008).  This in turn leads to
increased MAPK-phosphorylation and activation of ERα through phosphorylation
(Bunone et al. 1996).  Thus, these cells have enhanced EGFR-pathway activation to
compensate for endocrine therapy, as well as enhanced ERα activation.  This is not
only seen in tamoxifen-resistance: fulvestrant-resistant cells also show similarly high
EGFR signalling (McClelland et al. 2001).  These in vitro observations, suggestive
of a potential mechanism by which cells compensate for endocrine therapy-induced
blockage of ERα signalling induced by endocrine therapy, are supported by clinical
trials using the anti-EGFR agent gefitinib, which has been successfully used to treat
tamoxifen-resistant tumours (Gutteridge et al. 2009).
As well as EGFR, the HER2 pathway appears to be involved in the acquisition of
tamoxifen resistance.  HER2 is frequently over-expressed in tamoxifen-resistant
tumours (Moon et al. 2011). Over-expression can lead to aberrant activation of
HER2 and estrogen-independent growth.  Interestingly, tumours with high HER2
levels tend to be stimulated by tamoxifen, rather than inhibited (Shou et al. 2004).
HER2 has been shown to interact with the ERα co-activator AIB1, activating it
through phosphorylation (Shou et al. 2004), suggesting a potential cross-talk
mechanism by which HER2 can overcome ERα-inhibition.
Over-expression of the MAPK family is also a potential mechanism by which
tumours can overcome inhibition induced by endocrine therapy.  MAPK phosphatase
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3 (MKP3) expression initially rises after treatment with tamoxifen, but resistant cells
can have reduced MKP3 levels (Cui et al. 2006).  This may lead to increased
Extracellular signal-Regulated Kinase 1/2 (ERK1/2) phosphorylation (Nunes-Xavier
et al. 2010), which in turn leads to raised ERα phosphorylation (Thomas et al. 2008)
and increased levels of cyclin D1 (Lavoie et al. 1996), a proto-oncogene that
contributes to tumourigenesis and enhances cell growth.
In summary, there are several ways in which tumour cells could circumvent the ERα
pathway to regulate gene expression when undergoing endocrine therapy.  Whilst
these pathways represent druggable targets and prognostic markers, they are not the
causative events in the evolution of tamoxifen resistance, but corollaries to the initial
alterations in the tumour that lead to the development of resistance.  This means that
whilst these pathways play a role in resistance, they are indicative of earlier genetic
and epigenetic alterations that provide the initial impetus for the development of a
resistant phenotype. There are several theories as to what these initial alterations are
and how important they are in tumourigenesis and the evolution of endocrine-
resistance.
1.3.5 Genetic causes of resistance
It is clear that there must be heritable changes to a drug-resistant tumour compared to
a drug-sensitive one, alterations to gene expression that must take place such that the
cells are able to overcome endocrine therapy.  Whether or not these changes already
existed at the beginning of treatment in a subpopulation of cells is debateable, but the
underlying causes of these differences in gene expression may provide a greater
understanding of the mechanisms by which endocrine resistance occurs.
Mutations
Obviously, heritable changes in gene expression in a tumour can be caused by
mutations.  Randomly occurring changes in the DNA sequence at important genes
can give tumour cells a survival advantage, providing them with the means to
develop drug-resistance (reviewed in Tomlinson (2001)).  Several types of mutation
are clinically relevant in breast cancer, in both the development of a tumour and in
the acquisition of endocrine-resistance.  Whilst somatic mutations have been shown
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to lead to tumourigenesis, there are several mutations that have been associated with
not only a poor response to tamoxifen and de novo resistance, but the acquisition of
resistance as well.
One obvious site for mutations that might have an effect in the response to endocrine
therapy is in the gene coding for ERα, Estrogen Receptor 1 (ESR1).  A mutation that
causes lysine 303 (Lys-303) to be changed to arginine in the LBD of ERα, due to the
transition of guanine to adenine in exon 4 of ESR1, leads to estrogen hyper-
sensitivity and AI-resistance (Barone et al. 2009).  Similarly, a mutation of tyrosine
537 (Tyr-537) to asparagine confers constitutive activity upon the receptor,
circumventing tamoxifen-induced inhibition (Zhang et al. 1997). Mutation of
methionine 543 (Met-543) to valine in AF-2 actually leads to an inversion of ERα-
response, with tamoxifen and other anti-estrogens becoming more active than
estrogen (Nichols et al. 2010). In addition to these point mutations, deletion mutants
have been suggested as a potential way in which cells gain endocrine-resistance, with
a variant ERα isoform caused by a large scale deletion in exon 3 of ESR1
contributing to tamoxifen-resistance in cell lines (Han et al. 2004). A similar
deletion in exon 5 (Daffada et al. 1995) has been shown to play a role in estrogen-
independence. Whilst mutations in the clinical target are common for other cancers,
mutations in ESR1 appear to be under-represented (Herynk & Fuqua 2004).   This is
probably due to the fact that mutations in ERα are deleterious to the tumour cells in
normal conditions, only becoming advantageous during endocrine therapy.
Mutations in other growth pathways, however, may be more important, being
deleterious but compensated for by ERα signalling in normal tumours, aberrantly
taking over signalling after treatment in resistant cells. In cell line studies, mutations
in the cell cycle regulator Phosphatase and Tensin homolog (PTEN) have been
shown to desensitise cells to tamoxifen (McCubrey et al. 2006).  A recent study has
shown that PI3K mutations are common in recurrent breast tumours (Sanchez et al.
2011). These mutations are largely thought to be mutually exclusive in breast
(Hollestelle et al. 2007) but loss of expression of PTEN combined with PI3K
mutation is a common event (Stemke-Hale et al. 2008), suggestive of a role for the
PI3K/PTEN/AKT/mTOR pathway in the development of endocrine-resistance.
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Amplification
Whilst these point mutations are relevant to some cases, by far the most critical
genetic mechanism by which endocrine therapy is overcome is through
amplification, wherein regions of the genome are replicated multiple times, leading
to aberrantly high transcription.  Often this is not simply the amplification of a
specific gene locus, but of a larger region, known as an amplicon.  In these cases, it is
sometimes difficult to ascertain the mechanism by which resistance occurs, with
multiple genes in a region potentially contributing to endocrine-sensitivity.
However, in some cases the mechanism by which amplification alters the response to
therapy is clear. Variations in copy number of ESR1 have been shown to be
important in the response to tamoxifen, with patients possessing amplifications at the
locus having lower recurrence-free survival than patients with normal levels (Nielsen
et al. 2011). As discussed in chapter previously, co-regulator activity also plays an
important part in the function of ERα and endocrine-resistance. However, there are
conflicting views as to the importance of co-regulator amplification in endocrine-
resistance. For instance, whilst AIB1 amplification has been shown to decrease the
sensitivity of cell lines to tamoxifen, possibly through misregulation of an ERα-
independent pathway (Louie et al. 2004), amplification of AIB1 is also correlated
with better response to endocrine therapy and higher recurrence-free survival (Alkner
et al. 2010). By contrast, the consensus is that NCOR1 amplification is associated
with better response to tamoxifen and higher recurrence-free survival (Girault et al.
2003), with silencing of the gene causing tamoxifen-stimulated growth in cell lines
(Keeton & Brown 2005).
As well as amplifications of genes that are directly involved in ERα signalling, other
less obvious loci can be involved in the acquisition of resistance to endocrine
therapy. Amplification of the ERBB2 locus is well-known in tumourigenesis, with
HER2 over-expressing breast cancer comprising a significant minority of all
presenting breast cancers (reviewed in Donovan-Peluso et al. (1991)). However, in
ER+ breast cancer treated with endocrine therapy, there is significant crosstalk
between the HER2-pathway and the ERα-pathway in resistant tumours (Osborne et
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al. 2003), with HER2 signalling circumventing upstream ERα-pathway components.
This crosstalk is facilitated by amplification of the ERBB2 locus, as HER2 over-
expression desensitises the cells to tamoxifen (Dowsett et al. 2001) and can increase
the agonist activity of the drug to such an extent that cell growth is stimulated by the
presence of tamoxifen (Shou et al. 2004).
In addition to mutations in tumours, there are other mechanisms by which gene
expression can be stably modulated, without recourse to alterations to the DNA
sequence.  These mechanisms are frequently referred to as “epigenetic”.
1.3.6 Epigenetics
Based on the observation that inherited retinoblastoma occurred earlier than
spontaneous cases, Alfred Knudson Jr. posited the “two-hit hypothesis”, wherein
only two stable changes are required for tumourigenesis (Knudson 1971). These hits
were later discovered to occur at tumour suppressor genes, and rare mutation events
at two alleles of a single gene have been suggested as the means by which
tumourigenesis occurs.  However, whilst mutation at two alleles is a possible
mechanism, there are several other events that can induce the stable changes in
expression required for two-hit tumourigenesis.  One of the means by which this
stable change can occur is through epigenetics.  Here, I also suggest that these stable
changes not only influence tumourigenesis, but also other facets of tumour biology,
including resistance to therapy.
A key issue that needs to be addressed before a thorough analysis of epigenetic
mechanisms and their potential role in cancer is that “epigenetic” must be defined.
Whilst the definition of epigenetics has been (and to some extent, still is) the subject
of debate, the modern definition used here is as proposed by Eric Richards in 2006,
that epigenetics is the study of “heritable changes in gene expression that cannot be
tied to genetic variation…which can be perpetuated in the absence of the conditions
that established them.” (Richards 2006).  The key aspects of epigenetics are twofold.
Firstly, that it is heritable, passed down through generations of cells, such that
regulation of gene expression is not only altered in the parent cell, but in subsequent
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daughter cells after mitosis.  Secondly, that epigenetic states do not necessarily
require active refreshment, but can be perpetuated indefinitely as part of the normal
functioning of the cell.  Whilst there are certain active elements required for the
maintenance of epigenetic states, they are not by necessity the same as the initiating
event.
Whilst genetics is concerned with gene expression as a function of DNA sequence,
epigenetic alteration of gene expression encompasses several mechanisms, through
which genes are activated, repressed and modulated.
DNA methylation
In mammals, DNA methylation occurs at cytosine-guanine (CpG) dinucleotides, with
a methyl group covalently bonded to the C5 of the cytosine pyrimidine ring.  These
pairs are under-represented in the genome, occurring at approximately one-fifth of
the 4% frequency that would be expected if residues were distributed randomly
(Lander et al. 2001). This is thought to be due to the gradual degradation and
hydrolytic deamination of methylated cytosine-guanine dinucleotides to thymine-
guanine dinucleotides, leading to the evolution of reduced CpG content.  Because
unmethylated cytosine can only be deaminated to uracil, the hydrolysis reaction
occurring more slowly and the mismatch repair being more efficient contribute to
unmethylated CpG sites being evolutionarily conserved (Duncan & Miller 1980).
This idea is lent credence by the fact that CpG distribution is uneven, with the
majority of CpG sites concentrated in repetitive sequences that aren’t typically
methylated (Bird et al. 1986).  These regions are known as “CpG islands”, which are
defined as regions of DNA, over 200bp long, with a CG content of greater than 50%
and an observed/expected CpG ratio over 0.6 (Gardiner-Garden & Frommer 1987).
By this definition, CpG islands occur at over 70% of promoters (Saxonov et al.
2006). These CpG islands are typically unmethylated in somatic cells (Bird et al.
1986). Because methylation of promoter regions is associated with transcriptionally
inactive genes and hypomethylated promoters tend to be found at active genes
(reviewed in Deaton & Bird (2011)), CpG island methylation represents an important
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mechanism for stable changes to gene expression without recourse to alterations to
the DNA sequence, the key criterion in any definition of epigenetic regulation. The
deregulation of gene expression by DNA methylation may be an important
mechanism in disease pathogenesis and in resistance to therapy, as discussed
previously.  As such, an appreciation of the underlying mechanisms by which
methylation occurs and is maintained is essential to understanding the epigenetics of
breast cancer.  The most important agents of DNA methylation (in mammalian cells)
are the DNA Methyltransferases (DNMTs), of which there are two types, de novo
and maintenance methyltransferases. De novo methyltransferases, DNMT3A and
DNMT3B, act to set the initial methylation pattern of DNA (Okano et al. 1999), with
DNMT1 acting to maintain this state (Hermann et al. 2004), despite having some de
novo activity (Pradhan et al. 1999).
DNMT1, the maintenance methyltransferase
Full methylation of duplex DNA refers to the methylation of the 5’ cytosine in the
CpG dinucleotide, as well as the 5’ cytosine of the complimentary CpG of the
antisense strand.  When mammalian DNA undergoes replication, the newly-
synthesised daughter strand is at first unmethylated, so the DNA duplex becomes
hemi-methylated (Gruenbaum et al. 1983).  If this were not rectified, every
replication would lead to passive demethylation.  DNMT1 occupies a position at the
replication fork, adding methyl groups to hemi-methylated CpG sites, restoring the
methylation state of the parent DNA (Estève et al. 2006). DNMT1 is a processive
enzyme, binding to DNA and methylating long stretches without dissociation,
allowing for methylation to occur before chromatin assembly (Hermann et al. 2004).
If DNMT1 is removed from proliferating cells, the DNA is demethylated over the
course of generations, with only a few duplications accepted before the cells undergo
apoptosis (Jackson-Grusby et al. 2001). DNMT1 is also essential during
embryogenesis, with deletion in mice being embryonic lethal (Li et al. 1992).
DNMT1 is subject to several post-translational modifications that have an effect on
its activity and bioavailability, with Ser-515 phosphorylation being required for the
activation and normal functioning of the enzyme (Goyal et al. 2007) and methylation
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at Lys-142 causing degradation of the protein by targeting of the proteasome (Estève
et al. 2009).
The mechanism by which DNMT1 is targeted to the replication fork is via its binding
to accessory proteins.  Firstly, through its transient binding to Proliferating Cell
Nuclear Antigen (PCNA), DNMT1 is loaded onto the replicating DNA, with each
molecule diffusing down the DNA away from PCNA, allowing recruitment of
additional DNMT1 molecules (Estève et al. 2006).  Downstream of the replication
fork, DNMT1 may be tethered to the DNA by Ubiquitin-like, containing PHD and
RING finger domains, 1 (UHRF1), which has been shown to bind hemi-methylated
DNA (Bostick et al. 2007).  UHRF1 knockouts display reduced methylation and a
similar phenotype to DNMT1 knockout mice (Muto et al. 2002).
De novo methyltransferases
Whilst DNMT1 is important for maintaining the epigenetic state of CpG
dinucleotides, there are two important de novo methyltransferases that set up the
initial methylation state of DNA, DNMT3A and DNMT3B. Unlike DNMT1, these
enzymes display a preference for unmethylated over hemi-methylated DNA
(Yokochi & Robertson 2002), methylating DNA at unmethylated CpG sites (Hsieh
1999).  Both DNMT3A and B are essential during embryonic development, with 3B
knockout mice dying in utero and 3A knockouts dying shortly after birth (Okano et
al. 1999).
Normally, the initial pattern of methylation is set up during the early stages of
embryonic development.  Stem cell DNA in the zygote is largely demethylated, with
DNMT3-induced methylation patterns established at implantation.  A subsequent
large-scale methylation event occurs during germline development, eventually
establishing the overall methylation pattern through a series of rounds of methylation
(Santos et al. 2002).  These methylation events are thought to be targeted through
several mechanisms.  DNMT3A and DNMT3B have been shown to exhibit sequence
specificity, with flanking sequences surrounding CpG sites affecting the affinity of
the enzymes for their sites (Handa & Jeltsch 2005).  In addition, histone
modifications are thought to play a role in targeting.  Unmodified histone H3 lysine-
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4 (H3K4), which is associated with unmethylated DNA (Okitsu & Hsieh 2007), has
been shown to recruit DNMT3A via DNMT3L (Ooi et al. 2007), while
dimethylation at histone H4 arginine 3 (H4R3) directly recruits DNMT3A (Zhao et
al. 2009). So critical are histones to the function of DNMT3A and DNMT3B that
the removal of the N-terminal tail of histone H3 leads to a complete abrogation of de
novo DNA methylation (Hu et al. 2009).  Other proteins also play a role, with
transcription factor arrays showing direct interactions:  55 transcription factors
binding strongly to DNMT3A, 27 to DNMT3B (Hervouet et al. 2009). Recruitment
by DNMT3B of chromatin-interacting proteins, such as SETDB1 (Li et al. 2006),
PRC1 and 2 (Jin, B. et al. 2009) and NEDD8 (Shamay et al. 2010), acts to induce
transcriptional repression.  Conversely, there is evidence that regulation by DNA-
binding proteins such as VEZF1 can also occur to repress de novo methylation, with
promoters interacting with proteins that physically prevent DNMT3-binding
(Dickson et al. 2010).
Histone modification
When studying gene expression, it is important to bear in mind that DNA does not
exist as naked strands, but as chromatin, with DNA packaged around nucleosomes,
composed of complexed histones. Histones form octamers that DNA spools around,
assembled as a pair of histone H2A/2B dimers either side of a histone H3/4 tetramer,
itself composed of two H3/4 heterodimers (Arents et al. 1991).  In addition to the
core histones, histone H1 acts as a linker histone, tethering DNA to the histone
octamer (reviewed in Happel & Doenecke (2009)).  The core histones in the complex
have long N-terminal tails that protrude from the octamer, which commonly undergo
post-translational modifications that, when present at promoter regions, appear to
affect transcription (reviewed in Lennartsson & Ekwall (2009)).  Unlike the simpler
situation in DNA, wherein promoter methylation tends to lead to repression of
transcription, the addition of methyl and acetyl groups to histones can have a
markedly different effect dependent on the histone that is modified, the position of
the additional group, and how many groups are added.
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Histone methylation
Histone methylation commonly takes place on lysine residues in the long, protruding
N-terminal tail of the core histones.  These lysine residues can be mono-, di- or tri-
methylated by specific enzymes containing SET domains (named for their presence
in Suppressor of variegation, Enhancer of zeste and Trithorax proteins discovered in
Drosophila melanogaster) (reviewed in Xiao et al. (2003)). These enzymes from the
histone methyltransferase (HMT) family catalyse methylation events that can have
both an activating and repressing effect (Table 1.1), dependent on the histone and the
type of methylation. There are 48 HMTs containing a SET-domain encoded in the
human genome, as well as the DOT1-like (DOT1L) HMT, which does not contain a
SET domain (Albert & Helin 2009). There are, surprisingly, monomethylated
residues that are associated with activation that become repressive marks after further
methylation. In addition, methylation can also occur at arginine residues (reviewed
in Di Lorenzo & Bedford (2010)), and in the globular body of the histone as well as
the tail (Ng et al. 2002).
Table 1.1:  Histone lysine methylation can be both repressive and activating.
Summarised from Barski et al. (2007).
Histone Residue Methylation Status Abbreviation Transcriptional Effect










































H4 Lysine 20 Monomethyl H4K20me3 Activating
Early experiments examining methylation turnover concluded that methylation was a
permanent mark, only removable by dismantling the histone octamer and degrading
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the marked histones (Duerre & Lee 1974).  However, it is now known that histone
demethylases can act to remove methylation, modulating the transcriptional-
regulation effects. These enzymes include Lysine Specific Demethylase 1 (LSD1),
the first discovered, which can demethylate mono- and di-methylated lysine residues,
but has no activity at trimethylated sites (Shi et al. 2004), and a family of Jumonji C
(JmjC) domain-containing enzymes that were originally also thought to be active
only at mono- and di-methyl sites (Tsukada et al. 2006). Because of this, tri-
methylation was briefly posited as a permanent mark, but this was disproved with the
discovery of a JmjC domain-containing demethylase that has activity at trimethyl
lysine residues (Whetstine et al. 2006).
Histone acetylation
As well as methylation, histones can be acetylated, a mark which has long been
known to be associated with transcriptional activation (Hebbes et al. 1988). The
classic example of the correlation between acetylation and transcription is the
inactive X-chromosome, which is silenced and extensively deacetylated (Jeppesen &
Turner 1993). The mechanism of activation is thought to be due in part to the acetyl
group acting to reduce the magnitude of the positive charge present on the histone,
decreasing the strength of the DNA/histone bond (Hong et al. 1993), making the
DNA more permissive to transcriptional machinery.  The acetyl group is bound to
the histones through the action of histone acetyltransferases (HATs), which are often
found in large complexes, with multiple HAT enzymes also carrying out an
independent transcriptional function (reviewed in Lee & Workman (2007)). These
HATs contain bromodomains and extra terminal domains (collectively referred to as
BET domains), which are the only known protein domains that are capable of
binding acetylated lysine residues (reviewed in Zeng & Zhou (2002)). Some HAT
enzymes are not able to bind directly to the DNA but are recruited by sequence-
specific transcription factors (Elefant et al. 2000).  They also often have activity on
non-histone proteins (reviewed in Masumi (2011)). To modulate the effect of HATs,
there is a large family of histone deacetylases (HDACs), which remove acetyl groups
from histones and repress transcription in the promoter regions of genes (Taunton et
al. 1996). Mammalian HDACs are divided into four classes (reviewed in Witt et al.
(2009)).  Class I HDACs are typically localised to the nucleus and have a large C-
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terminal region that can be post-translationally modified to activate and repress the
enzyme.  Class II HDACs are generally found as part of a repressive complex with
DNMT1 and LSD1.  The third class are also known as the Sirtuin (SIRT) family,
which are dissimilar to other HDACs, in that their catalytic activity is NAD+-
dependent, whilst the other HDACs use a zinc ion co-factor (Landry et al. 2000).
Unlike class I and II, these enzymes are also insensitive to inhibition by trichostatin
A (Blander & Guarente 2004). There is only one class IV HDAC, HDAC11,
functionally similar to the class I and II HDACs but distinguished by its lack of
sequence similarity to either class (Gao et al. 2002), which may be involved in
regulating interleukin 10 (Villagra et al. 2009).
Other histone modifications
Whilst methylation and acetylation and their epigenetic consequences are well
characterised, other modifications to histones are less well understood.  It is
established within the literature that histones can be phosphorylated and that
phosphorylation at certain residues has a transcriptional effect (reviewed in Banerjee
& Chakravarti (2011)).  For example, H3 Ser-10 phosphorylation, catalysed by
Ribosomal protein S6 Kinase alpha 2 (RSK2) (He et al. 2003), is correlated with
transcriptional-activation (Nowak & Corces 2000). The mechanism by which this
affects transcription is unclear and controversial, with some evidence for
phosphorylation lowering DNA binding efficacy via a positive-charge reduction, and
other data suggesting that phosphorylation simply induces co-factor recruitment
(reviewed in Prigent & Dimitrov (2003)).
As well as phosphorylation, histone monoubiquitylation has been shown to have a
role in transcriptional regulation (Weake & Workman 2008).  Whilst
polyubiquitylation is usually considered a signal for proteasomal degradation
(Thrower et al. 2000), monoubiquitylation of histones has a role in regulating
transcription removed from its proteasomal role.  These marks are found in the C-
terminal ends of histones, rather than the N-terminal tails. Monoubiquitylation of
H2A is associated with silencing via polycomb group proteins (Wang et al. 2004)
and through RNA polymerase inhibition (Zhou et al. 2008), with H2B
monoubiquitylation at Lys-120 corresponding with actively-transcribed chromatin
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(Gatta et al. 2011). Whilst there is some debate over whether these constitute stable
epigenetic marks because of their transitory nature, it is clear that ubiquitylation has
an effect on transcription (reviewed in Cao & Yan (2012)). The ubiquitylation of
H2B by the sequential activity of an E1 ubiquitin activating enzyme, an E2 ubiquitin
conjugating enzyme and an E3 ubiquitin ligase has also been shown to stimulate
transcriptional elongation (Minsky et al. 2008).  Although the mechanism by which
this occurs is unclear, H2B ubiquitylation has been shown to recruit elements of the
proteasome system, which may rearrange the chromatin conformation at active loci
(Ezhkova & Tansey 2004).  In addition, Lys-123 ubiquitylation in yeast has been
shown to enhance the activity of HMTs, increasing the processivity of the enzymes
(Shahbazian et al. 2005). Ubiquitylation of histones H3 and H4 has been shown to
weaken the interaction between DNA and the histone octamer (Wang et al. 2006),
but the transcriptional effects of this remain to be seen.
The addition of a SUMO group to histones is associated with transcriptional
repression.  Histone H4 sumoylation, potentially recruited by acetylation (Nathan et
al. 2003), induces HDAC1 recruitment and repression of transcription (Yang &
Sharrocks 2004), alongside recruitment of Heterochromatin Protein 1 alpha (HP1α)
(Shiio & Eisenman 2003), which represses transcription through the formation of
heterochromatin.
Variant histones
As well as the core histones, H2A, H2B, H3 and H4, there are several variant
histones which have an effect on transcription.  A variant of histone H2, H2A.Z, is
associated with actively transcribed genes, replacing H2 in some promoters (Jin, C.
et al. 2009). This is thought to be more important in the establishment of
transcription than in the maintenance of a transcriptionally permissive state, and
H2A.Z has been posited as a means by which genes can be poised for transcription
(Santisteban et al. 2011).  However, genome-wide analysis shows that H2A.Z-
containing nucleosomes are enriched for both activating and repressive core histone
markers (Viens et al. 2006), suggesting a more complicated relationship than
previously thought.
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Another variant of histone H2, macroH2A, is significantly different from other
histones, with large regions that are unrelated to any other histone types (Pehrson &
Fried 1992). Generally found in the inactive X chromosome (Costanzi & Pehrson
1998), but known not to be essential for the maintenance of its inactivation
(Csankovszki et al. 1999), macroH2A plays a role in transcriptional repression
(Doyen et al. 2006).  The large degree of divergence from normal histones has been
proposed as a means by which epigenetic control is exerted, through binding to non-
coding RNAs (Bernstein et al. 2008), which will be discussed in more depth later.
This idea is lent credence by the observation that there is a large degree of homology
between macroH2A and RNA viral domains (Pehrson & Fuji 1998).
A histone variant first characterised by its absence from cellular Barr bodies
(Chadwick & Willard 2001), H2A-Barr body deficient (H2A-Bbd), is found in
regions of chromatin with an open conformation (Bao et al. 2004), containing
acetylated H4 (Angelov et al. 2004), suggestive of a role in transcriptional activation.
In addition to those of histone H2, a variant of histone H3 exists, called CENP-A,
which is found at centromeres (Palmer et al. 1987).  This variant does not appear to
play a direct role in the regulation of transcription, rather it indirectly affects gene
expression through the remodelling of chromatin structure.
Chromatin remodelling
In order for transcription to occur, the transcriptional machinery must be able to
physically interact with the DNA, which cannot occur if the chromatin structure does
not permit it.  In certain regions, such as the telomeres and centromeres, the
chromatin structure is tightly bound and not permissive to transcription. It has been
postulated that at active gene promoters, the chromatin structure is more open
(Vermaak et al. 2003). Promoters are thought to contain non-nucleosomal regions,
evinced by their DNase I hyper-sensitivity (Braastad et al. 2003). Inactive chromatin
tends to be associated with histone H3 Lys-9 (H3K9) methylation (reviewed in
Barski et al. (2007)) combined with binding of HP1α (Cowell et al. 2002), and the
recruitment of Polycomb Repressive Complex 2 (PRC2) (Cao et al. 2002). Evidence
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that histones are directly involved in the regulation of transcription comes from
experiments using a genetically engineered strain of yeast, in which histone H4
expression is under the control of the GAL1 promoter.  Here, depletion of histones,
by switching the carbon source from galactose to glucose, led to the decompaction of
the chromatin, and was a means by which rapid induction of gene expression could
occur (Wyrick et al. 1999). In normal physiology, chromatin may be remodelled for
transcription by a number of factors. ATP-dependent nucleosome-remodelling
complexes couple ATP hydrolysis to the displacement of histones from DNA to
other parts of  chromatin, or onto histone-chaperone proteins (Becker & Horz 2002).
This mechanism appears to be evolutionarily conserved across eukaryotes, with
mammalian promoters often containing nucleosome-free regions (Rach et al. 2011).
The removal of histones from these areas is facilitated by histone acetylation,
associated with transcriptional-activation at histone H3 lysine 14 (H3K14) (Luebben
et al. 2010).  There is also evidence that nucleosome depletion at promoters can be
carried out by large complexes of DNA helicases (Erdel & Rippe 2011; Xie et al.
2012) and topoisomerase (Durand-Dubief et al. 2010).
Non-coding RNA
Transcriptomic studies have discovered that not all RNA is used to encode protein.
In fact, a large number of non-coding RNAs (ncRNAs) have been discovered, which
can play a role in the regulation of gene expression.  These ncRNAs can be divided
into several types (reviewed in Mattick & Makunin (2006)). MicroRNAs (miRNAs)
are small ncRNAs that are approximately 23 nucleotides long, contributing to the
silencing of genes. The DNA coding for these miRNAs is primarily found in
intronic regions or as part of the antisense strand of a transcribed gene (Rodriguez et
al. 2004). Primarily, they bind to the 3’ untranslated region of genes (Fang &
Rajewsky 2011), but can also bind to coding regions, albeit more weakly (Forman &
Coller 2010). RNA polymerase II initially transcribes long non-coding RNAs called
primary RNAs (pri-RNAs) which are processed by the microprocessor complex,
which contains RNase type III Drosha and Pasha, with further processing by Dicer to
form double stranded miRNA (Lee et al. 2003; Denli et al. 2004). This miRNA is
incorporated into the RNA-induced silencer complex (RISC)-loading complex
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(RLC), whereupon one strand dissociates, with the remaining strand and the RLC
forming the mature RISC (Wang et al. 2009).  This complex can then act to cleave
the target mRNA, preventing protein translation, or the single stranded miRNA can
bind to an mRNA and target it for degradation.
Piwi-interacting ncRNAs, abbreviated to piRNAs and previously known as repeat-
associated short interfering RNAs (rasiRNAs), are between 26 and 31 nucleotides
long.  They are found primarily in repeat sequences and are thought to silence
retrotransposable elements through DNA methylation. They are always derived from
the antisense strand of a transcribed gene and do not appear to require the Dicer
complex in order to function. The majority of piRNAs are antisense to transposons,
which suggests that transposons are the primary target (Kuramochi-Miyagawa et al.
2008).
A further subtype, small RNAs, come in several types.  Short interfering RNAs
(siRNAs) are, like miRNAs, a product of longer ncRNAs, processed by the cellular
machinery into shorter lengths.  These act to silence genes either by binding to
mRNA and targeting it for cleavage (Mattick & Makunin 2005). Small nucleolar
RNAs (snoRNAs) are another subtype, which can function as normal miRNAs, but
are primarily involved in the modification of other RNAs (reviewed in Maden &
Hughes (1997)).
1.3.7 Epigenetics in breast cancer
Given the importance of transcriptional regulation in cancer, the question of whether
epigenetics plays an important role in the initiation and maintenance of ER+
tumours, as well as the acquisition of resistance to endocrine therapies, has become a
significant issue (reviewed in Lopez et al. (2009)).  If epigenetics is as important as
some suspect, not only could epigenetics be used as a prognostic indicator in breast
cancer, it could even be a druggable target, with drugs that modify the epigenetic
landscape of a tumour being employed to alter gene expression.  In addition, a
thorough understanding of epigenetic mechanisms might lead to increased insight
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into the underlying mechanisms of both tumourigenesis and the acquisition of a
drug-resistant phenotype.
DNA methylation in ER+ breast cancer
Global DNA hypomethylation is a common feature in cancers, with approximately
75% of breast cancers exhibiting significantly reduced global methylation compared
to normal cells (Soares et al. 1999).  This hypomethylation is frequently found in
repeat regions containing transposable elements (Weisenberger et al. 2005),
removing the repressive mark and potentially allowing activation of retrotransposons
that can relocate throughout the genome, causing insertional mutagenesis.  In
addition, there are several well-characterised examples in breast cancer of how
global hypomethylation can affect individual genes.  The tumour antigen Melanoma
Antigen family A, 1 (MAGE1), which is normally heavily methylated and silenced in
tissues except testes (De Smet et al. 1999), is hypomethylated and expressed in a
high proportion of breast cancer cell lines and excised tumours (Weber et al. 1994).
Interestingly, the Multidrug Resistance 1 (MDR1) gene, which is normally
unmethylated in somatic tissue (Tahara et al. 2009), becomes methylated and
silenced in the majority of breast cancers (Burger et al. 2003). Demethylation is
correlated with increased expression and the development of chemotherapeutic
resistance in acute myeloid leukaemia (Kantharidis et al. 1997).  This gene is
hypomethylated and expressed in approximately 25% of ERα over-expressing breast
cancers (Sharma et al. 2010).  In breast cancer cell lines, doxorubicin sensitivity is
associated with high methylation of MDR1, with low methylation correlated with
resistance (Chekhun et al. 2006), supportive of a role for DNA methylation
misregulation in the acquisition of resistance, albeit in this case to chemotherapy, not
endocrine therapy.
However, potentially more biologically interesting is the increase in CpG island
methylation at specific promoters.  In healthy tissues, tumour suppressor genes
typically have unmethylated promoter regions (Bird 1986), but in tumours these
regions are methylated, correlating with repression (reviewed in Widschwendter &
Jones (2002)).  Multiple studies looking at promoter methylation signatures have
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been carried out, with prognostic methylation signatures being posited as a means by
which to evaluate not only the status and prognosis associated with a particular type
of breast cancer (Li, L. et al. 2010; Moelans et al. 2011; Sun et al. 2011), but also the
probability of developing resistance to endocrine therapy (Jeong et al. 2010).  There
are even studies suggesting that the risk of developing breast cancer in the first place
can be determined from epigenetic profiling of peripheral blood cells, but as
prognostic indicators, rather than biologically and mechanistically relevant
phenomena (Widschwendter et al. 2008; Bosviel et al. 2012; Brennan et al. 2012).
These studies all suggest that aberrant methylation can be a factor in the development
of cancer and alter the phenotype of a tumour. However, there is some debate as to
the validity of this theory.  A number of genes with no obvious connection to cancer
pathology are methylated in tumours, suggesting that the tendency to hypermethylate
may be a paraphenomenon associated with transformation, and not causative of it.  A
recent study showed that the genes which were methylated in breast cancer are novel
and not expressed in the epithelial lineage.  Furthermore, treatment with global
demethylating agent 5-aza-2′-deoxycytidine (5-aza-dC) did not cause the re-
expression of most methylated genes in cell lines (Sproul et al. 2011).
In the search for methylation associated with resistance to endocrine therapy, the
ESR1 promoter seemed an obvious and promising target, with some studies showing
that ER– cancers exhibit increased ESR1 methylation (Ottaviano et al. 1994) which
can be removed through DNMT1 inhibition to induce the re-expression of ERα (Yan
et al. 2003). However, it seems endocrine-resistance is not correlated with
significant changes in ESR1 methylation, although there might be a role for aberrant
promoter methylation of ESR2, which encodes ERβ (Chang et al. 2005). The clinical
relevance of this is unclear and the subject of debate.  Some studies suggest that it is
actually raised ERβ expression that is correlated to endocrine-resistance (Dotzlaw et
al. 1999; Speirs et al. 1999; Chang et al. 2005), whilst others show that lower levels
of ERβ lead to resistance (Hopp et al. 2004) with high levels sensitising cells to
tamoxifen (Wu et al. 2011).
Whilst cell line studies seem to point to multiple significant changes in methylation
correlating to endocrine-resistance (Fan et al. 2006), there are many fewer significant
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and reproducible methylation markers in primary tumours.  Nonetheless, several
markers for tamoxifen-resistance have been discovered. A protein involved in drug
metabolism, Arylamine N-Acetyltransferase Type I (NAT1) is methylated in
tamoxifen-resistant tumours, which has been shown to correlate to low expression of
NAT1 mRNA, with tamoxifen-resistant tumours expressing lower amounts of NAT1
than control (Kim et al. 2010). The methylation of Pituitary homeobox 2 (PITX2)
has been correlated with tamoxifen-resistance (Maier et al. 2007), but whether or not
it has a direct role in the acquisition of resistance remains unclear.  More recently, a
multi-gene pattern of methylation has been discovered that is associated with
tamoxifen-resistance, but given that this was observed in plasma over the course of
therapy, it seems likely that it represents a means by which to monitor treatment,
rather than an elucidation of an underlying epigenetic mechanism (Liggett et al.
2011).  It seems likely that there will be methylation patterns associated with
resistance to other endocrine therapies, but currently tamoxifen is the most studied
therapy, with the effects of other drugs still to be revealed.
Histone modifications in ER+ breast cancer
Genome-wide studies suggest that histone modifications might be predictive of
breast cancer subtype, grade and prognosis, with ERα positivity correlated with
globally high levels of H3K18, H3K9 and H4K12 acetylation, H4R3 and H3K4
dimethylation and H4K20 trimethylation, but these modifications appeared not to
have any relation to responsiveness to endocrine therapy (Elsheikh et al. 2009).
However, whilst the exact relationship between histone modifications and endocrine-
resistance remains to be elucidated, it seems likely that they play a role, given the
multiple studies that have shown a benefit to giving HDAC inhibitors either in
combination with tamoxifen or after the acquisition of tamoxifen-resistance (Restall
et al. 2009; Munster et al. 2011; Thomas et al. 2011).
Chromatin remodelling in ER+ breast cancer
Physical remodelling of chromatin in breast cancer is not widely studied, but there is
evidence that remodelling factors such as SWI/SNF-related, matrix-associated, actin-
dependent regulator of chromatin, subfamily a, members 2 and 4 (SMARCA2 and
SMARCA4) are mutated in breast cancer.  It is believed that their mutations lead to a
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restructuring of chromatin and activation of normally inactive genes (Medina &
Sanchez-Cespedes 2008). In addition, aberrant expression of Transforming Growth
Factor beta 1-induced (TGFBI) has been shown to be related to the conformation of
chromatin in breast cancer cells, as chromatin in a more open configuration allows
transcription of TGFBI by Specificity Proteins 1 and 3 (Sp1 and 3) (Lee et al. 2011).
The TGFBI protein has also been shown to be involved in the sensitisation of other
cancer types to therapy, so it is possible that it has a role in endocrine-resistance, but
that remains to be seen (Ahmed et al. 2007).
Non-coding RNA in ER+ breast cancer
Similar to the way in which global expression and methylation patterns can be used
to subdivide breast cancer into types, so too can ncRNA expression patterns.  Studies
in cell lines have found several estrogen-responsive miRNAs, most of which showed
increased expression after tamoxifen treatment (Maillot et al. 2009). Negative
regulators of ERα, miR221 and miR222, have been shown to be involved in
tamoxifen-resistance in cell lines, with miR221/222 transfected cells becoming
sensitive to tamoxifen and miR221/222 down-regulation leading to resistance (Zhao
et al. 2008). This finding led to the hypothesis that miRNAs might play a role in
endocrine-resistance, which is borne out by the observation that tamoxifen-resistance
is associated with low expression of miR-342, a miRNA that regulates pathways
involved with tumour cell death (Cittelly et al. 2010).
Potential conflicts in epigenetics in breast cancer
The study of epigenetics and resistance to endocrine therapy has raised several
questions about our understanding of epigenetics and how cancer treatments work.
DNA methylation in healthy tissue vs. tumours
DNA methylation in healthy tissues is known to regulate transcription, both directly
through the inhibition of transcription-factor binding and indirectly through methyl-
binding proteins that remodel chromatin into less permissive states. This regulation
occurs at very few loci throughout the genome.  The conventional paradigm is that
this situation is mirrored in cancer, and that aberrant DNA methylation controls gene
expression in tumours. However, in breast cancer it has been shown across the
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genome not to be causative (Sproul et al. 2011), but merely correlative.  Whilst this
does not rule out more specific methylation events causing transcriptional repression,
it suggests that DNA methylation in breast cancer might be a marker for the
maintenance of repression, rather than the causative agent in the initiation of
transcriptional repression.
Heterogeneity vs. therapy-induced epigenetic change
Another key question is whether epigenetic changes in endocrine-resistant tumours
are the product of selection pressures on an epigenetically heterogeneous population,
or that therapy itself induces the epigenetic changes that lead to resistance.
Stochastic variation of CpG island methylation across a tumour population is often
very high when compared to that observed in normal cells, corresponding with a high
degree of variation in gene expression patterns (Hansen et al. 2011), indicating that
epigenetic heterogeneity is likely to be extremely high. Combined with the fact that,
in cell lines treated with tamoxifen, resistant cells tend to come from a single
progenitor cell (Coser et al. 2009), this lends credence to the idea that therapy selects
for pre-existing resistant cells in the heterogeneous tumour population.  However, the
observations that treating cell lines with tamoxifen induces up-regulation of
DNMT3B (Kubarek et al. 2009) and that tamoxifen-resistant cells have also been
shown to over-express DNMT1 (Phuong et al. 2010) both add weight to the idea that
tamoxifen itself may cause epigenetic misregulation. Two studies have shown that
treatment of tamoxifen-resistant cell lines with 5-aza-dC and trichostatin A can
restore sensitivity, certainly suggestive of a role for DNA methylation in the
acquisition of tamoxifen-resistance, and that up-regulation of DNMTs could be
important (Sharma et al. 2006; Hostetter et al. 2009).  However, both studies
focussed on the end result of restoring drug sensitivity, which ignores the possibility
of off-target effects of the drugs, and did not elucidate an epigenetic mechanism of
resistance.
1.4 The MCF7/LCC1/LCC9 cell line model
In 1970, the Michigan Cancer Foundation isolated breast cancer cells from a pleural
effusion from Frances Mallon, also known as Sister Catherine Frances, a nun at a
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Michigan convent.  These cells were immortalised and transformed into a cell line by
Herbert Soule et al. in 1973 (reviewed in Levenson & Jordan (1997)).
MCF7 cells
These cells are ER+ breast cancer cells, with a luminal epithelial phenotype. They
are routinely grown in media supplemented with estradiol, an estrogen metabolite.
They are highly sensitive to estrogen, with estradiol deprivation leading to
approximately 40% slower growth (Karey & Sirbasku 1988).  MCF7 cells are
sensitive to TGFß-induced colony formation inhibition, and are sensitive to both
SERMs and SERDs, with fulvestrant preventing all cell growth.  The genome of
MCF7 cells shows extensive intragenic hypomethylation, associated with regions of
fragile sites and breakpoints, correlating with high expression of the hypomethylated
genes (Shann et al. 2008).
LCC1 cells
When MCF7 cells were xenografted into ovariectomised mice, the resultant tumours
grew slowly, due to the absence of estrogen.  One of the three tumours was excised
and cultured, with a population of epithelial cells isolated and named MCF7/MIII
(Clarke et al. 1989).  These cells were then inoculated into the flanks of
ovariectomised mice for a second time, with proliferating tumours later excised, cut
into 1mm3 pieces and plated.  These cells were then named “LCC1”. Despite not
requiring estrogen for growth, LCC1 cells retain the endocrine-sensitivities of
MCF7.  They also have raised expression of estrogen-regulated genes, which is not
accompanied by any large-scale DNA amplifications. Interestingly, the cells greatly
over-express ERα, consistent with estrogen-deprived MCF7 cells in vitro. Aberrant
ERα-binding enables the estrogen-independent transcription of normally estrogen-
responsive genes, suggesting that over-expression of ERα is a compensatory
mechanism for the absence of estrogen (Kuske et al. 2006).  Subsequent to their




LCC9 cells are fully estrogen-independent, growing in the absence of estrogen and
unaffected by both tamoxifen and fulvestrant (Brunner et al. 1997). These cells
express significantly less ERα than their LCC1 parent line, with expression much
more similar to MCF7.  ERα Ser-118 phosphorylation is significantly reduced in
LCC9 cells (Kuske et al. 2006), consistent with ERα inactivation.
1.4.1 Modelling a clinical situation
The MCF7/LCC1/LCC9 cell line model is used to model the clinical development of
acquired resistance to endocrine therapy, allowing study of the genetic and
epigenetic events that might occur in the evolution of resistance.  By analysing the
changes in gene expression and methylation between MCF7 and LCC1 cells, the
modifications associated with the development of estrogen hyper-sensitivity can be
discovered, and by looking at the variation between MCF7, LCC1 and LCC9 cells,
those linked with endocrine-resistance can be elucidated.
1.5 Thesis aims
The primary aim of this thesis was to discover potential genetic and epigenetic
mechanisms involved in the evolution of endocrine-resistance in breast cancer, using
a cell line model. I first analysed the gene expression changes associated with
estrogen-independence and endocrine-resistance using an oligonucleotide mRNA
expression array, hoping to identify the genes and gene families which appeared to
exhibit deregulation correlated with drug sensitivity and resistance.  This approach
identified over 5,000 genes that were estrogen-regulated, and a large number that
might potentially be involved in the acquisition of resistance to endocrine therapy.
To identify the genes that might have been epigenetically deregulated, I performed a
global methylation analysis on the cell lines and focussed on genes that appeared to
be deregulated in association with significant changes in DNA methylation.
Surprisingly, very few genes were deregulated in this way.  However, one such gene,
a component of the NADPH oxidase complex, CYBA, was taken forward for further
investigation, as it appeared to be both estrogen-responsive in MCF7 cells, and





2 Materials and methods
2.1 Cell culture
2.1.1 Routine cell culture
MCF7, LCC1 and LCC9 cells were a gift from Catherine Naughton (University of
Edinburgh).  MCF7 cells were routinely grown in phenol red-free DMEM,
supplemented with 10-9M estradiol (E2), 1% penicillin/streptomycin (Gibco,
Invitrogen), 2mM glutamine and 5% charcoal stripped foetal calf serum (DCS-FCS).
This medium was referred to as “complete” medium for the duration of the
experiment.  Confluent cells were passaged first by washing in PBS (phosphate
buffered saline), followed by the addition of 5ml trypsin for 5 minutes at room
temperature.  After detachment, trypsin was inactivated by the addition of 8ml of cell
medium.  The cell suspension was then centrifuged at 1,300rpm for 5 minutes at
room temperature.  The pellet was then resuspended in an appropriate amount of cell
medium and a dilution placed in a new flask.  Estrogen-withdrawal experiments were
carried out by washing cells with PBS, then replacing cell medium, minus estrogen.
LCC1 and LCC9 cells were routinely grown in phenol red-free DMEM,
supplemented with 1% penicillin/streptomycin (Gibco, Invitrogen), 2mM glutamine
and 5% DCS-FCS.  This medium was referred to as “stripped” medium for the
duration of the experiment.  Estrogen-supplementation experiments were carried out
by washing cells with PBS, then replacing cell medium, plus estrogen.
All cell lines were maintained in a humidified incubator at 37°C and 5% CO2.
In all experiments, media was replaced 24 hours and 4 hours before cell harvesting.
2.1.2 Charcoal stripping of serum
Frozen foetal calf serum (Harlan Sera-Lab) was thawed overnight at 4°C, then heat
inactivated at 56°C for 30 minutes.  Sulphatase was added at 2000U per litre and
incubated at 37°C for 2 hours.  The pH was adjusted to 4.2 using 2M HCl.  A
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charcoal mix of 5g of activated charcoal and 25mg dextran T70 in 50ml ddH2O was
added per litre of serum.  The mixture was incubated at 4°C overnight, with stirring.
Charcoal was removed by centrifugation at 10,000rpm for 30 minutes at 4°C and pH
readjusted to 4.2.  A second charcoal mix was added and the mixture stirred
overnight at 4°C.  The mixture was centrifuged again to remove the charcoal and the
pH adjusted to 7.2 using 2M NaOH.  The serum was filter sterilised, aliquoted and
stored at -20°C.
2.1.3 Cryopreservation
Cells were washed in PBS, followed by incubation with 5ml trypsin for 5 minutes at
room temperature.  After cells detached from the base of the flask, the trypsin was
inactivated by adding 8ml of growth medium (without estrogen) and the suspension
was centrifuged at 1,300rpm for 5 minutes at room temperature.  The pellet was then
resuspended in 10% DMSO in DCS-FCS and transferred to a cryovial (Fisher
Scientific).  Cells were immediately frozen at -80°C and transferred to liquid
nitrogen after 48 hours.  Recovery was carried out by resuspending the frozen cells in
15ml growth medium.
2.1.4 5-aza-2'-deoxycytidine treatment
Cells were cultured on 10cm dishes in 1µM 5-aza-dC (Sigma Aldrich) for 3 days.
Growth medium supplemented with fresh 5-aza-dC was replaced every 12 hours.
2.2 RNA analysis
2.2.1 RNA extraction
Throughout RNA extraction, RNA-only reagents were used to avoid contamination.
Confluent cells in T75 flasks were washed in ice cold PBS and lysed in 7.5ml
TriReagant (Invitrogen).  Lysed cells were transferred to 15ml falcon tubes and
homogenised with five passages through a 25-gauge needle.  1.5ml of CHCl3 was
added and tubes were vigorously shaken by hand.  Tubes were incubated for 2
minutes at room temperature and centrifuged for 10 minutes at 10,000rpm at 4°C.
Supernatants were then transferred to fresh tubes, avoiding any interface material,
and 3.75ml isopropanol was added.  Tubes were mixed by inversion and incubated
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for 10 minutes at room temperature.  After incubation, tubes were centrifuged for 10
minutes at 4,600rpm at 4°C.  Supernatants were carefully aspirated and the pellet
washed with 70% ethanol.  The tubes were centrifuged for 5 minutes at 4,600rpm at
4°C.  After a second wash and centrifugation, supernatants were aspirated and the
pellet centrifuged again to remove any residual ethanol.  The pellets were air dried
for 5 minutes and resuspended in 170µl ddH2O.  The RNA samples were then
transferred to sterile eppendorfs and 20U Turbo DNase I in 1× DNase I buffer
(Ambion) was added.  Tubes were incubated at 37°C for 15 minutes, after which
200µl buffered phenol/chloroform (BP/C) was added.  Tubes were mixed by
inversion and centrifuged at 14,000rpm for 15 minutes at 4°C.  Supernatants were
transferred to fresh tubes, 200µl CHCl3 was added and tubes were centrifuged at
14,000rpm for 15 minutes at 4°C.  Supernatants were transferred to new tubes, 1/10th
volume of 3M sodium acetate (pH 5.3) and 2.5× volume of ethanol were added.
Tubes were incubated at –20°C overnight.  The following day, tubes were
centrifuged at 14,000rpm for 15 minutes at 4°C.  The pellets were then washed with
100µl 70% ethanol and centrifuged at 14,000rpm for 5 minutes at 4°C.  The
supernatant was then resuspended in 100µl of ddH2O.  Concentrations were initially
measured on a benchtop spectrophotometer and quality checked on formaldehyde
gels.
2.2.2 Formaldehyde gels
10× formaldehyde buffer (10×FA) was made up (20mM MOPS, 50mM sodium
acetate, 10mM EDTA) and pH was adjusted to 7.0 with 2M NaOH.  Gels were made
by adding 1.2g agarose to 10ml of 10×FA and 90ml ddH2O.  The agarose mixture
was heated in a microwave to dissolve the agarose, cooled to 65°C in a waterbath
and 1.8ml 37% formaldehyde was added.  Once gels were poured and set, gel tanks
were filled with FA buffer (100ml 10×FA, 20ml 37% (12.3M) formaldehyde, 880ml
ddH2O) and RNA samples were loaded with 5×RNA loading buffer (16µl saturated
bromophenol blue, 80µl 500mM EDTA (pH8.0), 720µl 37% (12.3M) formaldehyde,
2ml 100% glycerol, 3.084ml ddH2O, 4ml 10×FA).  RNA samples were run out for 1
hour at 80V.
52
2.2.3 RNA expression arrays
Illumina HT-12 expression arrays were used to assay mRNA expression.  RNA was
converted to biotin-tagged cRNA using the TotalPrep RNA Labelling Kit (Ambion)
according to manufacturer’s instructions.  Briefly, these were as follows:
RT synthesis of first strand cDNA
50-500ng RNA samples were brought to 11µl with kit-supplied nuclease-free water
in sterile eppendorf tubes.  Tubes were mixed by gentle vortexing and pulsed in a
centrifuge at room temperature to ensure samples lay at the bottom of their tubes.
9µl of RT master mix (per 9µl:  1µl T7 oligo(dT) primer, 2µl 10×1st strand buffer,
4µl dNTP mix, 1µl RNase inhibitor, 1µl ArrayScript) was added and tubes were
mixed by pipetting up and down 3 times, flicking 3 times and pulsing in a centrifuge
at 4°C.  Samples were incubated at 42°C for 2 hours, after which they were
immediately placed on ice in preparation for the next step.
Second strand cDNA synthesis
80µl of second strand master mix (per 80µl:  63µl nuclease-free water, 10µl 10×2nd
strand buffer, 4µl dNTP mix, 2µl DNA polymerase, 1µl RNase H) was added to each
tube, which were then mixed by pipetting, flicking and pulsing as before.  Tubes
were incubated at 16°C for 2 hours and placed immediately on ice, or at –20°C if
overnight storage was required before proceeding to the next step.
 cDNA purification
250µl cDNA binding buffer was added to each sample and mixed by pipetting,
flicking and pulsing.  cDNA filter cartridges were placed into sterile eppendorf tubes
and the samples pipetted onto the centre of the columns.  Columns were centrifuged
at 10,000g for 1 minute at room temperature.  Flowthrough was discarded, 500µl
wash buffer was added and columns were centrifuged at 10,000g for 1 minute at
room temperature.  Flowthrough was discarded and columns centrifuged a second
time to ensure removal of all the wash buffer.  Columns were then placed into clean
cDNA elution tubes and 10µl of preheated 50-55°C nuclease-free water was added.
Tubes were incubated for 2 minutes at room temperature, after which they were
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centrifuged at 10,000g for 1.5 minutes at room temperature.  Without discarding the
flowthrough, a further 9µl of preheated 50-55°C nuclease-free water was added to
each column, followed by centrifugation at 10,000g for 2 minutes at room
temperature.  Samples were then either immediately processed, or stored at –20°C
overnight until ready for the next step.
In vitro cRNA synthesis
7.5µl of IVT master mix (per 7.5µl:  2.5µl T7 10× reaction buffer, 2.5µl T7 enzyme
mix, 2.5µl biotin-NTP mix) was added to each cDNA sample.  Samples were then
incubated at 37°C for 4-14 hours, or overnight in a hybridisation oven.  75µl of
nuclease-free water was then added to each sample and mixed by gentle vortexing.
Samples were then either immediately processed, or stored at –20°C overnight until
ready for the next step.
cRNA purification
350µl of cRNA binding buffer was added to each sample, after which 250µl ACS-
reagent grade 100% ethanol was added.  Samples were mixed by gently pipetting 3
times.  Each sample was pipetted onto the centre of a cRNA filter column and
centrifuged at 10,000g for 1 minute at room temperature.  Flowthrough was
discarded and 650µl of wash buffer added to each sample.  After centrifugation at
10,000g for 1 minute at room temperature, flowthrough was discarded.  Samples
were centrifuged a second time to ensure all wash buffer was removed.  Columns
were placed into fresh collection tubes and 100µl preheated 50-60°C nuclease-free
water was pipetted onto the centre of each filter.  Columns were incubated at room
temperature for 2 minutes and centrifuged at 10,000g for 1.5 minutes at room
temperature.  The concentration of each sample was measured on a NanoDrop 1000
(Thermo Scientific) and any samples with a concentration lower than 150ng/µl were
concentrated by ethanol precipitation, by adding 0.1 volume 3M sodium acetate, 2.5
volumes ethanol, precipitating overnight at –20°C and washing precipitates in 70%
ethanol, after which samples could be resuspended in an appropriate volume of
water.
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Labelled RNA samples were given to the Edinburgh Wellcome Trust Cancer
Research Facility (CRF) for quality assurance on Agilent bioanalyser chips.  Any
samples with an RNA integrity number (RIN) below 7.0 were discarded and the
experiments repeated.  When sufficient high quality samples had been assembled,
Illumina HT-12 arrays were run by the Edinburgh Wellcome Trust CRF.
2.2.4 qRT-PCR
cDNA synthesis
Two reactions for each RNA sample were made up in PCR tubes, from 14.5µl
ddH2O, 4µl 50µM random hexamers, 100ng RNA.  Tubes were labelled RT+ and
RT–.  Tubes were incubated in a PCR block at 70°C for 10 minutes, then placed on
ice.  To each tube 8µl 5×RT mix (Invitrogen), 4µl (0.1M) dithiothreitol (DTT)
(Invitrogen), 1µl RNase inhibitor (Invitrogen) and 17µl 5mM dNTPs (Invitrogen)
were added.  Then to the RT+ tubes, 2µl (50U/µl) Superscript II Reverse
Transcriptase (Invitrogen) was added and 2µl of ddH2O was added to RT– tubes.
Tubes were incubated at 42°C for 1 hour, then heat inactivated at 95°C for 5 minutes.
qRT-PCR
Reactions were made up in qPCR tubes (Qiagen) as follows:  5µl 2×SYBR green
PCR master mix (Roche), 1µl cDNA from previous reaction, 0.3µM appropriate
primer, 3.7µl ddH2O.  Reactions were carried out in a Rotorgene RG-3000
thermocycler (Corbett Research) on the following program:
1. 95°C 5 minutes
2. 95°C 15s
3. Annealing temperature (AT) 30s
4. 72°C 20s Data acquisition step




Table 2.1:  qRT-PCR primers.
Target Primers AT (°C) Reference
CYBA (1)
F  5′- CGCTTCACCCAGTGGTACTT -3′
R 5′- GAGAGCAGGAGATGCAGGAC -3′
57 (Perner et al. 2003)
CYBA (2)
F  5'- GCCAACGAACAGGCGCTGGC -3'
R 5′- GAGAGCAGGAGATGCAGGAC -3′
57
Primer3
(Rozen & Skaletsky 2000)
CYBA (3)
F  5′- GGCAGATCGAGTGGGCCATG -3′
R  5′- GAGAGCAGGAGATGCAGGAC -3′
57
Primer3
(Rozen & Skaletsky 2000)
DUSP1
F  5’- GCTGTGCAGCAAACAGTCGA -3’
R  5’- CGATTAGTCCTCATAAGGTA -3’
55 (Kojima et al. 2000)
RPL32
F  5’- GCCCAAGATCGTCAAAAAGA -3’
R  5’- GTTGCACATCAGCAGCACTT -3’
57
Primer3
(Rozen & Skaletsky 2000)
Each sample was run in quadruplicate and expression values calculated relative to
RPL32 levels.
2.3 DNA analysis
2.3.1 Genomic DNA extraction
T75 flasks of confluent cells were washed in PBS and incubated with 3ml trypsin for
5 minutes at room temperature.  10ml of cell medium was added to inactivate the
trypsin and the cell suspensions transferred to 15ml falcon tubes.  Tubes were
centrifuged for 4 minutes at 1,600rpm at room temperature.  Pellets were
resuspended in 1ml genomic lysis buffer (10mM Tris (pH 7.4), 100mM EDTA, 0.5%
SDS, 300µg/ml proteinase K) and incubated at 37°C overnight.  The following day,
an equal volume of BP/C was added and mixed by inversion.  Tubes were
centrifuged at 13,000rpm for 10 minutes at room temperature.  Supernatants were
transferred to fresh tubes, 2µl RNase A/T1 (Ambion) added and incubated at 37°C
for 1 hour.  An equal volume of BP/C was added to samples, which were mixed by
inversion and centrifuged at 13,000rpm for 10 minutes at room temperature.
Supernatants were transferred to fresh tubes and 0.1×volume of 3M sodium acetate
and 2×volume of ethanol were added.  DNA was precipitated at –20°C overnight.
Samples were centrifuged at 13,000rpm for 10 minutes at room temperature and
pellets washed in 70% ethanol, followed by another centrifugation for 10 minutes.
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The supernatants were removed and the pellets allowed to air dry for 5 minutes.
Pellets were resuspended in 50µl of TE buffer (10mM Tris pH 8.0, 0.1mM EDTA)
and concentration assayed on a benchtop spectrophotometer.
2.3.2 Transformation of competent cells
Three 50µl aliquots of DH5α (New England Biolabs) were thawed on ice for
approximately 10 minutes, until no ice crystals were present.  To one tube 1µl of
pSg5 DUSP1 (from Stephen Keyse, Dundee University) was added.  1µl positive
control plasmid was added to the second aliquot.  Cells were incubated on ice for 30
minutes, heat shocked at 42°C for 45s and incubated on ice for 2 minutes.  400µl
SOC medium was added and cells were incubated with shaking at 37°C for 1 hour.
Cells were spread onto LB plates with ampicillin, in aliquots of 200µl and 20µl and
incubated overnight at 37°C.
2.3.3 Preparation of plasmid DNA
The next day, a colony from each plate was inoculated into 1ml LB with ampicillin
in a 1.5ml eppendorf.  Samples were incubated at 37°C for 6 hours in a shaker.
These tubes were then added to 400ml LB with ampicillin and incubated at 37°C
overnight in a shaker.
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Figure 2.1:  A schematic of the pSG5 DUSP1 over-expression vector.
(From Stephen Keyse, Dundee University)
The following day, flasks were immediately put on ice, to prevent DNA loss.
Cultures were split into 2×200ml Sorvall centrifuge flasks and centrifuged at
5,000rpm for 10 minutes at 4°C.  Supernatants were discarded and pellets
resuspended in 20ml buffer P1 (50mM Tris (pH 8.0), 10mM EDTA, 100µg/ml
RNase A (Invitrogen) added immediately before use).  20ml buffer P2 (200mM
NaOH, 1% SDS) was added and gently mixed.  Samples were incubated for 10
minutes at room temperature and 20ml buffer P3 (3.0M potassium acetate (pH 5.5))
was added and immediately mixed by swirling. Samples were incubated on ice for
15 minutes and centrifuged at 10,000rpm for 30 minutes at 4°C.  Supernatants were
decanted into fresh flasks through two layers of muslin, dampened with ddH2O.
0.6×volume 100% isopropanol was added to each sample and incubated at room
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temperature for 1h.  Samples were centrifuged at 10,000rpm for 30 minutes at 4°C.
Supernatants were carefully aspirated and pellets washed with 100ml 70% ethanol.
Samples were centrifuged at 10,000rpm for 5 minutes at 4°C.  Supernatants were
carefully aspirated, samples were pulsed at 10,000rpm at 4°C and any residual
ethanol carefully aspirated.  Samples were then left to air dry for 15 minutes to
ensure that absolutely all ethanol had been removed.  Pellets were then resuspended
in 2ml TE (10mM Tris pH 8.0, 0.1mM EDTA) overnight at 4°C.  Samples were then
transferred to 15ml falcon tubes and made up to 2.5ml with TE.  After being brought
to volume, 2.5g caesium chloride was added to each tube and slowly brought to 37°C
in a waterbath.  After ensuring that all caesium chloride had been dissolved, 370µl
ethidium bromide was added to each tube.  Samples were then centrifuged at
4,000rpm for 10 minutes at room temperature.  Using a 5ml syringe, solutions were
carefully transferred to 2.5ml ultracentrifuge tubes (Beckman-Coulter), avoiding the
black precipitate.  Tubes were heat-sealed and centrifuged at 80,000g for 24 hours at
room temperature.
After centrifugation, dense bands were present, where plasmid DNA was highly
concentrated.  After piercing the top of the centrifuge tubes with a needle, a 2ml
syringe was used to remove the DNA by inserting the needle 5mm below the band
and sucking it out from beneath.  The DNA was put into a 15ml falcon, which was
then filled with water-saturated butanol.  After rolling for 15 minutes at room
temperature, samples were centrifuged at 4,600rpm for 10 minutes at room
temperature.  The top layer of pink butanol was aspirated and fresh water-saturated
butanol added.  This was mixed by rolling and removed by centrifugation, and
repeated until all pink colour had been removed.  A 0.1×volume of 3M sodium
acetate and 2.5×volume of 100% ethanol were added and incubated on ice for 15
minutes.  Samples were centrifuged at 4,600rpm for 10 minutes at 4°C.  Pellets were
resuspended in 200µl TE, overnight at 4°C.  Plasmid concentration was measured
using a NanoDrop 1000 (Thermo Scientific).
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2.3.4 Transient transfection
LCC9 cells were trypsinised and replated in 2×10cm dishes.  When cells were
approximately 80% confluent, cells were transfected with caesium chloride purified
over-expression plasmids as follows:  In one 15ml falcon tube, 18µg of plasmid
DNA was made up to 1200µl with OptiMem reduced-serum medium (Invitrogen).
In a second 15ml falcon, 60µl Lipofectamine 2000 (Invitrogen) was added to 1140µl
OptiMem.  Tubes were incubated for 5 minutes at room temperature and tube 1 was
pipetted into tube 2.  The mixtures were incubated for 15 minutes at room
temperature, during which the cells were washed with PBS and had 10ml of
OptiMem added to them.  After incubation, the plasmid mixtures were added
dropwise to the cells.  After 4 hours, 500µl of stripped serum was added.
2.3.5 Bisulphite treatment of DNA
Bisulphite treatment was carried out using the EpiTect kit (Qiagen) according to
manufacturer’s instructions.  Briefly, the procedure was as follows.
Bisulphite deamination
The reaction mixture was made up in PCR tubes, from <20µl DNA, 85µl bisulphite
mix, 35µl DNA protection buffer, RNase-free water up to 140µl.  Tubes were mixed
thoroughly until the colour of the mixture changed from green to blue.  Samples were
denatured for 5 minutes at 99°C, followed by an incubation at 60°C for 25 minutes.
An additional denaturation step followed, then a second incubation at 60°C, this time
for 85 minutes.  After a third denaturation, the final incubation took place at 60°C,
for 175 minutes.  Reactions were left at room temperature until ready to use.
Cleanup
PCR tubes were pulsed in a centrifuge to ensure removal of any liquid from tube lids
and samples transferred to 1.5ml eppendorf tubes.  560µl of loading buffer (BL) was
added, tubes were vortexed and pulsed.  Samples were then transferred to EpiTect
spin columns and centrifuged at 13,000rpm for 1 minute at room temperature.
Flowthrough was discarded and 500µl of wash buffer (BW) was added to each
column.  Tubes were centrifuged again at 13,000rpm for 1 minute at room
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temperature.  Flowthrough was discarded and 500µl desulphonations buffer (BD)
added.  Tubes were incubated for 15 minutes at room temperature and centrifuged
again.  Flowthrough was discarded and 500µl buffer BW was added to each column.
Tubes were again centrifuged, flowthrough was discarded and a second wash of
500µl buffer BW was added.  After another centrifugation, spin columns were placed
into fresh collection tubes and centrifuged again to remove any residual buffer.
Columns were then placed into clean 1.5ml eppendorfs and 20µl of elution buffer
(EB) was added.  Tubes were centrifuged at 12,000rpm for 1 minute at room
temperature.  If DNA was to be used within 24 hours, it was stored at 4°C.  If longer
term storage (up to 12 weeks) was required, samples were stored at –20°C.
2.3.6 Methylation specific PCR
20µl PCR reactions (1×PCR buffer mix (2µl 10×PCR buffer –Mg2+ (Invitrogen),
2mM dNTPs, 1U Taq polymerase (Invitrogen), 2mM MgCl2 (Invitrogen), up to 20µl
ddH2O), 1µl (~100ng) bisulphite treated DNA, 1µM primer) were carried out with
the methylation specific primers.
Table 2.2:  Methylation specific primers.
Target Primers AT (°C) Reference
Methylated
F  5′- GAGGTATAGGAGGGGTTTTG -3′
R 5′- CACCTTATCCTACTATTAATAAACG -3′
54 Self-designed
Unmethylated
F  5'- GAGGTATAGGAGGGGTTTTG -3'
R 5′- CACCTTATCCTACTATTAATAAACA -3′
54 Self-designed
PCR reactions were carried out as follows:




5. Go to step 2 29 times




After bisulphite treatment, CYBA CpG island DNA was amplified by PCR using tiled
primers across the CpG island.  By necessity, these primers were limited to certain
CpG depleted regions of the CpG island, meaning that the success of the PCR
reaction was highly variable between primer sets.
CpG island PCR
20µl PCR reactions (1×PCR buffer mix (2µl 10×PCR buffer –Mg2+ (Invitrogen),
2mM dNTPs, 1U Taq polymerase (Invitrogen), 2mM MgCl2 (Invitrogen), up to 20µl
ddH2O), 1µl (~100ng) bisulphite treated DNA, 1µM primer) were carried out using
the following program:
1. 95°C 3 minutes
2. 95°C 30s
3. 55°C 30s (Primer pair 2 was 54°C)
4. 72°C 30s
5. Go to step 2 29 times
6. 72°C 3 minutes
7. End
Table 2.3:  CYBA CpG island PCR primers.
Target Primers AT (°C) Reference
Region 1
F  5′- GATTTTAGATGAGAAGGGTTGAGTTTTAG-3′
R  5′- CTAAAACCCCCAATAATTCCCTTACAAACC-3′
55 Self-designed
Region 2
F  5'- GGTTTGTAAGGGAATTATTGGGGGTTTTAG -3'
R  5′- CTACAACCTAAAAAAATATCCCAAAACCCC -3′
55 Self-designed
Region 3
F  5′- GGGGTTTTGGGATATTTTTTTAGGTTGTAG -3′
R  5′- CAATATTTAAAAACTAAAATTTAAAAAACCC -3′
54 Self-designed
Region 4
F  5’- GGGTTTTTTAAATTTTAGTTTTTAAATATTG -3’




PCR products were run out on 2% w/v agarose TBE (89mM Tris base, 89mM Boric
acid, 2mM EDTA) gels and bands cut out for ligation into the pGEM-tEasy vector
system.
Gel extraction
A UV transilluminator was used to observe the TBE gels and bands excised with
clean razor blades.  Gel slices were weighed and transferred to clean eppendorf tubes
for gel extraction using the MinElute Gel Extraction Kit (Qiagen) as per
manufacturer’s instructions.  Briefly, the protocol was carried out as follows:
30µl gel slice buffer (GS1) was added for every 10mg of gel and tubes were
incubated for 10 minutes at 50°C.  Every 3 minutes, tubes were mixed by inversion
to ensure complete gel dissolution.  After dissolution, tubes were incubated for a
further 5 minutes.  The dissolved gel mixtures were pipetted onto the centre of quick
gel extraction columns and centrifuged at 12,000g for 1 minute at room temperature.
Flowthrough was discarded and 500µl buffer GS1 was added to each column.  After
a 1 minute incubation at room temperature, samples were centrifuged at 12,000g for
1 minute at room temperature.  Flowthrough was discarded and 700µl wash buffer
(W9) added.  Columns were incubated for 5 minutes at room temperature and
centrifuged at 12,000g for 1 minute at room temperature.  Flowthrough was
discarded, columns centrifuged a second time to remove any residual buffer and
columns placed into clean 1.5ml recovery tubes.  50µl preheated 65°C TE ((10mM
Tris pH 8.0, 0.1mM EDTA)) buffer was pipetted onto the centres of the filters.  After
a 1 minute incubation at room temperature, samples were centrifuged at 12,000g for
2 minutes at room temperature.  Purified DNA was quantified using a Nanodrop
1000 (Thermo Scientific).
Ligation
The following calculation was used to ascertain the quantity of insert required for
ligations:
ng insert =
ng vector × kb size of insert × insert:vector ratio
kb size of vector
63
where 50ng of vector was used and the insert:vector ratio was 3 and the vector was
3.015kb.  The size of inserts was dependent on the primer pairs used (1: 0.30kb, 2:
0.19kb, 3: 0.39kb, 4: 0.12kb).  In general, an estimated insert size of 0.30kb was used
to simplify the protocol, so 15ng of insert was used for each ligation.
Each experiment was carried out with a standard ligation reaction (5µl 2×T4 DNA
ligase ligation buffer, 1µl vector, 15ng PCR product, 1µl T4 DNA ligase, ddH2O up
to 10µl), a positive control (5µl 2×T4 DNA ligase ligation buffer, 1µl vector. 2µl
control insert, 1µl T4 DNA ligase, ddH2O up to 10µl) and a background control (5µl
2×T4 DNA ligase ligation buffer, 1µl vector, 1µl T4 DNA ligase, ddH2O up to 10µl).
Samples were either incubated for 1 hour at room temperature or 4°C overnight.
Blue/white screening
10% of each ligation reaction was then added to 20µl JM109 competent cells
(Promega) and incubated on ice for 30 minutes.  Cells were then heat shocked at
42°C for 45s, followed by a 2 minutes incubation on ice.  80µl Super-Optimal broth
+ Catabolite-repression (SOC) medium (Promega) was added per reaction and
incubated with shaking for 1 hour at 37°C.  Cultures were then poured onto LB
ampicillin agar plates with X-gal/IPTG (per plate:  100µl 100mM Isopropyl β-D-1-
thiogalactopyranoside (IPTG) and 20µl 50mg/ml X-gal) and spread using a sterile
glass spreader.  Plates were incubated at 37°C overnight, white colonies picked and
given to Edinburgh University Medical Research Council (MRC) technical services
for T7 and Sp6 cloning and sequencing.
Sequence analysis
Sequences were manually checked using Chromas Lite (version 2.01) and were
aligned using BiQ analyser (version 2.00) .
2.4 Protein analysis
2.4.1 Protein extraction
Confluent cells in 10cm dishes were washed with PBS and lysed in 500µl SDS lysis
buffer (62.5mM Tris (pH6.8), 2% SDS, 10% glycerol, 1% β-mercaptoethanol, 0.05%
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bromophenol blue).  Samples were sonicated at 5A for 30s and boiled for 5 minutes.
For long term storage, proteins were stored at –20°C.
2.4.2 Western blotting
Proteins were run out on 10% Bis-Tris acrylamide gels (1×Bis-Tris (pH 6.7), 10%
acrylamide (29:1) (Severn Biotech)) and transferred to PVDF membrane (Millipore)
pre-soaked in methanol, either by wet or semi-dry transfer.  Membranes were
blocked in 4% marvel in TBST for 1 hour at room temperature, followed by probing
with primary antibodies (Table 2.4) in 5% BSA in TBST overnight at 4°C.  After
three 10 minute washes with TBST, secondary antibody (Table 2.5) conjugated to
horseradish peroxidise (HRP) at a 1:5000 dilution was applied in 4% marvel in
TBST (50mM Tris (pH 7.6), 150mM NaCl, 0.05% Tween 20) for 1 hour at room
temperature.  After three more 10 minute washes in TBST, membranes were washed
in Supersignal West Pico ECL reagent (Pierce) for 5 minutes and chemiluminescence
measured by exposure to film (Fujifilm).
Table 2.4:  Primary antibodies for western blotting.
Target Dilution Species Manufacturer Cat. Number
CYBA 1:1000 Rabbit Santa Cruz 20781
DNMT1 1:2000 Rabbit New England Biolabs 01231
DUSP1 1:1000 Rabbit Santa Cruz 1102
GAPDH 1:5000 Rabbit Cell Signalling 2118
ERα 1:1000 Mouse Santa Cruz 8002
pERK1/2 1:1000 Rabbit Cell Signalling 9102
tERK1/2 1:1000 Rabbit Cell Signalling 9101
Table 2.5:  Secondary antibodies for western blotting
Species Concentration Manufacturer Cat. Number
Rabbit 1:5000 Cell Signalling 7074
Mouse 1:5000 Cell Signalling 7076
To reprobe membranes with a different primary antibody, membranes were washed
in TBST three times for 10 minutes, then incubated in 100mM glycine (pH2.5) at
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room temperature for 1 hour, with shaking.  Membranes were then rewashed three
times in TBST for 10 minutes, then probed as normal.
2.5 Cell proliferation assays
2.5.1 SRB proliferation assay
After cell suspension, cells were counted using a haemocytometer and plated in three
96-well plates per experiment, with ~2,500 cells per well.  Plates were labelled day 0,
3 and 6.  When plates were ready to be assayed, cells were fixed in 50µl ice-cold
50% v/v Trichloroacetic acid (TCA) at 4°C for 1 hour.  Plates were washed 10 times
under running water and dried at 37°C for up to three days.  After drying, plates were
left at room temperature until ready to be dyed.  Cell proliferation was measured by
adding 50µl 1% sulphorhodamine-B (SRB) dye (1% w/v SRB in 1% v/v glacial
acetic acid (GAA) (Fisher Scientific)).  Plates were incubated at room temperature
for 30 minutes and washed 4 times with 1% GAA.  Excess liquid was removed by
tapping plates over blotting paper, after which they were dried at 37°C overnight.
150µl 10mM Tris (pH10.5) was added per well and plates were gently shaken for 1
hour.  Optical density was measured at 540nm on a plate reader (Biohit).
2.5.2 Hydrogen peroxide treatment
A fresh aliquot of 10mM hydrogen peroxide (H2O2) was made up for every
experiment, from a 1M stock, in stripped medium.  At the same time, a 100×E2
(10µM) stock was made up in stripped medium.  Confluent cells in T75 flasks were
trypsinised and an aliquot diluted for cell counting using a haemocytometer.  Each
cell line suspension was diluted to 25,000 cells/ml and three aliquots per cell line
made up in 15ml falcon tubes as follows:
1. 9.8ml cell suspension + 200µl stripped medium
2. 4.9ml cell suspension + 100µl 100×E2
3. 4.9ml cell suspension + 50µl 10mM H2O2 + 50µl stripped medium
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From these three tubes, twelve experimental samples were made:
1. MCF7 +E2 1.5ml tube MCF7.1 + 1.5ml tube MCF7.2
2. MCF7 –E2 3ml tube MCF7.1
3. MCF7 +E2 + H2O2 1.5ml tube MCF7.2 + 1.5ml tube MCF7.3
4. MCF7 –E2+ H2O2 1.5ml tube MFC7.1 + 1.5ml tube MCF7.3
5. LCC1 +E2 1.5ml tube LCC1.1 + 1.5ml tube LCC1.2
6. LCC1 –E2 3ml tube LCC1.1
7. LCC1 +E2 + H2O2 1.5ml tube LCC1.2 + 1.5ml tube LCC1.3
8. LCC1 –E2 + H2O2 1.5ml tube LCC1.1 + 1.5ml tube LCC1.3
9. LCC9 +E2 1.5ml tube LCC9.1 + 1.5ml tube LCC9.2
10. LCC9 –E2 3ml tube LCC9.1
11. LCC9 +E2 + H2O2 1.5ml tube LCC9.2 + 1.5ml tube LCC9.3
12. LCC9 –E2 + H2O2 1.5ml tube LCC9.1 + 1.5ml tube LCC9.3
By making up samples in this way equal concentrations of cells, estrogen and H2O2
could be ensured across the entire experiment.  These cell suspensions were
immediately used in cell proliferation assays.
2.5.3 N-acetyl cysteine treatment
A fresh aliquot of 10M N-acetyl cysteine (NAC) (Sigma-Aldrich) was made up for
every experiment, in ddH2O.  At the same time, a 100×E2 (10µM) stock was made up
in stripped medium.  Confluent MCF7 cells in T75 flasks were trypsinised and an
aliquot diluted for cell counting using a haemocytometer.  Each cell line suspension
was diluted to 25,000 cells/ml and five aliquots made up in falcon tubes as follows:
1. 39.2ml cell suspension + 800µl stripped medium
2. 29.4ml cell suspension + 600µl 100×E2
3. 9.8ml cell suspension + 200µl stripped medium + 40µl 1mM fulvestrant
4. 9.8ml cell suspension + 200µl 10M NAC + 40µl 1mM fulvestrant
5. 9.8ml cell suspension + 200µl 10M NAC
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From these seven tubes, two sets of four experimental samples were made in 15ml
falcon tubes.
Control:
C1. MCF7 –E2 4ml tube 1
C2. MCF7 –E2 +10mM NAC 3ml tube 1 + 1ml tube 5
C3. MCF7 +E2 2ml tube 1 + 2ml tube 2
C4. MCF7 +E2 +10mM NAC 1ml tube 1 + 2ml tube 2 + 1ml tube 5
Fulvestrant (fulv) co-treatment:
I1. MCF7 –E2 + fulv 2ml tube 1 + 2ml tube 3
I2. MCF7 –E2 + fulv +10mM NAC 2ml tube 1 + 1ml tube 3 + 1ml tube 4
I3. MCF7 +E2 + fulv 2ml tube 2 + 2ml tube 3
I4. MCF7 +E2 + fulv +10mM NAC 2ml tube 2 + 1ml tube 3 + 1ml tube 4
By making up samples in this way equal concentrations of cells, estrogen, fulvestrant
and NAC could be ensured across the entire experiment.  These cell suspensions
were immediately used in cell proliferation assays.
2.5.4 CYBA siRNA
Oligonucleotides for CYBA knockdown (KD) were taken from a published paper .
Sense: 5'- GUGGUACUUUGGUGCCUACUCCAUU -3'
Antisense: 5'- AAUGGAGUAGGCACCAAAGUACCAC -3'
Confluent cells were split into 10cm dishes and allowed to reach ~30% confluence.
In one 15ml falcon tube, 340µl OptiMem reduced-serum medium (Invitrogen) was
mixed with 60µl Oligofectamine (Invitrogen) by gentle flicking and incubated at
room temperature for 5 minutes.  In a second 15ml falcon tube, 40nmol
oligonucleotides were made up to 400µl with OptiMem.  Tube 2 was pipetted into
tube 1 and the mixture incubated at 37°C for 15 minutes.  In the meantime, cells
were washed twice with PBS.  9.2ml OptiMem was added to the
oligonucleotides/OptiMem mixture and poured over the washed cells.  After 4 hours
of incubation in a humidified incubator at 37°C and 5% CO2, 7.5ml stripped
medium, 0.5ml DCS-FCS and 2ml 10×E2 was added.  After a further 24 hours of
incubation, cells were either trypsinised for protein extraction or further processed.
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Cells were counted using a haemocytometer and diluted to 25,000 cells/ml and seven
aliquots made up in falcon tubes as follows:
1. 12ml cell suspension
2. 8ml cell suspension + 80µl 100×E2
3. 5ml cell suspension + 20µl 1mM fulvestrant (fulv)
From these four tubes, six experimental samples were made up in 15ml falcon tubes.
K1. MCF7 CYBA KD +E2 2ml tube 1 + 2ml tube 2
K2. MCF7 CYBA KD –E2 4ml tube 1
K3. MCF7 CYBA KD +E2 +fulv 2ml tube 2 + 2ml tube 3
K4. MCF7 CYBA KD –E2 +fulv 2ml tube 1 + 2ml tube 3
By making up samples in this way equal concentrations of CYBA KD cells, estrogen,
tamoxifen and fulvestrant could be ensured across the entire experiment.  These cell
suspensions were immediately used in cell proliferation assays.
This protocol was repeated using non-specific control SMARTpool siRNA
(Millipore), referred to as “control” for the duration of the experiment.
2.6 Statistical analysis
2.6.1 Array statistical analysis
Array data was initially normalised using cubic spline normalisation, after which
analysis was performed using a combination of R (version 2.15.0) and Microsoft
Excel.
Comparisons of methylation array probes and expression array probes was enabled
using the DAVID web application (Huang da et al. 2009) to convert probe IDs from
both arrays to RefSeq accession numbers.
Venn diagrams were constructed using tools from the Euler Diagram Visualisation
Project (Chow & Rodgers 2005).
Enrichment for GO terms was carried out by listing those genes which satisfied
various criteria for significance.  These lists were then compared to the rest of the
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genome for functional enrichment using the FatiGO tool from Babelomics (Al-
Shahrour et al. 2006).
Unless otherwise stated, p-values refer to the results of Student T-Tests.
2.7 Public datasets
Methylation array data were taken from Sproul et al. (2011).  CGH array data were






3 The identification of estrogen responsive genes
I identified the estrogen-responsive genes in MCF7, LCC1 and LCC9 cells using
Illumina HT-12 oligonucleotide expression arrays.  Several papers have been
published looking at estrogen responsive genes in cell lines, particularly MCF7
(reviewed in Ochsner et al. (2009)), but previous studies have not adequately
controlled for the confounding effects of “stripping” serum with charcoal to remove
estrogen.  Typically, previous reports have compared gene expression in MCF7 cells
grown in medium supplemented with normal fetal calf serum with expression in
MCF7 cells grown in medium supplemented with dextran-charcoal stripped serum.
Whilst this stripping undoubtedly reduces estrogen levels dramatically, several other
biologically important molecules are also removed (Table 3.1) (Cao et al. 2009).
These effects could potentially confound experiments, either by masking the genuine
effects of estrogen, or by masquerading as effects attributable to estrogen-
withdrawal, when they are in fact caused by the removal of another component from
the medium. In my experiments, MCF7 cells were routinely cultured in media
supplemented with stripped serum which was further supplemented with exogenous
estrogen. Estrogen-withdrawal could then be effected simply by non-inclusion of the
exogenous estrogen and changes in gene expression could be attributed solely to the
removal of estrogen.
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Table 3.1:  Summary of the effects of serum stripping.
*indicates values below detectable threshold, N/A indicates that previous detection levels were too
low to ascertain the effects of charcoal stripping.
(Further analysis of enzymes and chemical components can be found in Supplementary Table S.1).
Adapted from Cao et al. (2009).
Analyte (unit) Normal  FCS Charcoal stripped FCS Percentage remaining
Cortisol (µg/dl) 0.15 <0.04* <27%*
Estradiol (pg/ml) 19.8 <10.0* <50%*
Folic acid (ng/ml) 5.5 <0.5* <10%*
Triiodo-L-thyronine (T3) (pmol/L) 233.9 54.6 23%
Free T3 (pmol/L) 4.6 <0.4* <9%*
Progesterone (ng/ml) <0.03* N/A N/A
Testosterone (ng/ml) <0.02* N/A N/A
L-thyroxine (T4) (µg/dl) 14.29 0.64 4%
Free T4 (ng/dl) >7.77 0.02 <1%
Vitamin B12 (pg/ml) 246.3 126.2 51%
I analysed the effects of depriving MCF7 cells of estrogen, and the effects of
supplementing LCC1 and LCC9 with estrogen.  To differentiate between rapid and
slower responses to estrogen, I analysed expression at both four and twenty-four
hours after the change in estrogen regimen.
3.1 Analysis of the gene expression dataset
Gene expression microarray analysis generates a great deal of data.  As the aim of
this work was to identify a potentially small number of genes that might be of
mechanistic importance in endocrine-resistance, it was important to devise a strategy
or strategies to parse the data and identify the most compelling candidates.  I decided
that a dataset of this size could be analysed in three complementary ways.  Firstly, a
gross overview of the dataset would be employed, to determine the magnitude of
gene expression changes due to estrogen in the different cell lines, and to determine
the extent to which they were correlated (see chapter 3.2).  I hoped that this might
elucidate large-scale changes in gene expression in response to estrogen-stimulation
across the whole genome, perhaps betraying some larger trends in the magnitude and
speed of gene expression changes in the different cell lines. The second approach
was to identify those genes that might be mechanistically involved in conferring
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estrogen-independence or fulvestrant-resistance by identifying patterns of gene
expression across the three cell lines.  For example, genes which exhibited estrogen-
dependent expression in MCF7 cells, but maintained expression in the absence of
estrogen in LCC1 or LCC9 might be of interest, as it would indicate that LCC1 and
LCC9 cells had evolved an independent mechanism for regulating these genes,
which might not have occurred unless it conferred a selective advantage.  I used a
bioinformatics approach based on gene ontology (GO) term analysis to try to identify
genes that might have been co-ordinately deregulated within functional groups.
Finally, I ordered the genes by their degree of differential expression and manually
curated the most deregulated genes.  Combined with a literature review, I hoped to
identify a shortlist of genes that were of potential biological interest in breast cancer,
and might be worthy of further study.
3.2 Separation of related cell lines by differential
estrogen-response
Before beginning the experiment, several hypotheses were tabled as to what the
effects of estrogen supplementation/withdrawal would be.  It was expected that the
different cell lines would have different gene expression patterns, and that expression
values for the different cell lines could be used in an unsupervised hierarchical
clustering analysis to demonstrate these differences. I could not predict whether the
effects of estrogen-withdrawal in MCF7 cells would be so great as to cause them to
have a gene expression pattern that was totally different to that observed in MCF7
grown in estrogen, but I did predict that the effects of estrogen in LCC9 would be
less than they were in MCF7, as LCC9 cells are entirely estrogen-independent.
However, as LCC9 cells still express ERα, I expected estrogen-dependent
transcription to be maintained at some loci.  As LCC1 cells have high levels of ERα
and are still sensitive to tamoxifen and fulvestrant, I predicted that the addition of
estrogen to these cells might cause even more deregulation than would be observed
in MCF7 cells.
A heatmap of gene expression (Figure 3.1) shows that MCF7 cells routinely grown
in estrogen are more related to LCC1 than LCC9 cells, both of which were grown in
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the absence of estrogen.  Despite considerable deregulation of gene expression by
estrogen-withdrawal in MCF7 cells, as shown by separate clustering, the MCF7 cells
undergoing estrogen-withdrawal were still more similar to control MCF7 cells than
they were to LCC1 cells.  As predicted, gene expression in LCC9 cells was not
markedly altered by estrogen supplementation, but unexpectedly, gene expression in
LCC1 cells was also not markedly affected, a surprise given the high levels of ERα
in these cells.
Figure 3.1: Unsupervised clustering of gene expression across the genome shows distinctive
gene expression patterns between cell lines.
Using the Pearson correlation as the distance metric.
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Interestingly, whilst supplementing LCC1 cells with estrogen appeared to make their
gene expression more similar to that of MCF7, estrogen-withdrawal from MCF7
cells did not make them much more similar to LCC1, suggesting that acute estrogen-
withdrawal had been compensated for in the LCC1 cells.
Whilst it may not be entirely legitimate to compare the effects of estrogen-
withdrawal from MCF7 cells with those of estrogen-supplementation in LCC1 and
LCC9 cells, these data indicate that chronic estrogen-withdrawal may have long-term
deleterious effects on estrogen-responsiveness.  As the effects are widespread, they
may be explained by secondary epigenetic changes at estrogen-responsive loci.
However, these changes remain to be elucidated.
3.3 Estrogen-response was larger and more variable in
MCF7 cells than in LCC1/9 cells
Because these global differences appeared to be sufficient to differentiate between
the cell lines, I wanted to analyse the magnitude of the global estrogen-response in
each cell line, hypothesising that LCC9 cells would exhibit lower magnitude changes
in response to estrogen compared to MCF7 cells.  I speculated that, due to the
increased levels of ERα in LCC1 cells, their estrogen-response would be highly
variable and the magnitude of estrogen-regulation would be higher than in MCF7
cells.  In actuality, it was MCF7 cells that exhibited the greatest degree of estrogen-
response at both four and twenty-four hours, with LCC1 and LCC9 cells showing
similarly muted responses (Figure 3.2).
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Figure 3.2:  A frequency plot shows that MCF7 cells exhibited the greatest degree of estrogen-
response.
















MCF7 -E2 (4h) MCF7 -E2 (24h) LCC1 +E2 (4h) LCC1 +E2 (24h) LCC9 +E2 (4h) LCC9 +E2 (24h)
This plot demonstrates that LCC9 cells were the least modulated by estrogen, with
very few genes being deregulated by more or less than a log2 ratio of ±0.4.
To further illustrate the paucity of response to estrogen in LCC1 and LCC9 cells, I
found the mean modulus log2 ratio for all genes at 4 hours and 24 hours. By taking a
modulus, I eliminated any neutralising effects of negative and positive regulation,
focussing only on the magnitude of response. On average, the magnitude of response
to estrogen in MCF7 cells was twice that observed in LCC1/9 cells (Figure 3.3).
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Figure 3.3: A bubble plot of mean modulus estrogen-response at 24 hours against 4 hours shows
that estrogen response was muted in LCC1/9 cells compared to MCF7 cells.






















In these experiments and in the conclusions that I have drawn, I have assumed that
the kinetics of transcriptional changes induced by withdrawing estrogen from cells
would be similar to the opposite changes caused by the addition of estrogen, all other
things being equal.  However, it could be that the effects of estrogen-withdrawal are
more rapid.  As ERα is in the nuclear compartment in MCF7 cells, a reduction in
estrogen might have immediate effects on ERα-binding to DNA. In contrast,
addition of estrogen to LCC1/9 cells would require the translocation of ligand-bound
ERα to the nucleus, which could potentially require more time. However, there is
good evidence that this translocation occurs rapidly, within ten minutes of estrogen-
addition (Htun et al. 1999; Stenoien et al. 2000).  This being the case, one would
expect the kinetics of estrogen-withdrawal and addition to be similar.
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3.4 LCC1 and LCC9 cells exhibit muted and delayed
estrogen-response
The heatmap in Figure 3.1 uses the overall correlation in gene expression as the
distance metric between samples.  I was interested to see to what extent the genes
significantly regulated by estrogen-withdrawal in MCF7 cells overlapped with the
genes that were regulated by estrogen-supplementation in LCC1/9 cells.  In the first
instance, I identified all genes which exhibited significant estrogen-response by a 2-
tailed 2-sample T-test (p<0.05), and looked for genes down-regulated by estrogen-
withdrawal in MCF7 and up-regulated by estrogen-supplementation in LCC1/9 cells,
and vice versa, at 4 hours (Figure 3.4). Whilst the size of overlaps compared
favourably to an entirely randomised dataset (Supplementary Figure S.1), false
positives based on the numbers of genes called as estrogen-regulated in each cell line
showed that the overlap was less significant than it might have appeared. In this
analysis, the probability of a gene being called as estrogen-regulated in each cell line
was calculated by taking the number of estrogen-regulated genes and dividing it by
the total number of genes on the array (25,158).  By multiplying probabilities, the
chance of an overlap was calculated and multiplied by the number of genes on the
array to yield a false-positive figure (α). By this method, only MCF7 and LCC1
exhibited an overlap greater than α, with over twice as many genes called as
estrogen-regulated in both cell lines as expected by chance alone. A chi-squared test
showed that this overlap was highly significant (p<0.0001). However, there
appeared to be no significant overlap between LCC9 and MCF7 cells, LCC1 and
LCC9 cells, or all three lines, with all observed values falling below those expected
by chance.
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Figure 3.4:  Comparison of estrogen-regulation (p-value <0.05) at 4 hours shows overlap
between MCF7 and LCC1.
α indicates the false positive overlaps based on the probabilities of a gene being called as estrogen-
regulated in each cell line.
However, at twenty-four hours, there was a far more considerable overlap between
all cell lines (Figure 3.5).  Nonetheless, the overlaps in estrogen-regulated genes
between MCF7 and LCC9 cells, and LCC1 and LCC9 cells, were still below the
number expected by chance.  Statistically significant overlaps were observed
between MCF7 and LCC1 cells (p<0.0001) and between all cell lines (p<0.0001), as





















Figure 3.5: Comparison of estrogen-regulation (p-value <0.05) at 24 hours shows a greater
overlap between cell lines.
α indicates the false positive overlaps based on the probabilities of a gene being called as estrogen-
regulated in each cell line.
Thus, these data support a muted and delayed response in genes that would normally
be regulated by estrogen, particularly in LCC9 cells.
One interesting question was whether the genes that appeared to be deregulated in
LCC1 and LCC9 cells, but which did not overlap with the genes deregulated in
MCF7 cells, were in some way being aberrantly regulated by estrogen in LCC1/9
cells.  However, there were alternate and somewhat more prosaic potential
explanations.  Gene deregulation in LCC9 cells was not marked and it is likely that a
large proportion of the genes identified as being potentially estrogen-regulated in the
T-tests would not have been called as such after accounting for multiple testing.  For
example, as there were 25,158 genes on the array, using a p-value cut-off of <0.05
for estrogen-regulation, some apparent regulation would have been detected in over
1,200 genes just by chance.  This suggest that the majority of the 1,529 genes that
were ostensibly regulated by estrogen in LCC9 cells at twenty-four hours, but not in





















proportion of these genes might actually have been deregulated in MCF7 and LCC1
cells, but that the degree of expression change was not sufficient to be detected as
statistically significant.
To investigate these possibilities, I first tried to improve the detection of significantly
estrogen-regulated genes by only including those that were changed with a log2 ratio
of greater than ±0.2.  Using this approach dramatically reduced the false discovery
rate (Supplementary Figure S.2).  The number of genes called as estrogen-regulated
was decreased, but the proportion in common between cell lines increased at both
four hours (Figure 3.6) and twenty-four hours (Figure 3.7).
Figure 3.6: Comparison of estrogen-regulation at 4 hours (log2 ratio ±0.2, p-value <0.05) shows
fewer estrogen-regulated genes in LCC1 and LCC9, but an increased proportion of genes that


















Figure 3.7: Comparison of estrogen-regulation at 24 hours (log2 ratio ±0.2, p-value <0.05) shows
a large overlap between MCF7 and LCC1 cells, but an unexpected concomitant increase in
estrogen-regulation in LCC9 cells.
In addition, the genes which appeared to be estrogen-regulated exclusively at twenty-
four hours in MCF7, LCC1 and LCC9 cells (Figure 3.4) were actually regulated in
the predicted direction in the other cell lines, but the degree of regulation did not
reach statistical significance in other cell lines (Figure 3.8).
Figure 3.8:  Mean log2 ratios of those genes that were called as estrogen-regulated at 24 hours
show that there was some residual estrogen-response in all cell lines.



















































The delay in response of LCC9 cells to estrogen could also be seen by comparing the
genes significantly regulated by estrogen at four hours with those regulated at
twenty-four hours.  In the case of MCF7 cells, there is a large degree of overlap in
estrogen-dependent genes at four and twenty-four hours (Figure 3.9).  Far less
overlap was seen in LCC1 cells (Figure 3.10), and less again in LCC9 cells (Figure
3.11).
Figure 3.9: Comparison of estrogen-regulated genes at 4 hours and 24 hours (log2 ratio ±0.2, p-
value <0.05) in MCF7 shows temporal action of estrogen.
Figure 3.10: Comparison of estrogen-regulated genes at 4 hours and 24 hours (log2 ratio ±0.2, p-



















Figure 3.11: Comparison of estrogen-regulated genes at 4 hours and 24 hours (log2 ratio ±0.2, p-
value <0.05) in LCC9 shows temporal action of estrogen.
The apparent delay in the response of LCC9 cells to estrogen led me to wonder
whether there might be more overlap between those genes that were estrogen-
regulated in MCF7 after four hours compared with those that were regulated at
twenty-four hours in LCC1/9 cells.  This proved to be the case (Figure 3.12), and the
degree of overlap appeared to be greater than that observed when comparing
estrogen-regulation at twenty-four hours in all cell lines (Figure 3.7).
Figure 3.12: Comparison of estrogen-regulation in MCF7 at 4 hours and in LCC1 and LCC9 at
24 hours (log2 ratio ±0.2, p-value <0.05) shows that a large proportion of genes that were



























Taken together, these data demonstrate that, though there is some estrogen-response
in LCC1 and LCC9 cells, it is somewhat muted compared to MCF7 cells.  In
addition, this response is considerably delayed in the derivative cell lines,
particularly LCC9 cells.
3.5 A comparison with other published datasets
As the methods that I used to detect estrogen-responsive genes were different to the
methods of others, and as I used the Illumina gene expression platform rather than
the more commonly used Affymetrix platform, I compared my dataset of estrogen-
responsive genes to those of other authors.  Instead of correcting for multiple testing,
I used the fold-change cut-off of a log2 ratio of ±0.2 as well as a T-test (p<0.05) to
increase my confidence that genes that I called as being estrogen-regulated in my
dataset were genuinely so.
The Estrogen Responsive Genes Database (ERGDB) (Tang et al. 2004) is a manually
collated list of estrogen-responsive genes in all tissues.  When compared to my
dataset in MCF7 (Figure 3.13), approximately half of the estrogen-regulated genes in
the ERGDB were present in my dataset (Skerry).  However, because this dataset
represents estrogen-regulation in all tissues, it is likely that several of those genes are
estrogen-regulated in tissues other than breast.
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Figure 3.13:  Approximately half of estrogen-regulated genes in ERGDB were estrogen-
regulated (log2 ratio ±0.2, p-value <0.05) in Skerry-MCF7 cells.
In order to investigate gene expression specific to the cell type, I then compared my
dataset to the Gene Expression MetaSignatures (GEMS) dataset, a meta-analysis of
estrogen-regulated genes in MCF7 cells (Ochsner et al. 2009) (Figure 3.14), in which
approximately half of each dataset was represented in the other.  Genes in GEMS











Figure 3.14: Approximately half of estrogen-regulated genes in GEMS were estrogen-regulated
(log2 ratio ±0.2, p-value <0.05) in Skerry-MCF7 cells.
At first sight, the overlap between my MCF7 dataset and the meta-analysis appeared
unimpressive.  It seemed that there was not as much in common between the sets as
might be hoped.  However, the two meta-analyses themselves did not completely
overlap (Figure 3.15).  Although there appeared to be a larger number of genes in my
dataset that were not represented in either GEMS or ERGDB, my dataset still
compared favourably to another published dataset, the “Rae dataset” (Creighton et al.












Figure 3.15:  Comparing ERGDB, GEMS (p-val<0.05) and Skerry-MCF7 (log2 ratio ±0.2, p-
value <0.05) shows that the two meta-analyses did not entirely overlap.
In addition to the high degree of overlap between GEMS and my dataset, the GEMS
set has the advantage that it contains temporal analysis as well as simple estrogen-
responsiveness.  Thus the more differential response in my experiments can also be
compared to what has been previously published.  In my experiments, there were
many more estrogen-regulated genes after four hours than in the GEMS dataset
(Figure 3.16), with a large number of genes regulated in my dataset that were not


















Figure 3.16:  The majority of estrogen-regulated genes after 4 hours in Skerry-MCF7 (log2 ratio
±0.2, p-value <0.05) were not found in the GEMS 4 hour data (p-value <0.05).
However, the degree of concurrence between the datasets increased when comparing
estrogen-regulated genes after twenty-four hours (Figure 3.17).
Figure 3.17:  Estrogen regulation after 24 hours in Skerry-MCF7 (log2 ratio ±0.2, p-value <0.05)




















Whilst it appeared that a large amount of known estrogen-regulated genes were
found in my dataset, more than in other published datasets, there were also a large
number of genes that my experiments called as estrogen-regulated which were not
found in either the ERGDB or GEMS. It is possible that my approach of controlling
for the effects of charcoal-stripping has increased the sensitivity of detecting
estrogen-regulated genes and has revealed that many more genes are directly or
indirectly regulated by estrogen than was previously thought.
3.6 Identifying genes that are of biological relevance to
estrogen-independence and fulvestrant-resistance
In order to identify potentially relevant genes, I divided the dataset into four subsets
of genes (Table 3.2), based on differential gene expression profiles between the cell
lines, utilising both the log2 and p-value cut-offs used heretofore to call gene
expression as “altered”.  This analysis was based on several assumptions, most
important of which was that the altered gene expression was providing cells with a
selective advantage.
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Table 3.2:  Criteria used to subdivide the expression array data.
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Each subset contained genes (Supplementary Table S.2-Supplementary Table S.5)
which I hypothesised would contain a characteristic gene expression profile for each
set of conditions, which could then be further analysed using gene ontology (GO)
terms.
3.6.1 Overview: Gene ontology analysis
Using the online program Babelomics 4.2 (Al-Shahrour et al. 2006), gene ontology
analysis was carried out on all the datasets to determine what, if any, functional
groups were associated with each set of conditions. I determined whether the genes
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in each subset were enriched for GO-defined functional categories compared with the
whole genome, using the FatiGO web application.  This software uses Fisher’s exact
test and corrects for multiple testing to derive p-values for the differences in GO
terms. Using this data-driven approach, I hoped to further elucidate the mechanisms
of the evolution of tamoxifen-resistance, with an eye to using this parsing as a means
by which to begin taking a candidate gene approach to the dataset as a whole.
Set 1: Misregulated in chronic estrogen deprivation
Set 1 contained 642 genes (Supplementary Table S.2), with repeated (100,000 times)
iterations of the same selection criteria on a random dataset yielding an average of
4.00 results, a false discovery rate of under 0.02%.  Thus I was confident that the
subset represented a real corpus of genes that were not estrogen-regulated in MCF7
cells, but were misregulated after chronic estrogen-deprivation, as in LCC1 and
LCC9.
GO analysis for this set (summarised in Table 3.3, complete in Supplementary Table
S.6) yielded results that might be expected, such as insulin-response genes, which
could conceivably be an alternate pathway compensating for the reduced estrogen in
the cell media.  More surprising was the significant enrichment for genes involved in
oligodendrocyte differentiation.  However, it was difficult to interpret the relevance
of such information.  The absence of both ERα and FOXA1 from the list of
transcription factors was slightly surprising, but this might be explained by the fact
that the cells in chronic estrogen-deprivation had compensated for the lack of
estrogen-signalling in those genes which were normally estrogen-dependent.
Similarly hard to interpret was the pathway analysis, which showed that pathways
involved in antigen processing and presentation are enriched in response to chronic
estrogen deprivation.
To ensure that the resultant gene ontology groups were not simply a product of
chance, FatiGO analysis was repeated ten times with a random set of 642 genes.
Four iterations yielded at least one result (Supplementary Table S.7), which was not
encouraging, but further analysis revealed that in all but one case this was an
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enrichment for a single transcription factor, which may not be surprising, given the
promiscuity of transcription factors.  In the one case where GO terms were enriched,
only one molecular function and one biological process were represented, leading me
to conclude that the hundreds of enriched GO terms in this subset were likely to
represent a real result.  This random interrogation did imply that perhaps further
validation might be required to draw conclusions from enriched transcription factors.
Table 3.3:  Top five GO terms within subcategories for Set 1 genes.


























Response to insulin stimulus
Cellular response to insulin stimulus

















Pathway enrichment Antigen processing and presentation 1.60×10-2
Set 2: Estrogen-regulated, but not misregulated in LCC9
Set 2 contained 300 genes (Supplementary Table S.3) with 100,000 iterations of the
same cut-offs yielding an average of 4.00 returns from a random dataset.  I
hypothesised that this subset would contain those genes that provided a survival
advantage against tamoxifen exposure, controlling for those genes that were
misregulated simply in response to chronic estrogen-deprivation.
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GO analysis (summarised in Table 3.4, complete in Supplementary Table S.8)
showed an enrichment for stimulus- and stress-response genes.  Of particular interest
was the pathway enrichment, which suggested a potential role for dual specificity
phosphatases in the MAPK pathway.  As discussed previously, the MAPK pathway
is thought to play a role in the development of endocrine resistance, so I concluded
that this GO result might be worth further investigation.
Table 3.4:  Top five GO terms within subcategories for Set 2 genes.
Type GO Term Definition p-value







Regulation of cell projection organization
Cellular response to stress
Cell morphogenesis





















Regulation of MAP kinase pathways
through dual specificity phosphatases
1.30×10-2
As before, random dataset analysis was carried out on ten generated sets.  As
previously, the most common results were transcription factors, with one set
producing an enrichment in a molecular function GO term (Supplementary Table
S.9).  Again, this meant that any transcription factor data should be considered
carefully, but that it was likely that other GO terms were real results.
Set 3: Genes that have lost estrogen-regulation in LCC1
In this dataset (Supplementary Table S.4) were genes that were estrogen-regulated in
MCF7 cells, but not in LCC1 cells.  I hoped that by analysing this set, I might
discover those genes that were involved in the rapid desensitisation to estrogen.
These genes were estrogen-responsive initially, after an acute deprivation of
estrogen, but after the longer term estrogen-withdrawal that LCC1 cells have
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undergone, they no longer retained their estrogen-sensitivity.  There were 951 genes
in this dataset. As with the other subsets, a false discovery rate was ascertained using
100,000 reiterations of the same cut-offs on a random dataset, which yielded an
average of 20.50 results, or a false discovery rate of 0.08%.
GO analysis (summarised in Table 3.5, complete in Supplementary Table S.10)
returned no pathway enrichment, which was surprising, given that whole pathways
are perturbed by estrogen-deprivation.  An overview of the GO terms enriched in this
subset tended to suggest a slight enrichment for genes involved in DNA damage
response pathways, possibly not significantly enough to count towards a significant
enrichment of the DNA damage-response pathway as a whole.
Table 3.5:  Top five GO terms within subcategories for Set 3 genes.























Cellular response to stress
Intracellular transport
Response to DNA damage stimulus
Cell cycle

















As previously, random gene set analysis was carried out (Supplementary Table
S.11). Again, the majority of iterations yielded no results, with transcription factors
being the most common result.  The high numbers of transcription factors enriched in
the random datasets definitely means that GO terms analysis of transcription factors
must be validated properly to draw any conclusions.  One iteration returned a result
98
for GO enrichment for a molecular function group.  However, this did not invalidate
the results for the actual dataset, given that there were multiple enriched GO groups.
Set 4:  Estrogen-regulation lost after chronic deprivation
This dataset (Supplementary Table S.5) contained those 120 genes that were
estrogen-regulated in MCF7 cells, but were not misregulated in LCC1 and LCC9
compared to MCF7.  Thus these genes were normally estrogen-regulated, but not
affected by the chronic estrogen deprivation undergone by LCC1 and LCC9.  As
such, I hypothesised that these genes would be involved in the development of
estrogen-independence, perhaps through the evolution of an alternative
transcriptional mechanism.  Puzzlingly, this subset was not significantly enriched for
any GO terms, with no results at any stage.  Perhaps there were insufficient genes in
the group to yield significant results, as ten random datasets yielded no results either.
3.6.2 A data-driven hypothesis
After the GO analysis of set 2 revealed the enrichment of the regulation of MAP
kinase pathways through dual specificity phosphatases, I decided to look in more
detail at the list of genes in set 2, those that I had hypothesised were involved in
providing a survival advantage against tamoxifen exposure.
Although the automatic analysis used was adequate for hypothesis generation, to
progress to a candidate gene approach, I decided to go through the set manually, and
select a shortlist of genes. Manually parsing the list of genes in set 2 to select those
genes that had a connection with MAPK in any way, even due to pathway crosstalk, I
created a shortlist of 22 genes (Table 3.6) to look at in greater detail.
























As well as simply data-mining the literature concerning these genes, I also checked
the expression array data for likely candidates to pursue further.  After looking in
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detail at the expression signatures of all the shortlisted genes, I decided that the best
candidate for further investigation was the Dual Specificity Phosphatase, DUSP1.
DUSP1 as a candidate gene
Expression array data for DUSP1 (Figure 3.18), previously known as MAPK
phosphatase 1 (MKP1) showed that it was estrogen-responsive in MCF7, upregulated
by estrogen-withdrawal.  In addition, long-term estrogen-deprivation over the course
of the derivation of the LCC1 cell line led to an increase in DUSP1 expression in
LCC1 compared to MCF7.
Figure 3.18:  Expression data for DUSP1.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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Whilst estrogen-withdrawal caused the up-regulation of DUSP1 in MCF7, estrogen-
supplementation led to the down-regulation of DUSP1 in LCC1 cells (Figure 3.19),
with both a sufficient log2 ratio to be called as biologically relevant and statistical
significance.  This estrogen-regulation was not observed in LCC9 cells
(Supplementary Figure S.26).
In addition to expression data, dual channel CGH experiments, using Agilent arrays,
comparing DNA copy number in MCF7 cells with LCC1 and LCC9 cells, showed
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that any differences in DUSP1 expression were not due to copy number variation
(Figure 3.20).
These observations combined made DUSP1 an extremely interesting candidate for
further investigation.
Figure 3.19: Log2 ratios of expression for DUSP1 in estrogen-supplemented LCC1 against
untreated LCC1 suggests that the gene had retained its estrogen-regulation.





































Figure 3.20:  CGH data shows that the region surrounding DUSP1 was not amplified in either
LCC1 or LCC9 compared to MCF7 cells.
Red line shows location of gene, with surrounding regions above or below the axis respectively
representing deletions or amplifications compared to MCF7 cells.
CGH data from Sproul & Culley (unpublished data).
A putative model for DUSP1-induced estrogen-independence
After a literature review, I proposed a model in which the transcription factor USF1,
misexpressed in LCC9 (Supplementary Figure S.27), led to changes in DUSP1
expression (Figure 3.21).
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Figure 3.21:  A proposed model by which DUSP1 misexpression might lead to cell proliferation
and growth, and the concomitant proteasomal degradation of ERα, via ERK pathways.
Dashed lines represent putative mechanisms, with solid lines signifying results from literature review
(Pages et al. 1993; Sommer et al. 2000; Henrich et al. 2003; Pervin et al. 2003; Callige et al. 2005;
Thomas et al. 2008).
DUSP1 was undetectable by RT-PCR in MCF7 cells
In order to verify the results of the expression array experiment, RT-PCR was carried
out.  However, the experiment did not detect a measurable amount of DUSP1 in
MCF7 cells, even after twenty-four hours of estrogen-deprivation, with RT-PCR for
DUSP1 consistently failing to show any DUSP1 expression. The lack of expression
appeared to be a real result, as the DUSP1 mRNA was detected in the positive
control, HEK293T cells transiently transfected with a DUSP1 over-expression vector
(Figure 3.22), and RPL32 cDNA was consistently detected (Figure 3.23). This
indicated that the failure to detect DUSP1 mRNA could not be due to failure of the



















Figure 3.22:  RT-PCR for DUSP1 showed no expression in MCF7 cells, even after 24 houes
estrogen-deprivation, despite detecting expression in HEK293T cells transiently over-expressing
DUSP1.
Figure 3.23:  RT-PCR for RPL32 showed that genetic material was present in the experimental
samples.
As the possibility that DUSP1 might regulate ERα levels was central to the
hypothesis, I also transiently transfected LCC9 cells with the same DUSP1 vector
used as a positive control in previous experiments, hypothesising that if my model
were true, that ERK-phosphorylation and ERα-expression would increase.  However,
over-expressing DUSP1 in LCC9 cells had no effect on ERK-phosphorylation or
ERα-levels (Figure 3.24).  The very low level of DUSP1 expression in LCC9 cells,
coupled with its lack of effect on ERα-expression in LCC9 cells led me to reject the
hypothesis that DUSP1 deregulation was linked to estrogen-independence and
fulvestrant-resistance.
Figure 3.24:  DUSP1 over-expression in LCC9 had no effect on ERK-phosphorylation or ERα-
levels.
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After this experiment, I decided to finally abandon DUSP1 and concentrate on other
genes, with an emphasis on employing corroborative experiments, such as DNA
methylation analysis, to ensure that future hypothesis generation wasn’t so reliant on
one technique. It seems likely that the background DUSP1 level of expression
correlated with a very low level of transcript, making it impossible to conduct further
experiments on the gene.
3.7 Discussion
In previous experiments, the passaging of cells into media supplemented with
charcoal stripped serum has been used to assay the effects of estrogen-deprivation.
However, this approach is clearly flawed, in that charcoal-stripping of serum
removes several other important molecules. By conducting a well-controlled
experiment, I have been able to properly assay the effects of estrogen on gene
expression in MCF7, LCC1 and LCC9 cells, without any conflicting variables
interfering with the proper interrogation of the data.
In common with their differing physiology, the three lines exhibited marked
differences in global gene expression.  Interestingly, estrogen-deprivation in MCF7
cells did not make them much more similar to LCC1 cells.  It is possible that the
initial response of MCF7 to estrogen-deprivation is not a reflection of the cells
becoming more estrogen-independent, but is a stress response to the removal of an
important stimulus.  It seems likely that LCC1 cells will have significant differential
gene expression compared to MCF7, to cope with chronic estrogen-withdrawal.
These expression changes are likely to take longer than twenty-four hours to
establish, which might go some way to explain why gene expression patterns in acute
estrogen-deprivation are not concordant with those observed in the more chronic
state.  However, when looking at the genes which were estrogen-regulated, it became
clear that not only was there distinct differential gene expression across the cell lines,
but there was a temporal element to the differences observed, as well as a reduction
in the magnitude of response.  LCC1 and LCC9 cells appear to have a slower and
more muted response to estrogen than MCF7.  Initially, I hypothesised that the slow
response might be due to the reduced amount of nuclear ERα in these cells, with a
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methodological problem contributing to the observed result.  However, this did not
satisfactorily explain the results, not simply because the issue of estrogen-withdrawal
being incomparable to supplementation would not explain why the magnitude of
response was lower.  In fact, the more tempting speculation is that reduced co-factor
expression is the major contributor to the muted response, given that this would
explain both the reduced speed and magnitude. Interestingly, comparing the
estrogen-response in MCF7 after four hours and that observed in LCC1/9 cells after
twenty-four hours brings the cell lines much more into line.  This shows that these
cell lines have not completely lost their estrogen-response (running completely
contrarily to the literature in the case of LCC9), that they tolerate estrogen-
deprivation but retain some estrogen-regulated transcriptional response.  What this
means for LCC9 cells and fulvestrant-resistance is difficult to know, but suggests
that estrogen-independence is a continuum, rather than a discrete “on/off” state.
After looking at the global picture, analysing the data became more difficult, in that
biological relevance was difficult to tease out from such a large cohort.  One tool
used to narrow the search was the gene ontology analysis tool FatiGO. These gene
ontology results pulled out some intriguing possibilities, not least of which was
observed in set 2 (in which estrogen-regulation was observed in MCF7 cells, with
misregulation in LCC1, but no misregulation in LCC9) and in set 3 (in which
estrogen-regulation occurred in MCF7 but not in LCC1).  The results from both these
sets suggested a potential role for stimulus-response, stress-response, USF1 and
DUSPs.  It is tempting to put these sets together and speculate that the stress-
response DUSPs, under the transcriptional control of USF1, play a role in the
evolution of estrogen-independence.  Indeed, further experiments took that approach,
focussing on DUSP1 and its potential role in altering ERα expression. Although a
literature review suggested a possible model, in my hands not only were
DUSP1/DUSP1 undetectable in these cell lines, but over-expression of DUSP1 in
LCC9 cells did not alter the expression of several key markers in my model.  These
experiments do not preclude the possibility that this pathway still represents an
important pathway in the acquisition of endocrine-resistance.  It is possible that I
simply chose the wrong DUSP family member to look at, and that further analysis
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will reveal that these molecules do indeed play a role in estrogen-receptor dynamics
and the evolution of estrogen-independence.
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4 Detecting differential methylation in the MCF7 cell
line and derivatives
In order to further identify candidate genes that might have been epigenetically
deregulated in fulvestrant-resistant cells, I investigated global methylation changes in
these cell lines, with Illumina Infinium methylation 27K arrays.  These arrays can be
used to interrogate the methylation status of CpG sites within the proximal promoter
of 14,475 genes. On average, each promoter is interrogated at two distinct CpG
sites. Whilst published papers from my group have focussed on correlating
methylation and tumour type (Sproul et al. 2011), with an aim of discovering
epigenetic markers and targets, I decided to use the array data to investigate
differentially methylated genes between MCF7, LCC1 and LCC9 cells, hopefully
correlating these data with those from the previous expression array to discover
candidate genes for further investigation.
4.1 Separation of related cell lines by differential
methylation
Just as was observed with the gene expression data, cell lines could be separated
from each other by their distinct methylation patterns (Figure 4.1).
108
Figure 4.1:  Unsupervised clustering of CpG site patterns for each cell line shows that each cell
type clustered separately.
Using the Pearson correlation as the distance metric.
As in the previous expression array analysis, MCF7 replicates cluster together, with
LCC1 and LCC9 cells more closely related to each other than to the parent MCF7
line.
4.2 Overall methylation patterns were similar between
cell lines
As expected, a large majority of CpG promoters were unmethylated in all three cell
lines (Figure 4.2), and there was a bimodal frequency distribution of DNA
methylation, consistent with that observed by others (Cortese et al. 2011).  The array
mostly detects CpG sites within CpG island promoters, so it was not surprising that
most of these sites were unmethylated.  Indeed, approximately 40% of CpG sites
exhibited less than 10% methylation across all cell lines.
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Figure 4.2: Frequency plots for overall promoter methylation show that the majority of sites
were unmethylated, across all lines.
An average of 41.4% CpG sites exhibited less than 10% methylation (shaded) in all cell lines.






























































































Only a minority of CpG sites within CpG islands are methylated, such as at
imprinted genes, as well as a small proportion of genes that show tissue specific
expression and methylation.
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4.3 Methylation profiles were similar between cell lines
The heatmap (Figure 4.1) was generated by using the Pearson correlation of all CpG
sites between the cell lines as the distance metric.  Despite the higher correlation
between replicates than between the different cell lines, the correlation (R2) between
cell lines was still quite high (Figure 4.3).  Whilst the heatmap detected differences
between the cell lines, these were quite subtle and were consistent with all cell lines
being derived from the same original cells.
Figure 4.3:  Correlation of methylation at each CpG site between cell lines shows that cell lines
exhibited similar methylation profiles.
MCF7 cells were similar to both (A) LCC1 cells and (B) LCC9 cells, with (C) a comparison of LCC1
and LCC9 cells showing an even higher concordance.






















(A)  CpG methylation:  MCF7 vs. LCC1
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(B)  CpG methyla ion:  MCF7 vs. LCC9
(C)  CpG methyla ion: LCC1 vs. LCC9
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4.3.1 Expressed genes were not methylated, but there was
no correlation between expression and methylation
It is known that non-expressed genes are not necessarily methylated and my data
confirm this.  Because non-expression does not necessarily lead to methylation, there
was no inverse correlation between methylation values and expression values (Figure
4.4). However, expressed genes are, in general, never methylated.  Although there
appear to be a few genes which are expressed and have highly methylated CpG sites,
it is likely that these sites are in the region of active promoters, rather than being at
the promoters themselves.
Figure 4.4:  There was no global correlation between methylation and expression.
(A) MCF7, (B) LCC1 and (C) LCC9 cells.















































Estrogen-withdrawal does not lead to inevitable changes in
DNA methylation at estrogen-regulated genes
I was interested to see whether estrogen-withdrawal would have secondary effects on
DNA methylation, and whether this would enable me to investigate whether there
was any relationship between those genes that were differentially expressed after
estrogen-deprivation in MCF7 cells and differentially methylated between MCF7 and
LCC1 cells.  I hypothesised that those genes that were misregulated in response to
estrogen-deprivation in MCF7 cells would be more likely to be methylated in LCC1
cells.  In graphs correlating gene expression changes and differential DNA
methylation, these genes might appear as a distinct, highly methylated cluster.
Alternatively, if methylation was in some way an inevitable consequence of changes
in gene expression, it might have been possible to observe a continuous correlation
between changes in gene expression and DNA methylation.
I correlated changes in gene expression in MCF7 cells in response to estrogen-
withdrawal with differential methylation between long-term estrogen-deprived LCC1
and MCF7 (Figure 4.5). I observed no distinct cluster of highly methylated genes,
nor did I observe an obvious inverse correlation between changes in gene expression
and changes in methylation.  To refine the analysis, I included only those genes that
were statistically significantly differentially expressed.  Again, there was no obvious
cluster of hypermethylated genes, no correlation was detected, and the R2 value was
very low (Figure 4.6). Further selecting for estrogen-regulated genes based on a log2
ratio cut-off did not alter this result (Supplementary Figure S.28).  These data
demonstrate that there is not a significant cluster of genes which are methylated as a
consequence of long-term estrogen-withdrawal.  However, the analysis does not
exclude the possibility that there might be a small number of genes, albeit fewer than
would constitute a cluster, that are so affected.  I went on so see whether a more
categorical approach for looking at CpG methylation would reveal any trends in gene
expression and methylation.
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Figure 4.5:  Estrogen-regulation in MCF7 cells did not predict differential methylation in LCC1
cells.
After (A) four hours and (B) twenty-four hours.
(A)  Correlation of 4h estrogen regulation in MCF7 and
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(B)  Correlation of 24h estrogen regulation in MCF7 and
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Figure 4.6:  Statistically significant (p<0.05) estrogen-regulation in MCF7 cells did not predict
differential methylation in LCC1 cells.
After (A) four hours and (B) twenty-four hours.
(A)  Correlation of 4h estrogen regulation in MCF7 and
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(B)  Correlation of 24h estrogen regulation in MCF7 and
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4.4 Categorising methylation into functional discrete
groups reveals a relationship between methylation
and transcriptional repression
Without any restriction applied to probe β-value, using statistical significance only
(p<0.05), there would be 3,515 significantly methylated probes in LCC1 compared to
MCF7 and 3,767 significantly methylated probes in LCC9 compared to MCF7 (out
of 27,578).  By using the Bonferroni correction for multiple testing, these could be
reduced to 66 and 57 probes respectively (Supplementary Table S.12 and
Supplementary Table S.13). However, I believed the Bonferroni correction to be too
stringent in this case and preferred to rely on a more biologically relevant stricture.
This study, and a previous study carried out in this laboratory (Sproul et al. 2011),
have demonstrated that expressed genes generally have promoter methylation β-
values of less than 0.3.  Therefore, as in the previous study, I divided probes into
three categories: methylated (β>0.7), unmethylated (β<0.3) and partially methylated
(0.3<β<0.7). By this analysis, approximately 60% of CpG sites were called as
unmethylated, with around 23% called as methylated, across all three cell lines
(Figure 4.7). Previous work has shown that both methylated and partially methylated
probes are unlikely to be associated with expressed genes.  In my analysis, in order
for a gene to be called as differentially methylated between the cell lines, not only
must there be a statistically significant difference, but it also had to be unmethylated
(β<0.3) in one cell line and methylated (β>0.7) in another.
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Figure 4.7:  Methylation was divided into three types.

























Unmethylated Partially methylated Methylated
4.4.1 Cut-offs for methylation reveal differential expression
between sites of low and high methylation
Despite the overall picture observed in chapter 4.3.1, wherein methylation was not
predictive of expression, when cut-offs for methylation are introduced to create
distinct subsets of genes, rather than a continuum of methylation, there was a highly
significant difference in expression (Figure 4.8).
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Figure 4.8: Bubble plots of gene expression against low, partial and high methylation at CpG
sites show a significant difference in expression between categories.
In (A) MCF7, (B) LCC1 and (C) LCC9 cells, CpG sites that were classified as having low, partial and
high methylation exhibited significantly differential gene expression. Bubble diameter, as shown in
the centre of each bubble, represents standard deviation as a measure of spread, p-value shows


















































































So, although viewing methylation as a continuum showed that expression and
methylation were not correlated, by simply subsetting methylation into three types,
strongly significant differential expression was observed.
4.4.2 Highly differentially methylated CpG sites between cell
lines were infrequent
Parsing genes for biologically significant methylation revealed that of the 27,578
CpG sites on the array, only 42 unique gene promoters were differentially methylated
(β-values below 0.3 in one cell line, above 0.7 in another, and a p-value of <0.05)
between MCF7 and LCC1 cells (Table 4.1) and 36 between MCF7 and LCC9 cells
(Table 4.2).  Of the 42 differentially methylated sites between MCF7 and LCC1
cells, 14 were detected as differentially methylated by more than one probe.  Of the
36 between MCF7 and LCC9, there were 12 genes that exhibited significant
differential methylation at two or more probes.
Table 4.1: There were 42 differentially methylated genes between MCF7 and LCC1 cells.
Star (*) indicates gene where additional probe(s) exhibited statistically significant differential












































Table 4.2:  There were 36 differentially methylated genes between MCF7 and LCC9 cells.
Star (*) indicates gene where additional probe(s) exhibited statistically significant differential






































Only seven CpG sites were differentially methylated between LCC1 and LCC9 cells
(Table 4.3), only one of which was detected as differentially methylated by more
than one probe.
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Table 4.3:  There were 7 differentially methylated genes between LCC1 and LCC9 cells.










The low frequency of methylation events between MCF7 and LCC1/9 cells was
surprising, given that there are important physiological differences between the cell
lines.
If partially methylated genes were included in the analysis, wherein genes would be
called as differentially methylated if β-values were below 0.3 in one cell line and
above 0.3 in another, there were 1,098 differentially methylated genes between
MCF7 and LCC1. Between MCF7 and LCC9 there were 1,174 and there were 881
between LCC1 and LCC9. However, I felt that this analysis was not likely to
provide those genes for which epigenetic regulation was biologically important and
representative of a survival advantage for the cell.
4.4.3 Detecting differential expression in differentially
methylated genes
In order to discover those genes which might have been epigenetically misregulated
during the evolution of resistance to endocrine therapy, I decided first to limit my
investigations to those genes which were methylated in both LCC1 and LCC9
compared to MCF7 cells (Table 4.4).  I hypothesised that methylation caused by
estrogen-deprivation in LCC1 cells would provide a selective advantage to those
cells that would go on to become resistant to endocrine therapy. Genes that were
differentially methylated in both LCC1 and LCC9 cells would be, I hypothesised,
those that were involved in the evolution of endocrine-resistance via the acquisition
of estrogen-independence. However, in order to discover an epigenetic mechanism,
it was not enough to simply analyse methylation.  Rather a correlation between
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methylation and expression was needed, to identify those methylation changes that
were acting upon gene expression.
Table 4.4:  17 promoters contained statistically and biologically significantly differentially
methylated CpG sites between MCF7 and LCC1/9 cells.
Methylation array data shown in Supplementary Figure S.29-Supplementary Figure S.45.
Star (*) indicates gene where additional probe(s) exhibited statistically significant differential



















Of these genes, only six displayed significantly differential expression between
MCF7, LCC1 and LCC9 cells (Table 4.5).  However, as comparisons of methylation
levels and expression showed (Supplementary Figure S.46-Supplementary Figure
S.51), not all differentially methylated and expressed genes were expressed in a
manner consistent with their methylation.  Only three genes showed differential
methylation that was consistent with their differential expression i.e. high
methylation correlated to low expression and vice versa.
Table 4.5:  Of the 17 differentially methylated genes between MCF7 and LCC1/9, six were
significantly differentially expressed.









A methylated and differentially expressed candidate gene
Of the six genes that were differentially methylated and differentially expressed, only
PANX2, CYBA and KEAP1 were considered for further investigation.  This was due
to the fact that their expression and methylation best represented our understanding
of the function of DNA methylation. Of these genes, I decided to pursue CYBA as a
candidate gene for further investigation as it was the only gene to have been called as
differentially methylated by more than one probe on the array.  Both KEAP1 and
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PANX2 exhibited statistically significant differential methylation at one probe only,
with a second probe detecting no statistical difference between the cell lines.  Thus I
felt most confident that it was probable that the CYBA promoter was consistently
methylated, and therefore more likely to be epigenetically regulated.
4.5 Discussion
Despite being able to differentiate between the three related cell lines by global
methylation patterns, the striking result here is that, for the most part, the differences
were subtle, and that large differences at individual loci were rare.  Given the
phenotypic differences between them, and the gene expression patterns, one might
have expected large scale disparity in CpG methylation.
It is possible that the reason for the small number of significant changes in
methylation is that the cut-off decided upon for determining a biologically significant
difference in methylation (β-values <0.3 and >0.7) was too stringent.  However,
given that even large increases in methylation can have no biological effects at
unexpressed loci in cell lines, it seemed sensible to ignore small changes in
methylation as these were even more likely to have negligible biological effects.
The failure to detect more differentially methylated genes could also be technical.
Whilst the expression array contains 27,578 probes, these represent only 14,475 of
the ~30,000 genes in the genome.  Of the CpG probes, 11,802 are at sites that
correspond to promoters of genes found in the expression array. Thus the coverage
of these arrays is far from complete, and means that there are almost certainly more
methylated genes in the genome than were discovered in these experiments. If a
larger-scale analysis of the CpG sites throughout the genome were to be carried out,
perhaps using the Illumina Infinium 450K array, which interrogates over 485,000
CpG sites, it seems likely that a higher number of significantly methylated sites
would be found. Other approaches, such as reduced representation bisulphite
sequencing (RRBS) (Meissner et al. 2005) and bisulphite sequencing after exon
capture by liquid hybridization (Wang et al. 2011), both of which employ high-
throughput next-generation sequencing, could have afforded higher resolution
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mapping of CpG methylation across the genome.  However, RRBS, being dependent
on using sequence specific restriction enzymes to compartmentalise the genome and
enrich for gene-rich sequences before analysis, necessarily results in under-
representation of some gene-rich areas that do not contain these sites.  Exon capture
prior to next generation bisulphite sequencing results in an under-representation of
promoters in the analysis.  These latter techniques are also considerably more
expensive than array-based techniques.
Although it appeared that differential methylation did not correlate with estrogen-
response within any of the cell lines, if genes were stratified by methylation into
high, partial and low groups, statistically significant differences in expression
between lines could be seen. However, across the cell lines, differences in
methylation did not necessarily predict for differences in expression. Of the
seventeen genes with significant differences in methylation between MCF7 and
LCC1/9 cells, only six displayed significantly differential gene expression, of which
only three genes actually had the inverse correlation between methylation and
expression that one would expect. This could indicate that some of the differentially
methylated genes are not actually expressed in any of the cell lines, or that the CpG
sites interrogated are not ideal for showing the effects on expression, perhaps
because they are not close enough to the promoter.
Whilst there may well be other genes within the analysis that could be worthy of
further study, the combination of differential methylation and differential expression
arising at PANX2, KEAP1 and CYBA suggested that these genes offered the best
chance of finding a genuine epigenetically regulated gene amongst the cell lines
studied.  Whilst CpG sites interrogated at PANX2 and KEAP1 were not consistently
methylated, both probes for CYBA exhibited similar differential methylation patterns
across the cell lines.  Thus I decided to focus on CYBA as the subject for my analysis.
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5 The role of CYBA in endocrine-resistance
Previous research has shown that fulvestrant-induced cell death might be conferred
by oxidant damage (Newton et al. 1999). The possibility that the source of
damaging oxygen free-radicals might be CYBA, a component of the NADPH-
oxidase complex, encouraged me to pursue the epigenetic analysis of this gene.
Epigenetic down-regulation of CYBA in LCC9 cells might explain their resistance to
fulvestrant. However, further investigation was required to substantiate the
epigenetic change that was suspected from the DNA methylation and expression
arrays, and to determine whether CYBA down-regulation was a bona fide means of
effecting endocrine-resistance.
5.1 The function of CYBA
The CYBA gene encodes the protein cytochrome b-245 light chain (CYBA), formerly
known as p22phox.  This protein is a critical component of the active NAPDH-
oxidase complex (Ushio-Fukai et al. 1996), required for both the assembly of the
complex (Ambasta et al. 2004) and the localisation of the complex to the cell
membrane (Nakano et al. 2007).  Mutations in the gene are associated with chronic
granulomatous disease (Dinauer et al. 1990), a set of diseases characterised by an
inability of phagocytes to destroy engulfed foreign agents, leading to the formation
of granulomata (reviewed in Heyworth et al. (2003)).  However, that is not to say
that CYBA only plays a role in phagocytic cells, as increased CYBA expression has
been implicated in coronary artery disease (Azumi et al. 1999) and, more recently,
polymorphisms in CYBA have been connected with breast cancer in post-menopausal
women (Seibold et al. 2011). However, in non-phagocytic cells, the NADPH-
oxidase complex is composed slightly differently to that found in phagocytes.
In healthy, non-phagocytic cells, CYBA directly interacts with NADPH oxidase
complex components Nox1 and Nox4 (Ambasta et al. 2004) to form superoxide,
coupled to the oxidation of NADPH to NADP+, which, when converted to hydrogen
peroxide (H2O2), can diffuse back across the cell membrane to facilitate ROS-
dependent intracellular signalling (Figure 5.1).  Although H2O2 is highly diffusible,
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there is some evidence that its diffusion across cell membranes is facilitated by
aquaporins, allowing fine control over the redox potential of the cell (Bienert et al.
2007).
Figure 5.1: A schematic showing CYBA as a critical component of NAPDH-oxidase, interacting
directly with Nox family proteins.
Adapted from Novo & Parola (2008).
5.2 The genetics and epigenetics of CYBA
CYBA is a 7,760bp gene (Figure 5.2) located on chromosome 16, at 16q24, on the
complement strand from 88,717,457 to 88,709,697.  There is a CpG island associated
with the promoter, the methylation of which has been associated with inactivation in
melanoma cell lines (Gallagher et al. 2005).













RT-PCR primersCYBA 1: 200bpCYBA 2: 267bp
CYBA 3: 289bp
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After splicing, the primary mRNA transcript is 797bp long, translating to a 195
residue polypeptide.
5.3 CYBA was misexpressed in LCC1/9 cells
In MCF7 cells, CYBA was highly expressed and estrogen-responsive (Figure 5.3).
However, whilst this estrogen-regulation was also found in LCC1 cells after twenty-
four hours (Figure 5.4), expression was much lower. In LCC9 cells, as might be
expected, there was no significant estrogen-response (Figure 5.5).
Figure 5.3: Expression array analysis shows that CYBA was highly expressed and estrogen-
responsive in MCF7 cells.


















Figure 5.4: Expression array analysis shows that CYBA expression was lower in LCC1 cells, but
estrogen-regulation was retained.




















Figure 5.5:  Expression array analysis shows that CYBA exhibited low expression and no
significant estrogen-regulation in LCC9 cells.

















Whilst CYBA was still expressed in LCC1 cells to some extent and to a lesser extent
in LCC9 cells, expression was markedly lower than in MCF7 cells (Figure 5.6).
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Despite the obvious positive regulation of CYBA by estrogen in MCF7 cells, CYBA
was not affected by estrogen in LCC9 cells, in keeping with the idea that some form
of functionally significant epigenetic change had taken place in these cells.
Figure 5.6: CYBA expression was markedly lower in LCC1/9 cells than in MCF7 cells.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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5.3.1 CYBA misexpression was verified by qRT-PCR
To validate the array data, I quantified CYBA expression by qRT-PCR.  I first
validated the primer sets by agarose gel electrophoresis to verify that the PCR
products were of the expected size (Figure 5.7).  These primers were then used to
perform qRT-PCR on RNA extracted from MCF7, LCC1 and LCC9 cells, verifying
the  differences in expression that had been indicated by the expression arrays
(Figure 5.8).
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Figure 5.7:  RT-PCR primers detected CYBA mRNA.
Figure 5.8:  qRT-PCR (averaged from 3 primer sets) verified CYBA under-expression in
LCC1/9 cells.


























Using Agilent arrays to conduct dual channel CGH experiments, I compared DNA
copy number in MCF7 cells with LCC1 and LCC9 cells, demonstrating that the
differences in expression between the cell lines could not be explained by
amplification or deletion at the locus (Figure 5.9).
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Figure 5.9: CGH data shows that copy number changes were not effecting expression changes
in LCC1/9 cells.
Red line shows location of gene, with surrounding regions above or below the axis respectively
representing deletions or amplifications compared to MCF7 cells shown as a log2 ratio.
CGH data from Sproul & Culley (unpublished data).
5.3.2 CYBA protein expression correlated with mRNA
expression
Western blots (Figure 5.10) detected the presence of a 22kDa band corresponding to
CYBA in MCF7 cells, but it was undetectable in LCC1 and LCC9 cells. In LCC1
cells, a faint low molecular weight band of approximately 20kDa was consistently
seen, which I speculated might be a fragment of the CYBA protein that was
expressed from a cryptic promoter. Unfortunately, there were few clues as to the
nature of this lower molecular weight protein, because the antibody used in the
western blot was raised against the full-length protein.  Another possibility was that
the LCC1 cells possessed an activity that cleaved the mature protein into a small N-
terminal fragment, as has been suggested occurs in human polymorphonuclear
leukocytes (Foubert et al. 2001), potentially retaining some functional activity (von
Löhneysen et al. 2008).  However, such a hypothesis would suggest retained active
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usage of the canonical promoter, which the methylation arrays had suggested was
highly methylated and likely inactive.
Figure 5.10:  Western blots for CYBA show that protein expression was reduced in LCC1/9 cells
compared to MCF7 cells.
5.4 CpG island methylation in the CYBA promoter
region
In the methylation array experiment, the CpG island found in the CYBA promoter
region contained two methylation probes (cg19,790,294 and cg26,537,639).  One
was within the actual CpG island, whilst the other was distal to the promoter region,
both of which showed differential methylation, albeit to different extents (Figure
5.11).  In MCF7 cells, both probes satisfied my criteria for being unmethylated.  In
LCC1/9 cells, the probe within the CpG island satisfied my criterion for being fully
methylated and was statistically significantly differentially methylated when
compared to MCF7 cells, whilst the probe upstream of the CpG island was partially









































Figure 5.11:  There was significant differential methylation of the CYBA promoter-associated
CpG island.
Differential methylation was observed both (A) within the CpG island and (B) distal to it.
I hypothesised that this methylation was functionally relevant in the silencing of
CYBA in LCC1/9 cells, either as a direct effector of silencing or as a marker of an
already silenced gene. Because methylation was coincident with gene silencing, it
led me to hypothesise that either the methylation was involved in the maintenance of
the silenced state, or that promoter methylation was actually inducing silencing.
5.4.1 Bisulphite sequencing verified methylation array data
By treating DNA with sodium bisulphite, unmethylated cytosine residues are
deaminated to uracil, but methylated cytosines are not converted. Initially, I
attempted to use methylation-specific PCR (Herman et al. 1996) to assay the
methylation status of the CpG sites, but the PCR probes were unable to differentiate
between methylated and unmethylated loci (Supplementary Figure S.52). I therefore
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decided to PCR amplify the bisulphite-deaminated promoter region containing the
transcription start site (TSS).  This region contained 64 CpG sites, of which CpGs 34
and 64 were interrogated by the methylation array.  I cloned and sequenced the PCR
products to determine the degree of methylation at each CpG.  The sequencing
analysis demonstrated that there was little CpG methylation at the MCF7 promoter,
but that LCC1/9 cells showed considerable methylation (Figure 5.12).
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Figure 5.12: A schematic of methylation across the CYBA promoter-associated CpG island.
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5.5 Hypothesis: CYBA and cellular redox in endocrine-
resistance
The observed differences in CYBA expression and methylation between MCF7 and
LCC1/9 cells led me to hypothesise that the methylation and subsequently reduced
expression of CYBA played a functional role in the acquisition of endocrine-
resistance.  Because both methylation and expression changes became more
pronounced from MCF7 to LCC1 to LCC9 cells, I hypothesised that methylation-
induced misexpression of CYBA might provide a survival advantage in estrogen-
deprivation, with further silencing providing a selection advantage after fulvestrant
treatment.  As previously mentioned, there is evidence that fulvestrant induces
oxidant damage when killing cells, so a defect in superoxide generation could play a
part in the development of resistance to the drug.  There are conflicting data on the
effects of estrogen with respect to cellular redox pathways, suggesting that estrogen-
supplementation leads to both an increase in sensitivity to oxidant damage (Mobley
& Brueggemeier 2004) and an inhibition of NADPH oxidase and ROS generation
(Zhang et al. 2009).  Given the homeostasis required in cellular redox systems, I
hypothesised that the deleterious effects of estrogen-withdrawal on MCF7 cells, and
on LCC1 cells during their derivation, might have been attenuated by a reduction in
CYBA expression, because of lowered superoxide generation.
5.5.1 Long-term estrogen-deprivation led to reduced CYBA
expression
A critical component of this hypothesis was that CYBA expression fell when cells
were deprived of estrogen.  I decided to deprive MCF7 cells of estrogen for sixty
days, whilst supplementing LCC1/9 cells with estrogen at the same time.  Western
blotting for CYBA showed that expression of the full-length protein was indeed lost
in cells deprived of estrogen (Figure 5.13), but that expression was not rescued by
supplementation of LCC1 cells with estrogen for the same period.  Interestingly, the
low molecular weight band faintly seen in LCC1 cells was expressed in the MCF7
cells deprived of estrogen.  This isoform of CYBA therefore appears to be a
reproducible consequence of estrogen-withdrawal in MCF7 cells.  However, in the
estrogen-deprived MCF7 cells, the protein is well expressed, indicating that its
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promoter is active and unmethylated. As one might expect, there was no change in
LCC9 cells, which I hypothesised had silenced CYBA expression in order to survive
treatment with fulvestrant.
Figure 5.13: Long term estrogen-deprivation led to a loss of CYBA expression in MCF7 cells,
with no rescue of expression in LCC1 cells.  Deprivation also led to the appearance of the same
low molecular weight band found in LCC1 cells.
The appearance of the low molecular weight band in MCF7 cells chronically
deprived of estrogen suggests that its presence in LCC1 cells was not due to a genetic
deletion. As discussed previously, it is possible that the observed band was a
cleavage product of the original protein, but it could potentially be a splice variant.
Given that the three primer sets for qRT-PCR (Figure 5.2) span the first four exons
of the gene, with no observable differential expression dependent on which primer
set was used (Figure 5.14), it seems likely that any splice form would either stop in,
or splice out, exon five.  However, mRNA ending in exon five corresponds to a
14kDa protein, with excision of exon five resulting in an 18kDa protein, both of
which are too small to satisfactorily explain the observed result.  I have not excluded
the possibility that there might be a post-translational modification of the protein in
MCF7 cells, which is removed on estrogen-withdrawal.  It is recognised that
phosphorylated proteins run more slowly than their equivalent unphosphorylated
forms, and other modifications, such as monoubiquitylation, would be predicted to
have significant effects on molecular weight.
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Figure 5.14: Expression measured by qRT-PCR was consistent across 3 primer sets.





















5.5.2 5-aza-2’-deoxycytidine treatment does not rescue
CYBA expression in LCC1 and LCC9 cells
I treated cells with 1µM 5-aza-dC for 3 days, to induce DNA demethylation.
Demethylation occurs when 5-aza-dC is incorporated into the DNA and traps
DNMT1, preventing its processive activity at the replication fork (Taylor & Jones
1982; Schermelleh et al. 2005). Some demethylation may also occur through the
resulting proteasomal degradation of DNMT1 (Patel et al. 2010).  Previous work in
my laboratory has shown that this duration of therapy is sufficient to induce
significant demethylation in cell lines (Figure 5.15) (Sproul et al. 2011).
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Figure 5.15: 5-aza-2′-deoxycytidine demethylated the DAZL promoter in three independent cell
lines.
Methylated CpG sites are represented by filled circles and unmethylated sites by open circles (Sproul
et al. 2011)
I hypothesised that by removing DNA methylation, CYBA expression would be
restored in LCC1/9 cells, leading to a re-expression of CYBA and, potentially, a
sensitisation to estrogen-withdrawal and a loss of fulvestrant-resistance in LCC1 and
LCC9 cells respectively. However, after drug treatment and the subsequent
demethylation (Figure 5.16), not only were CYBA mRNA (Figure 5.17) and protein
(Figure 5.18) expression not restored, they were removed in MCF7 cells.  Also, the
low molecular weight band seen in LCC1 cells could no longer be detected. I
speculated that this was in fact due to the secondary toxic effects of 5-aza-dC,
altering transcription at the locus, and had no relevance to methylation. These results
show that DNA methylation has no role in maintaining gene silencing in LCC1/9
cells.  This does not preclude the possibility that other epigenetic mechanisms, of
which DNA methylation is a part, are not responsible for the silencing of the gene.
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Figure 5.16: A schematic of methylation across the CYBA promoter-associated  CpG island



















F7 cells included as a control rem
ained enriched for unm
ethylated C
pG












ethylated sites (filled circles) across the w
hole region.  The location of the C
pG
 probes on the m
ethylation array are show
n, as is the transcription start site (TSS)
of the gene.
M
ethylation at several sites w
as im
possible to determ
ine, represented as com
m
a sym






























Figure 5.17:  qRT-PCR for CYBA shows that 5-aza-2′-deoxycytidine treatment did not restore
CYBA expression, but significantly decreased expression in both MCF7 and LCC1 cells.





























Figure 5.18:  Western blots for CYBA and DNMT1 show that despite DNMT1 depletion, CYBA
expression was not restored in LCC1/9 cells.
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The fact that the low molecular weight band observed in LCC1 cells cannot be seen
in 5-aza-dC treated cells, concurrent with the disappearance of CYBA in MCF7, is
another datum that suggests that the band might be a fragment of the CYBA protein.
5.6 LCC9 cells show reduced sensitivity to oxidative
stress
Before testing whether CYBA and the NADPH oxidase complex were involved in
the development of resistance to fulvestrant, I decided first to test the sensitivities of
the three cell lines to oxidative stress.  I hypothesised that MCF7 cells would be
extremely sensitive, with LCC1 and LCC9 cells showing respectively greater
resistance. In three experiments, each with eight replicates, MCF7 cells were treated
with 50µM hydrogen peroxide, and there was no measurable cell proliferation after
six days (Figure 5.19).  However, in LCC1 cells, whilst proliferation was
significantly reduced, there was still some proliferation after six days (Figure 5.20),
suggesting that LCC1 cells were more able to cope with the stress of H2O2 treatment.
Although H2O2 still significantly reduced proliferation in LCC9 cells (Figure 5.21),
these cells showed markedly lower sensitivity to the effects of oxidative stress, in
that proliferation still continued, albeit at reduced rate.  The relative responses of
each cell line (Figure 5.22) clearly show that, as predicted, LCC1 and LCC9 cells
were less sensitive to oxidative stress than MCF7 cells.  The effects of H2O2 on cell
proliferation were not rescued by alterations to the estrogen regimen of the cells
(Supplementary Figure S.53).
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Figure 5.19:  MCF7 cells treated with H2O2 showed no cell proliferation..
p-value shows statistical significance at day 6, error bars represent standard deviation.
Figure 5.20:  LCC1 cells treated with H2O2 showed a significant reduction in cell proliferation.




















































Figure 5.21: Although LCC9 cells treated with H2O2 showed a significant reduction in cell
proliferation, proliferation was consistently observed.
p-value shows statistical significance at day 6, error bars represent standard deviation.
Figure 5.22:  Relative responses of each cell line to H2O2 show that LCC9 cells were markedly
less sensitive to oxidative stress than MCF7, with LCC1 showing a smaller but still significant
resistance.





















































These experiments clearly demonstrated that there were significant differences in the
sensitivity of these cell lines to oxidative stress.  I hypothesised that this reduced
sensitivity played a functional role in the acquisition of resistance to fulvestrant.
5.7 Reactive oxygen species scavenging mitigated the
anti-proliferative effects of fulvestrant
If fulvestrant-treatment and -resistance were genuinely related to ROS, treating cells
with N-acetyl cysteine (NAC), a ROS scavenger, at the same time as fulvestrant
should mitigate the anti-proliferative effects of the drug. As expected, the toxic
effects of fulvestrant on MCF7 cells completely stopped proliferation (Figure 5.23).
Treating cells with 10mM NAC led to a significant but not complete reduction in
proliferation (Figure 5.24), which was expected, due to the fact that any interference
with finely balanced ROS homeostasis would be likely to have a negative effect.
Figure 5.23:  Fulvestrant completely stopped proliferation in MCF7 cells.



























MCF7 MCF7 + Fulvestrant
p=1.41E-20
148
Figure 5.24: N-acetyl cysteine treatment of MCF7 cells led to a significant reduction
in proliferation.
p-value shows statistical significance at day 6, error bars represent standard deviation.
Given that both NAC and fulvestrant have deleterious effects on cell proliferation,
one would have predicted even greater effects on proliferation when both agents
were used together, unless their mechanisms of action were in some way connected.
When I exposed cells to these agents simultaneously, I found that the effects of
fulvestrant were actually reduced by co-treatment with NAC, consistent with my
hypothesis that fulvestrant acts by generating oxidant damage (Figure 5.25).
Although the effect appears to be small, it is worth bearing in mind that MCF7 cells
do not proliferate at all in the presence of fulvestrant, whereas NAC/fulvestrant






























Figure 5.25:  Co-treatment of MCF7 cells with N-acetyl cysteine and fulvestrant led to a
mitigation of the anti-proliferative effects of fulvestrant.
p-value shows statistical significance at day 6, error bars represent standard deviation.
5.8 Experimental CYBA depletion reduced the anti-
proliferative effects of fulvestrant
The combination of evidence, that expression of the ROS generator CYBA was
reduced in fulvestrant-resistant cells, that fulvestrant-resistant cells were less
sensitive to oxidative stress and that ROS scavenging mitigated the effects of
fulvestrant, indicated that CYBA loss of function might indeed be important for
conferring resistance to fulvestrant in MCF7 cells.  To further substantiate this, I
experimentally depleted CYBA in MCF7 cells, using RNA interference, predicting
that reduced CYBA expression would be associated with relative fulvestrant-
resistance.
5.8.1 CYBA siRNA and CYBA protein depletion in MCF7
cells
I targeted the CYBA mRNA using a single siRNA targeted to exon 2 of the gene,
transfected into cells using Oligofectamine.  The sequence was taken from Nakano et
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specific effects of transfection.  Western blots confirmed that CYBA siRNA was
reducing CYBA expression in MCF7 cells (Figure 5.26) and that this reduction
lasted long enough to carry out a proliferation assay.
Figure 5.26: CYBA siRNA led to a reduction in CYBA protein expression in MCF7 cells.
5.8.2 CYBA depletion partially rescued fulvestrant-treated
MCF7 cells
I transfected siRNA for CYBA into cells twenty-four hours before beginning the six-
day proliferation assays. As before, fulvestrant was shown to completely prevent
proliferation in MCF7 cells (Figure 5.27).  As one might expect, given the effects of
NAC treatment, CYBA siRNA had a toxic effect (Figure 5.28), probably due to fact
that interfering with ROS homeostasis is deleterious to the cells.
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Figure 5.27:  Fulvestrant completely stopped proliferation in MCF7 cells.
p-value shows statistical significance at day 6, error bars represent standard deviation.
Figure 5.28: CYBA knockdown had a negative effect on MCF7 cell proliferation.













































































MCF7 + Fulvestrant MCF7 CYBA siRNA + Fulvestrant
p=3.76E-07
However, despite the negative effect of the knockdown, CYBA siRNA led to a partial
but significant rescue from the effects of fulvestrant over the course of six days
(Figure 5.29). After the six days, there was a significant increase in proliferation of
cells in which CYBA expression was reduced. Whilst the effect appears small, with
only an average 20% relative increase in cell number, it is important to consider that
the development of fulvestrant resistance takes place over months and that the
statistically significant result shown here could represent an important step in the
acquisition of resistance.
Figure 5.29:  The anti-proliferative effects of fulvestrant were somewhat ablated by the reduced
expression of CYBA.
p-value shows statistical significance at day 6, error bars represent standard deviation.
The effect of the reduction in CYBA expression can be more easily visualised by a
boxplot of cell numbers after six days, which shows that it was effective in reducing
the anti-proliferative effects of the drug (Figure 5.30).
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Figure 5.30:  A boxplot of fulvestrant-treated MCF7 cells shows that CYBA siRNA was effective




CYBA is clearly estrogen-regulated gene in MCF7 cells, which is methylated in
conjunction with silencing in estrogen-independent LCC1 and LCC9 cells.  Because
of previous studies linking fulvestrant to oxidant damage, I hypothesised that
epigenetic regulation of CYBA might have been instrumental in rendering the cells
insensitive to estrogen-deprivation and resistant to fulvestrant.  It appears that LCC1
cells do express a variant of the protein, albeit at low levels and at a reduced size
compared to MCF7 cells.  This might explain why these cells are estrogen-
independent, but not fulvestrant-resistant (unlike LCC9 cells, which do not express
the protein at all).  It is tempting to speculate that this variant form of CYBA,
induced by the chronic withdrawal of estrogen, represents a survival advantage to
estrogen-deprived cells and an important first step in the acquisition of endocrine-
resistance.  This low molecular weight band, observed in LCC1 cells and chronically
estrogen-deprived MCF7 cells, presents a fascinating puzzle.  The question of
whether or not the low molecular weight band represents a cleaved CYBA protein,
perhaps with some residual activity has not been answered here.  The identification
of this fragment, perhaps by mass-spectrometry, might be an important step in
understanding why estrogen-deprivation leads to the expression of this low
molecular weight form of the protein, beyond the scope of the work presented here.
Despite being a toxic drug in its own right, the ROS scavenger NAC reduced the
anti-proliferative effects of fulvestrant.  Thus, I have shown biochemically that
fulvestrant acts through a mechanism intimately connected with oxidant damage.  To
further demonstrate that redox systems within these cells play a role in the
development of resistance, I conducted genetic experiments, showing that reduced
levels of CYBA had an equivalent, if more modest, effect on fulvestrant-sensitivity.
Although this effect was slight, the experimental reduction of CYBA expression
appeared to reduce the sensitivity of MCF7 cells to fulvestrant.  It must be
emphasised that the model I propose is that the evolution of resistance to fulvestrant
is a slow process, in which reduced CYBA expression leads to estrogen-independence
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over the course of months, if not years.  In the scope of these experiments, the fact
that an average 20% increase in proliferation was observed is significant and
meaningful, given that the experiment was limited to six days. Perhaps if a longer or
more complete silencing of gene expression could be achieved, cells could be
entirely rescued from fulvestrant-induced proliferation arrest.
Given the methylation and expression data for CYBA, epigenetic silencing is an
obvious mechanism by which cells could acquire endocrine-resistance.  Here, I
presented data showing a correlative link, but experiments to determine the exact
nature of the epigenetic silencing have been difficult to conduct.  Although the
maintenance of silencing by methylation can probably be ruled out, it is impossible
to ascertain whether or not methylation of the CYBA promoter contributes to the
initial silencing of the gene.  It would be interesting to see what the methylation
status of the CYBA promoter was at various time points along the evolution of
fulvestrant-resistance in MCF7 cells. From these results, I would posit that the
methylation of the promoter would gradually increase, until gene silencing was
effected, rendering the cells more resistant to the drug.
It is possible that a more effective ablation of CYBA expression could be achieved
by other means, such as shRNA or multiplex siRNA, or even targeted gene
knockout, using engineered zinc-finger nucleases (Santiago et al. 2008).  However,
based on the fact that attempting to carry out two rounds of siRNA resulted in
extremely high cell death, probably due to excessive disruption of ROS homeostasis,








The acquisition of endocrine-resistance in breast cancer remains a significant clinical
problem in the treatment of the disease.  The increased use of fulvestrant as a front-
line therapy in the treatment of ER+ breast cancer and the inevitable development of
resistance mean that a thorough understanding of the mechanisms of resistance is
essential to prevent patient relapse. Although the mode of action of fulvestrant has
been well-studied, it still remains unclear how the drug kills tumours and how
resistance develops.   Whilst selection pressure on tumour cells has been posited as a
means by which cells gain the ability to proliferate in the presence of drug, it has not
been fully established how this occurs.
In this study, a model of resistance based on the MCF7 cell line was used to
investigate the acquisition of resistance to fulvestrant.  The three cell lines were used
as a model of tumour progression on treatment, with MCF7 cells representing
untreated or early-stage tumour cells.  The MCF7-derived LCC1 cells retain
sensitivity to tamoxifen and fulvestrant, despite being able to survive in serum
depleted of estrogen.  These cells could emulate the clinical situation in which breast
cancer cells that are resistant to the estrogen-depleting effects of aromatase inhibitors
could still be controlled with tamoxifen and fulvestrant.  By contrast, LCC9 cells,
which are derived from LCC1 cells by stepwise treatment with fulvestrant, are
resistant to fulvestrant and cross-resistant to tamoxifen.  These cells perhaps mimic
the clinical situation in which resistance has developed to all endocrine agents, and
where chemotherapy or novel therapies offer the only hope of regaining disease
control.
Postulating that these phenotypic differences would be accompanied by large-scale
gene expression changes, I carried out gene expression array analysis in these cells.  I
hypothesised that there would be significant differential gene expression between the
cell lines, and that each cell line would exhibit differential estrogen-response. In
LCC1 cells, I predicted that there would be several normally estrogen-dependent
growth pathways still active in the absence of ligand.  Initially, I speculated that this
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was either due to residual estrogen in the stripped serum, or that high levels of ERα
meant that signalling was estrogen-independent, but ERα-dependent. However,
subsequent experiments in this lab have shown that MCF7 cells grown in the absence
of serum can survive, still exhibiting very high levels of ERα, suggesting that
residual estrogen is not responsible for the continued survival of LCC1 cells.  In
LCC9 cells, it seemed that some other mechanism controlling growth and
proliferation existed, bypassing ERα in order to survive fulvestrant treatment.  The
identification of these mechanisms might contribute to the reversal of fulvestrant-
resistance in these cells.
Using expression arrays, I have shown that the cell lines possess characteristic gene
expression profiles and characteristic estrogen responses. Despite the lines being
closely related, their estrogen-response profiles are strikingly dissimilar.  One might
have reasonably expected that LCC9 cells, being estrogen-independent and
fulvestrant-resistant, would exhibit no response to estrogen of any kind.  Similarly,
given the large amount of ERα in LCC1 cells, one hypothesis was that there would
be dramatic changes in gene expression after estrogen supplementation.  However,
neither of these hypotheses are supported by these data.  In fact, the general
observations were that LCC1 and LCC9 cells both exhibited transcriptional changes
on estrogen supplementation, but that this response was observed in fewer genes than
in MCF7, that the magnitude of modulation by estrogen was lower than that in
MCF7, and that the response was slower. It appears that LCC1/9 cells, whilst not
dependent on estrogen-regulated gene expression for growth or proliferation, still
retain sensitivity to estrogen, but that this response is muted. This suggests that the
acquisition of estrogen-independence and endocrine-resistance does not require a
complete ablation of estrogen-signalling, but that other growth pathways become
dominant in the cells.  It seems highly likely that this muted response is a result of
some epigenetic changes between the cells, given the prominent role that co-factor
interactions play in the transcriptional response to estrogen.  These interactions are
not necessarily limited to classical transcriptional co-factors:  it could be that
interactions with histone modifying factors, DNA methyltransferases or other
epigenetic factors are playing a part in reducing the magnitude and speed of
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transcriptional response. In order to test this hypothesis, a thorough interrogation of
ERα binding sites would be required in LCC1/9 compared to MCF7 cells, in
conjunction perhaps with analysis of histone modifications across the genome.
The results of estrogen-response experiments in MCF7 cells differ somewhat from
currently available data, with approximately half of those genes called as estrogen-
regulated in these experiments being shared. However, it is likely that there is a
prosaic technical explanation for this, in that previous experiments have tended to
use the replacement of medium, supplemented with complete serum, with medium
supplemented with charcoal-stripped serum.  This has the potential to introduce
confounding effects, either due to incomplete removal of charcoal leading to a stress-
response, or the stripping of other biologically-active molecules.  Thus, effects
ascribed to estrogen-withdrawal may, in fact, be caused by other factors.  In my
experiments, cells were habituated to medium supplemented with stripped serum and
exogenous estrogen, such that changes to gene expression were solely due to the
withdrawal of estrogen, and not other factors.
A difficulty with discovering meaningful pathways and mechanisms is that these
experiments contain a large amount of data, which can be hard to parse.  One method
I tried was to use gene ontology analysis to discover those pathways that were
enriched within certain defined subsets.  However, this approach has a number of
problems.  Firstly, gene ontology analysis, by necessity, relies on previous work that
has been used to annotate genes into various functional groups.  Thus, it can be rather
limited in its potential for discovering new mechanisms, slave as it is to current
perceived wisdom.  Secondly, as seen in my analysis, GO terms can be difficult to
interpret, given their broadness and number.  The tendency to identify very general
functional categories means that the analysis generates large amounts of
inconsequential data with no biological relevance.  In addition to these difficulties,
the large dataset leads to the generation of false-positives, such as observed in the
case of DUSP1.  The data for this gene seemed to suggest that it might play a role in
the acquisition of endocrine-resistance, but after several months of work, I was
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forced to conclude that the array experiments could not be independently verified in
this case.
The inherent problems associated with the scale of the expression array dataset
meant that an additional layer of analysis was required to parse those genes that were
biologically important.  To this end, I conducted methylation array analysis, hoping
to discover epigenetically-regulated genes. Perhaps unexpectedly, although cell lines
could be separated on the basis of their methylation profiles, these profiles were
remarkably similar.  In light of the large differences in gene expression, I had
expected much greater differences between the cell lines based on methylation,
despite their common derivation.  If anything, the methylation array data demonstrate
the lack of impact methylation appears to have in these cell lines, with only very
slight differences in methylation profiles being observed.  Strikingly, methylation
and expression did not appear to correlate in the vast majority of genes, even after
somewhat artificial strictures to remove ostensibly unimportant genes.  However, if
genes were categorised as exhibiting high, partial or low methylation, a trend could
be observed, wherein highly methylated genes were less expressed than those with
low methylation.  This correlation validated the approach of dividing methylation
into discrete groups.  This approach was then used to investigate genes exhibiting
biologically significant methylation.
Given the ostensible importance of methylation, it was extremely surprising that so
few CpG sites exhibited significant differential methylation between cell lines. With
only seventeen differentially methylated promoters between MCF7 and LCC1/9
cells, of which only six were differentially expressed, the approach used to combine
the data from expression and methylation arrays in tandem seemed to be approaching
the limits of stringency. When these genes were further parsed to those with
expression profiles in keeping with what is known about methylation and its effects
on expression, only three genes satisfied the criteria for additional investigation.
These small-scale changes in methylation suggest that methylation is relatively
immutable and depends on lineage, that only subtle changes can be expected between
related cell lines.  However, although few changes were observed, I did discover
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some genes exhibiting bona fide diffential methylation, of which CYBA, a critical
component of the NADPH-oxidase complex, exhibited the most significant and
consistent DNA methylation.
The balance of redox and ROS generation is clearly important in the mechanism of
action of fulvestrant, given the effects of co-administration with NAC and the
differential sensitivity of these cell lines to oxidative stress.  This is in accordance
with previously published data that show that fulvestrant acts via ROS generation to
induce senescence and cell death.  Further to those experiments, this study showed
that fulvestrant-resistance correlated with reduced sensitivity to oxidative stress.  In
addition, here I showed for the first time that co-treating with NAC at the same time
as fulvestrant reduced the anti-proliferative effects of the drug in cell lines with
endogenous ERα expression.
However, these results were corollaries to the main experimental data, which showed
that down-regulation of CYBA could play a functional role in the acquisition of
resistance to fulvestrant. Whilst MCF7 cells with normal levels of CYBA did not
proliferate in the presence of fulvestrant, whilst those transfected with siRNA for
CYBA did, despite the toxic effects of the knockdown.  An obvious criticism of the
experiment is that the difference in proliferation is small.  However, not only is the
result statistically significant and consistently observed, the experiment takes place,
by necessity, over the course of six days.  If in only six days, an average increase in
cell number of 20% occurs, it is tempting to speculate that a long-term reduction in
CYBA levels would eventually lead to a complete recovery.  Even if CYBA silencing
were not solely sufficient for the complete development of resistance, the fact that
there is an observable increase in proliferation might mean that tumour cells with
reduced CYBA levels have a selection advantage, such that further physiological
changes can occur.  The silencing of CYBA might therefore be an early event in the
acquisition of resistance to fulvestrant.  If the effects seen here in cell lines were
observed in patients, there might be potential in using agents to modulate ROS-




Although considered estrogen-independent, the LCC1 and LCC9 cells, derived from
MCF7, retain a transcriptional response to estrogen.  This response is smaller and
slower than that observed in MCF7 cells, but is still present, even in the case of
fulvestrant-resistant LCC9 cells.
Differential methylation between the cell lines was rare, despite the physiological
differences between them.  Rarer still were those methylation events that were
inversely correlated with expression, suggesting that epigenetic differences between
the cell lines are more subtle than previously supposed.
The gene CYBA represents an epigenetically-regulated locus, exhibiting high
promoter methylation in LCC1 and LCC9 compared to MCF7 cells, and significantly
reduced expression.  Combined with the reduced sensitivity of fulvestrant-resistant
cells to oxidant damage and the observation that fulvestrant-induced proliferation
arrest can be ablated by a ROS scavenger, there appears to be a role for ROS
generation suppression in the acquisition of fulvestrant-resistance.
Reduced CYBA expression somewhat mitigates the effects of fulvestrant, suggesting




Whilst short-term experiments indicate a potential role for the gene CYBA in the
acquisition of resistance to fulvestrant, further work is required to show its
importance.  Long-term, inducible knockdown using shRNA would be desirable,
with the aim of showing that CYBA down-regulation in MCF7 cells could lead to
complete fulvestrant-resistance, rather than the small reduction in sensitivity
observed over six days.  In addition, long-term experiments involving the sequential
treatment of MCF7 cells with fulvestrant whilst monitoring both CYBA promoter
methylation and CYBA expression would be desirable to prove that the epigenetic
regulation of CYBA really represents a valid pathway to resistance.  Further
investigation of the NADPH-oxidase complex might continue from this, in order to
discover the mechanism of action of fulvestrant, as well as the evolution of resistance
to the drug.  Finally, analysis of tumour data from patients before and after
fulvestrant treatment would be required to show that this theory is not only true in
vitro, but is clinically relevant.
In addition to validating the role of CYBA and NADPH oxidase in fulvestrant-
resistance, it would be desirable to identify and characterise the short form of the
CYBA protein.  Mass spectrometry of the fragment, followed by in vitro synthesis to
discover any residual enzymatic activity would be an important step in discovering
its role in the acquisition of estrogen-independence.
As well as the further validation of the CYBA story, it would be desirable to further
investigate the genes discovered to be significantly differentially methylated between
MCF7 and LCC1/9 cells, inversely correlated to expression, PANX2 and KEAP1.
Given the discoveries stemming from using CYBA as a candidate for further
investigation, it seems likely that these two genes, demethylated and activated in
LCC1/9 compared to MCF7, might represent new targets for increasing our
understanding of the acquisition of endocrine-resistance.  To my knowledge, neither
of these genes has been studied as a candidate for endocrine-resistance or as an
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S.1
S Supplementary Data
Supplementary Table S.1:  Enzymes and chemical components removed by charcoal stripping
of serum.
*indicates values below detectable threshold, N/A indicates that previous detection levels were too
low to ascertain the effects of charcoal stripping..
Adapted from Cao et al. (2009).
Analyte (unit) Normal  FCS Charcoal stripped FCS Percentage remaining
Alkaline phosphatase (U/L) 152 22 14%
α-Amylase (U/L) 9 3 33%
Aspartate aminotransferase (U/L) 20.9 12 57%
Calcium (mg/dl) 13.5 10 74%
Cholesterol (mg/dl) 31 33 N/A
Chloride (mmol/L) 103 99 96%
Creatinine (mg/dl) 2.7 0.3 11%
Creatine kinase (U/L) 48 4 8%
Glucose (mg/dl) 137 62 45%
Lactate dehydrogenase (U/L) 330 244 74%
Magnesium (mg/dl) 3.3 3.4 N/A
Phosphorous (mg/dl) 9.7 6.3 65%
Potassium (mmol/L) 10.9 11.9 N/A
Total bilirubin (mg/dl) <0.1* <0.1* N/A
Uric acid (mg/dl) 2.3 <0.2* <8.5%*
pH 8.12 8.47 N/A
Supplementary Figure S.1: Comparing random datasets shows false-positive differential











Supplementary Figure S.2: Comparing random datasets shows false-positive differential
expression (log2 ratio ±0.2, p-value <0.05) between cell lines.
Results shown are a product of 100,000 iterations.



























Supplementary Table S.2:  Genes in subset 1; genes not estrogen-regulated in the short term,






































































































































































































































































































































































































































































































































































































































































Supplementary Table S.3:  Genes in subset 2; genes misregulated in response to both acute and











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table S.5:  Genes in subset 4; genes that were estrogen-regulated in MCF7, but


























































































































Supplementary Table S.6:  GO terms within subcategories for Set 1 genes.

























protein serine/threonine kinase activity




transferase activity, transferring phosphorus-containing groups





































































































transferase activity, transferring glycosyl groups























flavin adenine dinucleotide binding
nucleotide kinase activity
nucleobase-containing compound kinase activity
nucleoside kinase activity

















oxidoreductase activity, acting on paired donors*
NADP binding
calmodulin-dependent protein kinase activity
glucosyltransferase activity
non-membrane spanning protein tyrosine kinase activity
nucleotidyltransferase activity
tetracycline transporter activity
drug transmembrane transporter activity




transferase activity, transferring pentosyl groups




protein transmembrane transporter activity




DNA-directed DNA polymerase activity
RNA cap binding
RNA helicase activity

































































































calcium activated cation channel activity
fatty acid binding
cobalt ion transmembrane transporter activity
carbon-sulfur lyase activity




mitogen-activated protein kinase binding
MAP kinase kinase activity
protein serine/threonine/tyrosine kinase activity
racemase and epimerase activity













































































response to insulin stimulus
cellular response to insulin stimulus




chondroitin sulfate metabolic process
organic acid metabolic process
carboxylic acid metabolic process
post-translational protein modification
protein transport





establishment of localization in cell








chondroitin sulfate biosynthetic process





transcription from RNA polymerase II promoter
central nervous system neuron differentiation
neurogenesis
neuron differentiation
cellular response to hormone stimulus
cell projection organization
cell development























































































































































positive regulation of neurogenesis
2-oxoglutarate metabolic process
G2/M transition DNA damage checkpoint
polysaccharide metabolic process
glycogen metabolic process
energy reserve metabolic process
Golgi to plasma membrane transport
response to virus
negative regulation of acute inflammatory response
inositol metabolic process
fructose 6-phosphate metabolic process






response to carbohydrate stimulus
response to chemical stimulus
heme biosynthetic process
insulin receptor signalling pathway
phosphorylation
gliogenesis




regulation of G-protein coupled receptor protein signalling pathway
citrate metabolic process







positive regulation of transcription, DNA-dependent








regulation of Notch signalling pathway
apical protein localization
response to interleukin-1
response to purine-containing compound
response to caffeine
energy derivation by oxidation of organic compounds
carbohydrate metabolic process
cell morphogenesis involved in differentiation
generation of precursor metabolites and energy
secretion by cell
positive regulation of gene expression
heme metabolic process
integrin-mediated signalling pathway
detection of chemical stimulus


































































































































positive regulation of cell development
phospholipid metabolic process
cell morphogenesis
cellular carbohydrate metabolic process
cellular protein localization




negative regulation of translation
polysaccharide catabolic process
Golgi vesicle budding





dorsal spinal cord development
melanocyte differentiation
activin receptor signalling pathway
vesicle fusion
neurological system process involved in regulation of systemic arterial blood pressure
response to iron ion
intermediate filament cytoskeleton organization
proteoglycan biosynthetic process
response to dsRNA








positive regulation of metabolic process
actin filament-based process
cellular amino acid metabolic process
porphyrin-containing compound biosynthetic process
tetrapyrrole biosynthetic process
intermediate filament-based process
response to molecule of bacterial origin
vesicle-mediated transport
brain morphogenesis






regulation of macrophage activation
response to exogenous dsRNA










































































Pathway enrichment Antigen processing and presentation 1.60×10-2
*with incorporation or reduction of molecular oxygen, NADH or NADPH as one donor, and incorporation of one atom
of oxygen
S.13
Supplementary Table S.7:  Set 1 analysis repeated with a random dataset yielded very few
results.
Iteration Type GO Term Definition p-value
5 Molecular function 0050998 nitric-oxide synthase binding 2.57×10-2






















Supplementary Table S.8:  GO terms within subcategories for Set 2 genes.
Type GO Term Definition p-value



































regulation of cell projection organization
cellular response to stress
cell morphogenesis
cellular response to stimulus
cell projection organization
positive regulation of pseudopodium assembly
response to fatty acid
cell morphogenesis involved in differentiation
cellular component movement
receptor catabolic process
response to DNA damage stimulus
response to DNA damage stimulus
low-density lipoprotein receptor particle metabolic process
neuron differentiation






response to testosterone stimulus
Golgi vesicle budding
regulation of cellular component movement
cell projection assembly
generation of neurons
regulation of blood vessel endothelial cell migration
vesicle targeting, to, from or within Golgi
limbic system development
forebrain cell migration
regulation of mRNA stability
positive regulation of protein complex assembly
















































Pathway enrichment Regulation of MAP kinase pathways through dual specificity phosphatases 1.30×10-2
S.14
Supplementary Table S.9:  Set 2 analysis repeated with a random dataset yielded very few
results.
Iteration Type GO Term Definition p-value











Supplementary Table S.10:  GO terms within subcategories for Set 3 genes.






























DNA-directed RNA polymerase activity
cytoskeletal protein binding
microtubule motor activity
Ran guanyl-nucleotide exchange factor activity
transforming growth factor beta binding
protease binding
kinase activity



























































cellular response to stress
intracellular transport
response to DNA damage stimulus
cell cycle
response to DNA damage stimulus
Golgi vesicle transport








negative regulation of blood coagulation
rRNA processing
regulation of blood coagulation
vesicle localization
cellular protein localization









































































negative regulation of coagulation
collagen fibril organization
base-excision repair
aromatic amino acid family metabolic process
fibrinolysis
interspecies interaction between organisms
cellular macromolecule catabolic process
response to drug
pyrimidine nucleoside metabolic process
muscle fiber development
mitotic cell cycle






























Supplementary Table S.11:  Set 3 analysis repeated with a random dataset yielded very few
results.
Iteration Type GO Term Definition p-value


























Supplementary Figure S.4:  Expression array data for BAIAP2
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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Whilst BAIAP2 showed statistically significant estrogen-response in both MCF7 and LCC1 cells, the
combination of relatively low expression values and fold-changes meant this gene was eliminated
from further investigation.
Supplementary Figure S.5:  Expression array data for CACNG4.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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Expression of CACNG4 was too low to make it a candidate for further investigation, as it was likely
that expression of the gene was insufficient to detect with any accuracy.
S.17
Supplementary Figure S.6:  Expression array data for CASP2.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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CASP2 had sufficiently high expression to warrant further investigation, but fold-changes were
slightly low.  Also, the lack of estrogen-response in LCC1 cells made it a less attractive candidate.
Supplementary Figure S.7:  Expression array data for CASP6.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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With expression on the slightly low side and small fold-changes, CASP6 was not considered for
further study.
S.18
Supplementary Figure S.8:  Expression array data for CDC42.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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Expression of CDC42 was likely to be high enough for further experimentation, but the small fold-
changes upon estrogen-stimulation meant this gene was not a good candidate for further investigation.
Supplementary Figure S.9:  Expression array data for DUSP1.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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High expression, good fold-changes in MCF7 cells after estrogen-withdrawal (and between MCF7
and LCC1), significant estrogen-response in LCC1 cells and a lack of estrogen-response in LCC9
cells made DUSP1 a highly attractive gene for further analysis.
S.19
Supplementary Figure S.10:  Expression array data for DUSP8.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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In spite of high fold-changes in estrogen-deprived MCF7 cells, expression values for DUSP8 were too
low to warrant its inclusion in an experiment with a candidate gene approach.
Supplementary Figure S.11:  Expression array data for FICD.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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FICD initially seemed to hold promise as a candidate gene, with high expression and fold-changes in
MCF7 cells, but estrogen-response in LCC1 was muted, so much so as to make the gene a weak
candidate when compared to DUSP1.
S.20
Supplementary Figure S.12:  Expression array data for GRM4.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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Low expression, small fold-changes and evidence for an estrogen-response in LCC9 cells all meant
that GRM4 was eliminated from further study.
Supplementary Figure S.13:  Expression array data for HMGN1.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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HMGN1 was highly expressed, but fold-changes were small in LCC1 cells.  However, this gene was
considered for further analysis, but rejected in favour of DUSP1.
S.21
Supplementary Figure S.14:  Expression array data for KCTD13.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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Good fold-changes and high expression made KCTD13 a reasonably attractive candidate, but the
somewhat inconsistent estrogen-response meant it was eliminated from further study.
Supplementary Figure S.15: Expression array data for MAPK8IP3.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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MAPK8IP3 was an interesting candidate, with high expression and good fold-changes in MCF7 cells,
but estrogen-response in LCC1 was less impressive, so the gene was not considered for further
investigation.
S.22
Supplementary Figure S.16:  Expression array data for MZF1.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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Reasonably high expression and fold-changes in MCF7 made MZF1 appear to be a good candidate,
but the lack of a meaningful estrogen-response in LCC1 made it less attractive for further study than
other shortlisted genes.
Supplementary Figure S.17:  Expression array data for PIP5K1C.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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Whilst PIP5K1C appeared to have a good estrogen-response in MCF7, the lack of any regulation in
LCC1 cells meant it was eliminated from further study.
S.23
Supplementary Figure S.18:  Expression array data for PLEKHG4.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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Although initial observations suggested PLEKHG4 would be a good candidate for further study,
evidence for estrogen-responsiveness in LCC9 cells meant it was eliminated.
Supplementary Figure S.19:  Expression array data for PRKCH.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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High expression and good fold-changes in MCF7 cells made PRKCH a good candidate for further
investigation, but a delayed estrogen-response in LCC1 cells suggested that DUSP1 might be a still
better candidate.
S.24
Supplementary Figure S.20:  Expression array data for RASIP1.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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Low expression, small fold-changes and a lack of significant estrogen-response in LCC1 made
RASIP1 a poor candidate for further investigation.
Supplementary Figure S.21:  Expression array data for SREBF1.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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SREBF1 showed high expression, good fold-changes in MCF7, but no estrogen-response in LCC1 and
some slight, but significant, estrogen-response in LCC9 cells, so was eliminated from further study.
S.25
Supplementary Figure S.22:  Expression array data for TNFRSF1A.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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TNFRSF1A fitted the criteria for a good candidate gene in all but one very important respect, in that it
exhibited estrogen-response in LCC9 cells, so had to be eliminated.
Supplementary Figure S.23:  Expression array data for UBB.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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Extremely high expression paradoxically made UBB  an unattractive candidate for further study, as
expression was likely to be so high that differences in expression due to stimulus might be hard to
detect.  In addition, the lack of estrogen-response in LCC1 cells meant it was eliminated.
S.26
Supplementary Figure S.24:  Expression array data for VEGFA.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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Evidence for an estrogen-response in LCC9 cells meant that, despite good fold-changes in MCF7
cells, VEGFA had to be eliminated from further investigation.
Supplementary Figure S.25:  Expression array data for YWHAQ.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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High expression, coupled with high fold-changes meant that YWHAQ was considered for further
investigation, but eventually eliminated in favour of DUSP1.
S.27
Supplementary Figure S.26: Log2 ratio of DUSP1 expression in estrogen-supplemented LCC9
cells.

































Supplementary Figure S.27:  Expression array data for USF1.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.
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Supplementary Figure S.28:  Biologically and statistically significant (log2 ratio ±0.2, p-value
<0.05) estrogen-regulation in MCF7 cells did not predict differential methylation in LCC1 cells.
After (A) four hours and (B) twenty-four hours.
(A)  Correlation of 4h estrogen regulation in MCF7 and
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(B)  Correlation of 24h estrogen regulation in MCF7 and
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Supplementary Table S.12:  Significantly methylated genes in LCC1 compared to MCF7 cells,



































































Supplementary Table S.13:  Significantly methylated genes in LCC9 compared to MCF7 cells,




























































Supplementary Figure S.29: Methylation array data for ALK.




















Supplementary Figure S.30:  Methylation array data for ATP10A.





















Supplementary Figure S.31:  Methylation array data for C9orf142.




















Supplementary Figure S.32:  Methylation array data for CYBA.





















Supplementary Figure S.33:  Methylation array data for GFPT2.




















Supplementary Figure S.34:  Methylation array data for GOLPH2.





















Supplementary Figure S.35:  Methylation array data for HIST1H4D.




















Supplementary Figure S.36:  Methylation array data for KEAP1.





















Supplementary Figure S.37:  Methylation array data for KLF11.




















Supplementary Figure S.38:  Methylation array data for MAPK12.





















Supplementary Figure S.39:  Methylation array data for MCM2.




















Supplementary Figure S.40:  Methylation array data for NAALAD2.





















Supplementary Figure S.41:  Methylation array data for PANX2.




















Supplementary Figure S.42:  Methylation array data for PDE4C.





















Supplementary Figure S.43:  Methylation array data for QIL1.




















Supplementary Figure S.44:  Methylation array data for SNCB.





















Supplementary Figure S.45:  Methylation array data for TCF4.




















Supplementary Figure S.46:  A comparison of methylation array and expression array profiles
of C9orf142 shows that although there was differential methylation and expression between
MCF7 and LCC1/9 cells, expression was not consistent with methylation.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.






















Supplementary Figure S.47: A comparison of methylation array and expression array profiles
of CYBA shows differential, correlative methylation and expression between MCF7 and LCC1/9
cells.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.





















Supplementary Figure S.48: A comparison of methylation array and expression array profiles
of KEAP1 shows differential, correlative methylation and expression between MCF7 and
LCC1/9 cells.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.





















Supplementary Figure S.49:  A comparison of methylation array and expression array profiles
of MCM2 shows that although there was differential methylation and expression between MCF7
and LCC1/9 cells, expression was not consistent with methylation.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.



















Supplementary Figure S.50: A comparison of methylation array and expression array profiles
of PANX2  shows differential, correlative methylation and expression between MCF7 and
LCC1/9 cells.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.






















Supplementary Figure S.51:  A comparison of methylation array and expression array profiles
of QIL1 shows that although there was differential methylation and expression between MCF7
and LCC1/9 cells, expression was not consistent with methylation.
p-values show statistical significance when compared to MCF7, error bars represent standard
deviation.



















Supplementary Figure S.52:  Methylation specific PCR for the CYBA probe 1 CpG site was
unable to detect differential methylation.
S.42
Supplementary Figure S.53:  Changes to the estrogen regimen of cell lines did not rescue from
the effects of H2O2 treatment after six days.
p-values show statistical significance when compared to untreated cells, error bars represent standard
deviation.
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